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Abstract 
Lentiviral vector delivery of anti-HIV elements could provide the basis of alternative 
therapies against HIV, potentially providing long term protection after a single 
intervention. Some primate species have evolved restriction factors formed by the 
fusion of TRIM5α and Cyclophilin A (TRIM5Cyp) following retrotransposition of 
CypA cDNA into the TRIM5 gene, which provide potent resistance against certain 
lentiviruses. We have designed humanised versions of these proteins combining both 
TRIM5 and TRIM21 with CypA, and investigated their potential for use in gene 
therapy against HIV-1. Both TRIM5- and TRIM21-Cyp fusion proteins provided 
strong restriction of HIV-1 in all of the systems tested, including primary human T 
cells. However, TRIM5Cyp was shown to disrupt the antiretroviral effect of 
endogenous TRIM5α and rescue murine retrovirus infection, whereas TRIM21Cyp 
caused no interference. In contrast, neither TRIM5CypA nor TRIM21CypA 
expression affected the antiviral activity of endogenous TRIM21.  
In addition to TRIMCyp restriction factors, a second anti-HIV strategy was 
investigated using zinc finger nucleases (ZFNs) to knockout the HIV-1 co-receptor, 
CCR5. ZFNs introduce a double stranded break into the CCR5 gene, which can be 
restored by homology directed repair. Provision of a green fluorescent protein (GFP) 
or TRIM21Cyp donor template exploits this repair mechanism to allow site specific 
integration at the CCR5 locus, although at low efficiency. Using integrating vectors, 
we have shown that TRIMCyp mediated restriction is so potent that no additional 
inhibition was conferred by CCR5 knockout. 
In conclusion, delivery of TRIMCyp genes using lentiviral vectors could form the 
basis of an intracellular vaccination strategy against HIV-1, with TRIM21Cyp 
having benefits by maintaining endogenous TRIM function. With further 
optimisation to improve efficiency, this could be combined with ZFNs for site 
specific integration of the transgene and knockout of CCR5 to provide a dual 
method of HIV-1 inhibition.  
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1 Introduction 
Since the widespread introduction of highly active antiretroviral therapy (HAART) 
for the treatment of human immunodeficiency virus-1 (HIV-1) there has been a 
significant decline in morbidity and mortality (1). The categories of drugs currently 
available include nucleoside/nucleotide analogue reverse transcriptase inhibitors, 
non-nucleoside analogue reverse transcriptase inhibitors, protease inhibitors, 
integrase inhibitors and fusion inhibitors. However, there are numerous associated 
drawbacks with drug treatments, including cost, toxicity and problems with 
adherence to the strict drug regimen. In addition, once therapy is halted, there is 
often viral rebound. Also, this mode of treatment does not offer the possibility of 
curative therapy. All of these issues have driven research into finding a longer term 
solution. This includes an alternative approach to drug treatment based on gene 
therapy, which theoretically could provide a one-off treatment against HIV-1. 
There are numerous possible anti-HIV-1 genes which could be employed in gene 
therapy, targeting both viral and cellular molecules, at different stages of the viral 
lifecycle. These strategies for restriction can be broadly categorised into two main 
groups: RNA-based and protein-based, examples of which include short hairpin 
RNA (shRNA) and neutralising antibodies respectively. There are also different 
methods of delivery to consider, including adenoviral and retroviral vectors, with 
lentiviral vectors derived from HIV-1, HIV-2, simian immunodeficiency (SIV) and 
feline immunodeficiency (FIV) becoming increasingly attractive.  
One basic strategy for treating HIV-1 infection by gene therapy would be to modify 
a population of susceptible cells, for instance T cells, with an anti-HIV-1 gene to 
confer resistance, allowing them to function as normal in the presence of infection. 
If these HIV-1 resistant cells have a survival advantage in vivo, they would replicate 
and be able to repopulate the immune system, relieving the patient of the pathology 
associated with the dramatic reduction of the T cell population. 
Some anti-HIV gene therapies have reached clinical trials testing both the safety and 
efficacy of various strategies. 
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The aim of this project is to develop the use of restriction factors formed by the 
fusion of TRIM proteins with the HIV-1 binding enzyme, cyclophilin A. These are 
based upon the naturally occurring TRIM5-Cyclophilin fusion proteins found to 
provide some primate species with resistance to HIV-1, suggesting that they are an 
ideal candidate for a therapeutic agent. 
1.1 The HIV-1 genome  
HIV is a member of the Retroviridae family. This family can be divided into the 
simpler viruses, such as murine leukaemia virus (MLV) and the more complex 
lentiviruses, which includes HIV-1 and -2. HIV shares many of its genes with those 
of other retroviruses. Common to all retroviruses are the four major structural genes: 
gag (group specific antigen), pro (protease), pol (polymerase) and env (envelope).  
In addition to these, HIV-1 also carries six regulatory and accessory genes: Both tat 
(transactivator of transcription) and rev (regulator of virion expression) are critical 
for viral replication. The accessory genes vif (viral infectivity factor), vpr (viral 
protein R), vpu (viral protein unique) and nef (negative factor), although not 
compulsory for infectious virus, are all involved in multiple roles in the viral 
lifecycle and enhance infectivity (Figure 1.1). 
Once integrated into the host genome, the viral genome is termed provirus and is 
flanked by two identical long terminals repeats (LTR). LTRs are further divided into 
unique U3, repeat (R) and U5 regions. Transcription is initiated from the 5’LTR to 
produce full length viral transcripts. 
 
Figure 1.1 Schematic of the HIV-1 provirus 
The HIV-1 genome encodes the structural genes gag, pro, pol and env, which are common to all 
retroviruses. In addition, there are the regulatory genes, tat and rev, and accessory genes, vif, vpr, vpu 
and nef. The provirus is flanked by two identical long terminal repeats (LTRs), which are subdivided 
into the U3, R and U5 regions. The genome also includes the packaging signal (Ψ), polypurine tract 
(PPT) and central PPT (cPPT). 
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1.2 HIV lifecycle 
Virus binds and enters a target cell via interaction with cell surface receptors. Once 
in the cell, the viral particle is disassembled to reveal its inner viral core through a 
complex process termed uncoating. The viral core is where reverse transcription of 
the viral RNA genome takes place, producing double stranded (ds) DNA capable of 
integration into the host genome. The viral complex, now referred to as the pre-
integration complex (PIC) enters the nucleus and integrates into the host DNA to 
form a provirus. Transcription and nuclear export of the RNA transcripts occur, 
followed by translation and assembly of viral particles at the cell membrane. Virions 
eventually bud from the host cell and maturation occurs within this particle, which 
involves proteolytic cleavage of the viral structural polypeptides and rearrangement 
to form a mature virus particle capable of infecting other cells. These steps are 
discussed in further detail below. 
1.2.1 Attachment and cell entry 
The first step of the HIV-1 lifecycle is attachment to target cells. The main receptor 
for entry is CD4 (2, 3), a member of the immunoglobulin (Ig) superfamily, 
expressed on thymocytes, certain mature T lymphocytes and macrophages. CD4 
functions to stabilise interactions between the T cell receptor (TCR) and major 
histocompatibility complex (MHC) class II molecules on antigen presenting cells 
and is involved in signal transduction downstream of the TCR.  
After the identification of CD4 as the receptor for HIV-1 cell entry, further work 
suggested the requirement of one or more additional co-receptors for cell entry as 
mouse cells expressing human CD4 alone could not be infected with HIV-1(4). In 
1996, two co-receptors for HIV-1 were identified, CCR5 (5-9)  and CXCR4 (10). 
These chemokine receptors are both G protein coupled receptors expressed on 
haematopoietic cells and play a role in cell migration and inflammation. CCR5 is 
found on macrophages and some T cell subsets, such as memory T cells. CXCR4 is 
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broadly expressed on virtually all cells of haematopoietic origin, particularly T cells 
and CD34
+ 
haematopoietic progenitor cells. 
HIV-1 attachment to target cells is mediated by the viral glycoprotein Env. Env is 
made up of two subunits, glycoprotein 120 (gp120) and gp41. A trimer of gp120 on 
the viral surface is covalently associated with a trimer of transmembrane gp41.  
The two subunits are transported to the cell surface membrane where they are 
arranged in a trimer of gp120 on the virus surface (11), non-covalently associated 
with a trimer of transmembrane gp41 (12). On average, 10 trimers are incorporated 
per virion (13). 
Initially, CD4 is bound by gp120, which allows the subsequent interaction between 
gp120 and the co-receptor on the host cell, either CCR5 or CXCR4, depending upon 
the viral tropism. This binding induces a conformational change in the gp120-gp41 
complex, revealing two heptad repeats and a hydrophobic region called the fusion 
peptide. This is inserted into the target cell membrane promoting membrane fusion. 
The heptad repeats are reassembled into a hairpin structure, bringing together the 
cellular and viral membranes to allow fusion.  
1.2.2 Reverse transcription 
Following fusion, the viral core is released into the host cell cytoplasm where it is 
partially disassembled in a process known as uncoating. Although this process is 
poorly understood, correct timing is thought to be critical for productive infection 
(14). The stability of the viral core is important, and mutations that either increase or 
reduce core stability can lead to non-infectious virions. Uncoating occurs sometime 
between cell entry and nuclear import, with conflicting evidence suggesting different 
time points. It is at this early stage in the virus life cycle, before reverse transcription 
occurs, that host cytoplasmic proteins TRIM5α and Cyclophilin A interact with the 
virus. These interactions and their importance in the HIV-1 lifecycle will be 
discussed further in sections 1.5 and 1.6. 
Uncoating produces the reverse transcription complex (RTC). Reverse transcription, 
the defining feature of retroviruses, occurs within in the RTC to produce dsDNA 
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from the single stranded viral RNA genome. The enzyme responsible, reverse 
transcriptase (RT), is composed of two subunits, p66 and p51 (15). p66 is 
responsible for the enzymatic function of the protein, whereas p51 has a structural 
role (16). The two key enzymatic functions of RT are RNA- and DNA- dependent 
DNA polymerisation and RNase H activity to degrade RNA in a RNA-DNA duplex. 
Two polypurine tracts, the 3’ PPT (17) and central PPT (18), are resistant to RNase 
H activity, and therefore remain after degradation to function as primers for plus 
strand DNA synthesis.  
 
Reverse transcription begins with the synthesis of the minus strand of DNA using a 
lysine tRNA packaged into the virion from the producer cell as a primer (19). At its 
3’ terminal, tRNALys3 has 18 nucleotides that are complementary to the primer 
binding site (PBS) located towards the 5’ end of the viral RNA. tRNALys3 binds and 
DNA synthesis is carried out to the 5’ end producing the minus strand strong stop 
DNA (-sssDNA), which consists of the U5 and R regions of the LTR. Homology 
between the 5’ and 3’ R region allows minus strand transfer of the -sssDNA to the 3’ 
R element of either the same strand of RNA or the second strand that was packaged 
within the virion. RNA dependent DNA synthesis (RDDP) of the minus strand is 
continued from here to the 5’ end of the RNA, whilst the RNA strand of this RNA-
DNA duplex is degraded by the RNase H activity of RT. The exception is at the two 
PPT which are resistant to RNase H activity and remain to act as primers for DNA 
polymerisation of the positive (+) strand (20). The DNA dependent DNA 
polymerase (DDDP) function of RT occurs from the major primer at the 3’ PPT and 
from another primer at the cPPT. Synthesis continues up until the tRNALys3, where 
the first 18 nucleotides at the 3’ end, which are complementary to the PBS, are 
reverse transcribed, restoring the PBS. Synthesis stops at a modified nucleotide of 
the tRNA, with the resultant DNA called positive strand strong-stop DNA 
(+sssDNA). The tRNA and the RNA PPT are degraded by RT, leaving an overhang 
of the PBS on the positive strand DNA. 
Positive strand transfer occurs with the +ssDNA fragment binding to the 
homologous -DNA strand PBS. Positive strand DNA synthesis continues to the 
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cPPT, terminating at the central termination sequence (CTS), where it displaces a 99 
nucleotide DNA sequence of plus strand DNA to form the ‘DNA flap’ (21). The 
relevance of this flap has not been fully elucidated, and HIV-1 mutants disrupted in 
this area can still be infectious in vivo suggesting it is not vital for infection (22). 
Bidirectional DNA synthesis occurs in both directions to the ends of the LTRs using 
the DDDP function of RT by strand displacement. Finally, this forms a complete 
double stranded DNA viral genome, which is capable of integration.  
During RT, the RTC moves towards the nucleus in preparation for nuclear import. 
1.2.3 Nuclear import 
Once reverse transcription has taken place the RTC is renamed the PIC. Although 
there is little distinction between the two, the key difference is that reverse 
transcription is not complete in the RTC and therefore contains RNA or a RNA-
DNA intermediate. In the PIC, reverse transcription has been completed and 
consequently the nucleic acid consists solely of dsDNA capable of integration.  
 
Although retroviral PICs must wait for the breakdown of the nuclear envelope 
during mitosis to gain access to the genome for integration (23), lentiviruses are able 
to actively cross the nuclear membrane to successfully infect non-dividing cells (24). 
Passage across the nuclear membrane occurs even in actively dividing cells, showing 
the importance of this mechanism for lentiviral infection (25). The diameter of the 
PIC greatly exceeds that of the nuclear pore, so nuclear entry does not simply occur 
by diffusion through these pores. The mechanism utilised by HIV-1 to overcome this 
and enter the nucleus is still not understood, but many viral and host molecules have 
been suggested to be involved.  
The viral elements MA, CA, IN, Vpr and cPPT and host proteins LEDGF/p75, 
importins and nucleoporins have all been implicated in driving nuclear import, either 
independently, or in association with each other. However, results supporting the 
involvement of these proteins have often been conflicting. 
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Active nuclear import involves recognition of proteins containing a nuclear 
localisation signal (NLS) by importins. This complex subsequently interacts with 
nuclear pore complexes (NPC) which transport proteins into the nucleus. 
Initially MA was thought to be involved in nuclear import due to its nuclear 
localisation signals (NLS) (26), but has since been shown to be non-essential for 
viral replication (27).  
Vpr alone predominantly localises in the nucleus, despite its lack of classical NLS 
(28). It has also been shown to aid docking of the PIC to NPCs (29) and can bind to 
importin α and nucleoporins, leading to its accumulation at the nuclear membrane 
(30) and transport through the NPC (31). However, like MA mutants, HIV-1 lacking 
Vpr is still able to infect non-dividing macrophages in vitro (32). 
Several NLSs have been identified in IN (33) but their actual importance is 
debatable. In addition to its NLS, the interaction of IN with host importins may be 
crucial for nuclear import (34, 35).  
Viral DNA structure may also play a role in nuclear entry. Some groups have shown 
that mutants lacking the DNA flap synthesised during reverse transcription 
accumulate at the nuclear membrane and are unable to enter the nucleus (36-38). 
Conversely, other groups suggest HIV-1 with a mutant or absent cPPT was still 
capable of infection equal to that of wild type virus (39, 40).  
However, replacement of each of these karyophilic elements of HIV-1 with that of 
MLV suggests that it is the HIV-1 CA that is essential for nuclear import (41-43). 
This is further supported by the demonstration that certain HIV-1 CA mutants are 
defective for nuclear entry in cells after cell cycle arrest (44).  
CA is able to directly interact with nuclear pore protein 358 (Nup358), a component 
of the NPC. The interactions with both host cyclophilin A and Nup358 influences 
the mode of nuclear import to utilise a Nup358/Nup153 dependent pathway. Some 
CA mutations disrupt these interactions, promoting integration through alternative 
pathways and consequently altering the genomic region of integration to less 
favourable locations (45). This implies that CA is present in the PIC and plays an 
important role in nuclear entry through interaction with host proteins. 
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Not all PICs enter the nucleus and are integrated into the host genome. Non-
productive transcripts remain in the cytosol, and HIV-1 exploits the host 
exonuclease, TREX1, to degrade surplus DNA. In TREX knockout cells, this 
degradation is absent allowing the extra viral DNA transcripts to be recognised and 
promote innate type I IFN signaling, restricting viral replication (46). 
1.2.4 Integration into the host genome 
IN is the principal enzyme responsible for the integration of viral DNA into the host 
genome. Its two major catalytic functions are 3’ processing of the viral genome and 
strand transfer to integrate into the host genome. IN is made up of three domains; N 
terminal zinc binding domain, catalytic core domain and C terminal DNA binding 
domain which are joined by linker regions and are all essential for catalytic activity. 
IN acts as a multimer and mutant IN can still support integration if combined with 
wild type IN (47). 
IN binds to attachment sites at the end of the LTRs and cleaves 3’ of a conserved 
CA dinucleotide at the end of the viral DNA to produce 3’ hydroxyl groups (48) 
soon after reverse transcription and prior to nuclear localisation. This is called 3’ 
processing and occurs in the cytoplasm. Once the PIC is imported into the nucleus, 
strand transfer occurs whereby each 3’-hydroxyl group of the viral LTRs carries out 
a nucleophilic attack on a phosphodiester bond on opposing strands of DNA of the 
host genome. IN catalyses the ligation of the 3’ viral DNA ends to the 5’ ends of the 
host chromosomal DNA. This results in a five base pair (bp) single stranded region 
of host DNA and a two bp overhang on the 5’ viral DNA at either end. The viral 
DNA overhang is cleaved before extension from the 3’ end of genomic DNA by host 
machinery. This results in five bp duplications flanking the integrated provirus. 
 
The host sequence has only a mild influence on the site of integration with no strict 
consensus sequences identified (49, 50). In addition to sequence recognition, 
integration site is influenced by other factors, such as proximity to genes and 
transcriptional start sites, and their activity. HIV-1 preferentially integrates into 
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transcriptionally active genes (51), an ideal location for transcription and therefore 
viral production. 
Host proteins are also thought to be involved in and promote integration, through 
interaction with IN and/or DNA. Several proteins have been identified; of particular 
importance is the nuclear protein lens epithelium-derived growth factor/transcription 
co-activator p75 (LEDGF/p75). LEDGF/p75 is able to bind both IN and chromatin, 
promoting integration of the viral genome (52). However, this protein is not essential 
for integration as shown in LEDGF knockout cells (53). Instead, the typical pattern 
of HIV-1 integration within actively transcribed genes is disrupted and there is 
increased integration within transcriptional start sites and CpG islands (53, 54). 
1.2.5 Transcription of the HIV-1 genome 
Once integrated into the host genome, viral transcripts can be produced from the 
provirus using host machinery, including RNA polymerase II (RNA pol II). Like 
host mRNA, viral transcripts are subject to 5’ capping and 3’ polyadenylation. 
Transcription can be initiated when chromatin is relaxed, allowing access of host 
enzymes to the provirus. Transcription begins at the U3-R junction of the 5’ LTR, 
and terminates at the polyadenylation signal just after the R region of the 3’LTR.  
U3 is further divided into the core promoter, enhancer and modulatory regions. U3 
contains various elements that guide RNA pol II to the viral DNA as well as 
promoter and enhancer sequences (55). There is an ever growing list of transcription 
factors that have been shown to interact with the LTR and influence transcription. Of 
particular importance are the three binding sites for Specific protein (Sp) 
transcription factors (56) and a TATA box (57) found in the core promoter. 
Upstream of the core is the enhancer region, which contains nuclear factor κB 
(NFκB) binding sites (58), and the modulatory region, which recruits various factors 
that are able to either enhance or inhibit transcription.  
 
Initial basal levels of viral transcription are low in the absence of Tat. Before Tat 
expression, Vpr enhances transcription from the 5’LTR. As Vpr is packaged into 
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virions through its association with the C terminal of immature Gag (59, 60) it can 
promote transcription early after infection before viral protein synthesis has 
occurred, through interaction with Sp1 (61).  
This low level of Vpr mediated transcription results in synthesis of the viral Tat 
protein, which is essential for efficient transcription  and plays a critical role in 
transcription elongation (62). A stem-loop structure is formed by the transactivation 
response element (TAR) at positions +1 to +59 after the transcriptional start site in 
the LTR (63). Tat binds to this secondary structure, recruiting P-TEFb. P-TEFb is a 
protein kinase complex made up of a regulatory subunit, Cyclin T1 (CycT1) and the 
CDK9 catalytic subunit. Tat makes contacts with both subunits (64). CDK9 
phosphorylates the carboxyl terminal domain of RNA pol II, leading to 
transcriptional elongation. 
1.2.6 RNA nuclear export mediated by Rev 
Transcription of the provirus results in over thirty alternatively spliced viral RNAs 
through the use of several splice donor and splice acceptor sites (65, 66). These 
transcripts can be grouped into three main categories: 9kb full length RNAs which 
are translated into Gag and GagPol and are also packaged into virions as genomic 
RNA, 4kb partially spliced mRNAs that lack gag-pol and encode Env, Vif, Vpu and 
Vpr, and finally, 2kb mRNAs encoding Rev, Tat and Nef which have been fully 
spliced to remove gag-pol and most of env. 
These mRNAs must be exported from the nucleus, but under normal circumstances 
unspliced or partially spliced RNA containing introns is sequestered in the nucleus 
through interaction with host pre-mRNA splicing factors (67). HIV-1 has avoided 
this by using the accessory protein Rev. Rev, and also Tat and Nef, are expressed 
from the fully spliced transcripts that are exported out of the nucleus to the 
cytoplasm by normal host mRNA export pathways (68). Once expressed, Tat and 
Rev are imported back into the nucleus via their arginine rich NLS (69, 70) where 
they assist in transcription and export of unspliced and partially spliced transcripts 
respectively. 
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Rev is able to transport longer transcripts by binding via its N terminal domain to a 
conserved cis-acting RNA sequence called the rev responsive element (RRE). This 
sequence of approximately 200bp forms stem loop secondary structures and is 
located on unspliced mRNA within the env gene of viral transcripts (71). 
Subsequent oligomerisation of up to eight Rev molecules at the RRE is required for 
export (72). The C terminal leucine rich domain of Rev functions as a nuclear export 
signal (NES) which, in combination with its NLS, enables it to shuttle between the 
nucleus and cytoplasm (70, 73-75). Through its NES, Rev is able to mediate an 
interaction between incompletely spliced transcripts and host proteins involved in 
nuclear export, such as chromosome maintenance region 1 (CRM-1) to allow 
nuclear export. CRM-1 mediated nuclear export is usually used for export of 
proteins, small nuclear RNAs and ribosomal RNAs and uses a different export 
mechanism to that normally employed for export of host mRNAs, or fully spliced 
HIV-1 transcripts (76-79).  
1.2.7 Translation, viral assembly and budding 
In the cytoplasm, host ribosomes synthesise viral proteins. Ribosomal frameshifting 
occurs at the gag-pol junction where the ribosome slips back to -1 to translate the 
full length Gag-Pol polyprotein which encodes the viral enzymes RT, PR and IN 
(80). 
Gag is the main polyprotein involved in virion assembly and its expression alone is 
sufficient to promote viral assembly, budding and release of an immature virus 
particle. The MA domain of Gag is primarily responsible for localisation of Gag at 
the plasma membrane through myristoylation of an N terminal glycine (81) and an N 
terminal basic region (82) providing a signal for trafficking to the membrane. 
Interaction between negatively charged phosphoinositides and the basic region of 
MA can lead to the accumulation of Gag with phosphatidylinositol (4,5) 
bisphosphate (PIP2) which is concentrated on the cytoplasmic side of the plasma 
membrane (83). Gag proteins accumulate and multimerise at the plasma membrane 
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through its interaction (I) domain forming a roughly spherical shape with the N 
terminal associated with the membrane and C terminal at the sphere’s centre (84). 
 
Full length RNA transcripts include a 5’ packaging signal (Ψ) which spans the 5’ 
UTR into the Gag coding sequence (85). This sequence forms a stable secondary 
structure of four stem loops, which interacts with Gag to mediate incorporation into 
the virion. Specifically, it is the NC region of Gag that binds the packaging signal, 
leading to its recruitment into budding virions. This signal also enables dimerisation 
of RNA resulting in the packaging of two strands of RNA per virion. The packaging 
signal is removed during splicing to ensure that only full length transcripts are 
packaged into virions. 
Also incorporated into the budding virion are a collection of host and viral proteins. 
These include Vpr (60), Vif (86) and Nef (87), tRNALys3 (19) and the host protein, 
cyclophilin A (88, 89). 
 
The Env precursor glycoprotein, gp160, is synthesised in the rough endoplasmic 
reticulum (RER), where it undergoes extensive glycosylation of certain asparagine 
residues. Gp160 is inserted into the lumen of the RER and forms trimers which are 
transported to the Golgi apparatus where they are subject to mannose trimming (90) 
and cleavage into the subunits gp120 and gp41 by furin (91) which is essential for 
function. gp41 anchors gp120 to the membrane surface non-covalently in a trimeric 
structure. The complexes are transported to the cell surface via the secretory 
pathway and incorporated into virus particles with an average of 10 per virion. The 
method by which Env is localised to the site of viral budding has not been 
elucidated. HIV-1 virions are able to incorporate envelope proteins from unrelated 
viruses in a process called pseudotyping, suggesting that there is not simply an 
interaction between viral proteins and Env, but that there is also an involvement with 
cellular structures. 
 
As the virion is forming and budding from the host cell, it is coated in the host cell 
plasma membrane, which must subsequently be excised at the neck of the bud to 
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allow release. To do this, HIV exploits host machinery, namely the endosomal 
sorting complex required for transport (ESCRT) pathway, which is normally 
involved in multivesicular budding and cell division. Components of this pathway 
are recruited to the budding virion via late or L domains in the p6 region at the C 
terminal of Gag and mutation of this domain results in an accumulation of virions 
trapped at the cell surface (92).  
1.2.8 Virus maturation 
During or shortly after budding, viral maturation occurs and involves a structural 
rearrangement from a spherical structure to a cone shaped core. Gag polypeptide is 
cleaved by PR to form MA, NC and CA monomers, as well as spacer peptides SP1, 
SP2 and p6. Gag-Pol cleavage produces the viral enzymes RT and IN. These 
molecules reassemble to form the mature virus particle which consists of an outer 
layer of lipid membrane associated MA with a CA conical core surrounding NC 
complexed with the RNA genome, and IN and RT.  
The Fullerene cone core consists of approximately 1500 CA monomers, assembled 
into 250 hexamers via its N terminus. The hexamers in turn are associated with each 
other by their C terminal domains (93). In addition, a Fullerene cone includes 12 
pentamers of CA, five at the narrow end and seven at the wide end, which are 
required to allow the curvature and closure of the structure at either end (94). 
Maturation is essential to produce infectious viral particles. 
1.3 Gene therapy 
1.3.1 History of gene therapy 
The basic principle of gene therapy is the introduction of a therapeutic transgene into 
target cells. Depending upon the disease being treated, the vector could carry a wild 
type gene to replace an endogenous, mutated copy in a genetic disease. Alternatively 
gene therapy could be used to express a novel protein that would be advantageous, 
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for instance, by conferring resistance to particular pathogens, or enabling cells to 
target and destroy cancer cells. 
There are different mechanisms that can be employed to deliver transgenes into 
target cells, both viral and non-viral. Retroviruses have characteristics that make 
them highly desirable as gene therapy vectors, including their integration into the 
host genome to mediate long term gene expression, susceptibility to genome 
manipulation to enable insertion of novel genes and efficient infection of a range of 
different target cells. Consequently these vectors have been used extensively for 
research and are being developed for therapy of a vast array of diseases.  
 
The first approved gene modification studies were initiated in 1990 with the 
modification of tumour infiltrating lymphocytes using a retroviral vector carrying 
the neoR gene (95). This trial demonstrated safety of the procedure with normal 
functioning of T cells, no insertional mutagenesis and no recombinant replicating 
virus observed. Modified cells were still detectable several months after introduction 
into the patient. 
A second gene therapy clinical trial began to treat severe combined 
immunodeficiency (SCID) by delivery of a gamma retroviral vector expressing the 
adenosine deaminase (ADA) gene to CD34
+
 cells. The procedure was well tolerated 
in terms of safety and there was detectable increase in ADA levels in modified cells. 
However, the effect was short lived with only transient transgene expression (96, 
97). Despite a dramatic rise in the number of gene therapy clinical trials being 
performed throughout the 1990s, most studies failed to show sustained efficacy 
In 2000, a gamma retroviral vector carrying the interleukin (IL) γ chain gene was 
shown to mediate ex vivo transduction of bone marrow HSCs of X-linked SCID 
(SCID-X1) patients in a multicenter study. There was an increase in T, B and NK 
cells and improved immunological function and sustained benefit (98, 99). However, 
unanticipated adverse events were uncovered when several trial participants 
developed leukaemia due to insertional mutagenesis (100, 101). 
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1.3.2 The development of HIV derived vectors 
Gamma retroviral vectors, such as MLV, are being tested in clinical trials for various 
diseases. However, the development of leukaemia in five patients due to insertional 
mutagenesis in the SCID-X1 trials demonstrated the safety concerns of these vectors 
(100, 101). Modifications of the vector used in the SCID-X1 trial by removal of 
enhancer elements and use of an internal promoter rather than the viral LTRs, can 
improve safety (102). Lentiviral vectors, such as those derived from HIV-1, are also 
in development and share advantageous characteristics with gamma retroviral 
vectors in that they are both able to integrate within the host cell genome, 
theoretically providing stable, continuous transgene expression. Gamma retroviral 
vectors also have a preference for integration into transcriptional start sites and 
regulatory regions (103). In comparison, although HIV-1 has a tendency to integrate 
within active genes, it does not target promoter regions, reducing the likelihood of 
insertional mutagenesis (51). Significantly higher copies of SIN lentivirus are 
required than SIN gamma retrovirus to induce oncogenesis in a tumour prone mouse 
model used to measure insertional mutagenesis. This is most likely to be due to the 
differences in integration profiles of the two vectors (104). 
Lentiviral vectors have several additional advantages over retroviral vectors, 
including their larger packaging capacity of potentially up to 10kb (although this is 
generally accompanied by a decrease in titre) and their ability to efficiently 
transduce both dividing and non-dividing cells. This significantly increases the 
possible target cell populations to include muscle cells, neuronal cells and various 
haematopoietic cells including haematopoietic stem/progenitor cells and minimally 
active T cells. In contrast, gamma retroviral vectors will only transduce fully 
activated T cells, which could have deleterious effects on their lifespan, immune 
function, and repertoire. 
 
Lentiviral vectors are frequently derived from HIV-1. Using a vector based on a 
pathogenic virus has obvious safety concerns, and extensive modifications of the 
HIV-1 genome have improved the safety profile to reduce the likelihood of 
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recombination events producing replication competent lentivirus (RCL). Protein 
expression is not required for the early stages of the lentiviral lifecycle, as RT and 
IN are carried within virions into target cells. This means that the majority of the 
lentiviral genome, apart from some critical cis-acting sequences, can be removed 
from the transfer vector plasmid (Figure 1.2A). Viral protein expression is then 
limited solely to the packaging cells, rather than in patient target cells. Only the 
transfer vector contains the necessary cis-acting sequences required for packaging 
into virions in the packaging cells. Separation of the cis-acting sequences of the 
transfer vector from the viral genes results in virions which are only capable of a 
single round of infection (105). 
The first generation of lentiviral vectors consisted of three plasmids; the packaging 
plasmid carrying all HIV-1 genes except env, the envelope plasmid which frequently 
encoded the G envelope glycoprotein of VSV (VSV-G), and the transfer vector 
plasmid which carried the transgene of interest and cis-acting elements of HIV-1 
required for packaging, reverse transcription and integration. The presence of all 
HIV-1 genes, except env, was a cause for concern, as it would only require minimal 
recombination events to produce a full length genome and functional virulent 
particle.  
Therefore the second generation packaging system, in addition to env, also deleted 
the non-essential accessory genes vif, vpr, vpu and nef from the packaging plasmid 
(105, 106) (Figure 1.2B). These genes are not required to produce high titre 
lentiviral vectors capable of both in vitro and in vivo gene delivery, but their deletion 
improved the safety of the vector. This second generation packaging system is 
already in widespread use, but additional alterations to the lentiviral vectors have 
been made to further reduce the risk of recombination and the formation of RCL.  
The third generation system has further separated HIV-1 genes onto four separate 
plasmids, which are transfected into packaging cells to produce vector particles 
(Figure 1.2C). In this system, U3 of the 5’ LTR in the transfer vector plasmid is 
replaced with a constitutively active promoter, removing the requirement of Tat for 
sufficient transcription. Furthermore, Rev is expressed in trans from the fourth 
32 
 
plasmid, which maintains a high titre of vector whilst limiting Rev expression 
exclusively to the packaging cells (107). 
Enhancer and promoter sequences have been deleted from U3 in the 3’ LTR to 
develop self-inactivating (SIN) vectors. During reverse transcription the 3’ U3 is the 
template for both LTRs, so the deletion is found in both provirus LTRs resulting in 
their inactivation and the absence of transcription of full length viral RNA. This 
reduces the likelihood of activation of adjacent genes or interference with the 
internal promoter through the promoter and enhancer activity of the LTRs (108). 
As the promoter activity of the LTR is abolished in SIN vectors, an internal 
promoter is used to drive transgene expression. The Spleen focus-forming virus LTR 
(SFFV) is commonly used as a promoter as it provides high, constitutive expression. 
Different promoters can be used to alter the level of expression and for tissue 
specificity. In a clinical setting, SFFV is not favourable as it is derived from a 
gamma retrovirus, causing safety concerns, and it is prone to methylation induced 
silencing (109). The ubiquitously expressed human phosphoglycerate kinase (PGK) 
promoter can be used to drive high levels of expression in human cells and has been 
approved for use in clinical vectors. 
In many cases it is desirable to express two different genes from one vector. Often 
this includes the transgene of interest alongside a marker gene, such as green 
fluorescent protein (GFP) or an antibiotic resistance selectable marker. This can be 
achieved by different strategies, including the use of two promoters, or separation of 
the transgenes by an internal ribosomal entry site (IRES) or a 2A peptide. The most 
common method is the use of an IRES, which promotes ribosomal access to mRNA 
to allow translation of a second protein from a single transcript (110, 111). The 2A 
peptide is a 18-22 amino acid sequence that is readily cleaved as translation occurs, 
separating the two proteins (112). This leads to equal amounts of the co-expressed 
proteins, which is not always observed when using an IRES. 
Certain HIV-1 elements must be maintained in cis on the transfer vector to allow 
vector production and reverse transcription and integration following transduction. 
These include a promoter and polyA signal in the vector genome, the packaging 
signal, the PBS, PPT and R region required for reverse transcription and the correct 
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repeat ends at the end of the LTRs to facilitate integration. Inclusion of the cPPT 
increases the vector transduction efficiency by promoting nuclear import of the viral 
transcript (113-115). 
As well as the removal of HIV genes to improve safety, other elements are added to 
vectors for different functions. The woodchuck hepatitis virus post transcriptional 
regulatory element (WPRE) can be added at the 3’ non-coding region of a vector to 
increase vector titre and gene expression (116). However, the native WPRE has 
enhancer and promoter activity, potentially driving expression of a peptide fragment 
of the woodchuck hepatitis virus protein X and this is thought to be oncogenic (117). 
Therefore, mutant variants have been developed that delete these regions, yet 
maintain their ability to enhance titre and gene expression (118). 
Alternative envelope proteins expressed in trans can be used in place of HIV-1 Env, 
a process termed pseudotyping, to alter the tropism of the vector. VSV-G is 
commonly used as it very stable; allowing concentration of vector by 
ultracentrifugation and its broad tropism allows transduction of multiple cell types 
(119). Particular envelope proteins can be used to target vectors to specific cell 
types, and recombinant envelope proteins are being developed to further enhance 
cell transduction efficiency and specificity.  
 
In 2006, details of the first clinical trial using lentiviral vectors were published 
(120). This phase I trial against HIV-1 used a vector to deliver an antisense 
transgene targeting the HIV-1 envelope to autologous T cells ex vivo. In contrast to 
most examples, this gene therapy vector was conditionally replicating, utilising the 
wild type HIV-1 LTR. This meant that transgene expression was upregulated by Tat 
upon HIV-1 infection and that transcripts could be packaged using wild type HIV-1 
proteins, allowing mobilisation of the transgene to other CD4
+ 
T cells. There was 
detectable gene marking in patients and CD4
+
 cell levels increased in some patients. 
Consequently, this trial is still ongoing and has progressed into HSCs. These results 
provide important information about the efficiency and safety of the procedure, 
assisting the development of further trials. 
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Since then, lentiviral vectors have been tested in clinical trials for other diseases, 
including X-linked adrenoleukodystrophy (ALD) (121), β-thalassaemia (122), and 
Wiskott-Aldrich syndrome (WAS) (123) which are normally treated with HSC 
transplants if human leukocyte antigen (HLA) matched donors can be found. 
ALD is a severe demyelinating disease caused mutations in the ABCD1 gene 
leading to a lack of ALD protein. Two patients received autologous CD34
+
 cells 
transduced with a lentiviral vector carrying the ABCD1 gene. Following transplant, 
cells of all haematopoietic lineages were found to express ALD, and there was 
significant reduction in demyelination similar to that seen following an allogenic 
HSC transplant (121). This trial is important in showing that lentivirally modified 
HSCs can mediate sustained benefit. 
Another lentiviral vector trial that has shown clinical benefit is in a patient with β-
thalassaemia, a disease caused by mutations in the globin gene leading to the 
requirement of regular blood transfusions. Autologous CD34
+
 cells were transduced 
ex vivo and delivered back to the patient. However, in this patient there has been 
clonal dominance of cells with integrated vector copies in the HMGA2 gene. Target 
sites for let-7 microRNAs, which bind and promote RNA degradation, were absent 
from the resulting truncated mRNA, leading to its increased stability. In addition 
many copies of integrated vector had deletion of one of the vector cHS4 insulators 
(122). Although this incident of clonal expansion has not progressed to 
transformation, this trial has demonstrated the potential risks of adverse events also 
occurring in lentiviral gene therapy and further studies must proceed with caution. 
In early phase trials are lentiviral vectors for Wiskott-Aldrich syndrome (WAS), an 
inherited immunodeficiency caused by mutations in the WAS gene. Previously, 
gamma retroviral vectors have been used in trials for this disease and have caused 
transactivation of LMO2 leading to leukaemia (124), but recently an HIV-1 derived 
WAS vector has been developed and has entered clinical trials (123).  
In addition to HSC gene therapy, lentiviral trials have also targeted T cells. A 
chimeric tumour specific antigen receptor has been designed to recognise CD19, the 
expression of which is restricted to normal and malignant B cells. Delivery of this 
receptor to T cells using lentiviral vectors has been used to treat a patient with 
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chronic lymphoid leukaemia (125). Modified cells were detectable for at least 6 
months following infusion and there was a specific loss of CD19
+
 B cells. 
These trials demonstrate that there is significant clinical progress in the use of 
lentiviral vectors in gene therapy for a range of diseases. 
 
 
Figure 1.2 Second and third generation lentiviral vectors 
A. Self-inactivating lentiviral transfer vector. The second generation system uses the native HIV-1 
U3, whereas the third generation packaging system replaces U3 in the 5’ LTR with the Tat 
independent Rous Sarcoma virus (RSV) promoter. RRE=rev responsive element, cPPT=central 
polypurine tract, WPRE=Woodchuck hepatitis virus post transcriptional regulatory element  
B. Second generation lentiviral packaging plasmid. CMV= Cytomegalovirus promoter 
C. Third generation lentiviral packaging plasmid. The rev gene is provided in packaging cells in trans 
using the RSV-rev plasmid. 
D. Envelope plasmid with vesicular stomatitis virus glycoprotein (VSV-G) 
1.3.3 Gene therapy against HIV-1 
Due to advancements in gene therapy and the requirement of a different approach to 
treat HIV-1 infection in patients who are unable to continue, the field of anti-HIV 
gene therapy research is extensive. There are many different transgenes being 
generated and tested in vitro, targeting both viral and host components at different 
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points of the viral lifecycle. Modeling suggests that the most effective transgenes 
will inhibit HIV-1 early in its lifecycle, either at the point of viral entry, or prior to 
integration (126). This reduces the opportunity for HIV-1 to develop mutations as 
reverse transcription is not occurring, limits cytotoxic effects on infected cells and 
prevents establishment of a latent reservoir. Alongside analysis of anti-HIV 
transgenes, vector development and transduction protocols are being tested and 
improved. HIV gene therapy has progressed into the clinic, with various different 
preclinical, phase I and phase II clinical trials currently underway.  
Early work was primarily involved with the use of gamma retroviral vectors to 
deliver transgenes to target cells; either HSC or T cells and consequently these 
vectors have been more extensively tested. Typically, these vectors carried 
transgenes that inhibited late stages in the HIV lifecycle, such as inhibiting Rev and 
Tat, and RNA interference (RNAi) of viral genes to preventing translation. Some of 
these transgenes have reached clinical trial using retroviral vectors to transduce both 
HSC and T cells. However, as a more effective therapy, transgenes targeting early 
stages in the viral lifecycle have been developed. This includes stages prior to 
integration and formation of the provirus, such as restriction of viral entry. 
Although these retroviral vectors initially appeared safe, clonal expansion of 
modified cells in clinical trials for SCID-X1 (100, 101), WAS (124) and CGD (127) 
have created a move towards lentiviral vectors. These have an improved integration 
safety profile and also have the ability to transduce non-dividing cells, many of 
which are natural targets of HIV-1. These include HSCs, T cells, macrophages and 
dendritic cells. As gamma retroviral vectors can only transduce dividing cells, it is 
necessary to activate T cells and HSCs to allow transduction, which can affect their 
function and pluripotency upon infusion back into a patient. Extensive research is 
being performed testing lentiviral vectors carrying various anti-HIV transgenes in 
vitro and in mouse models, and some lentiviral vectors are now in clinical trials. A 
summary of several anti-HIV clinical trials that have been performed to date are 
presented in table 1.1. 
Preliminary results from these trials have provided safety data for the procedure and 
important information about persistence of the transgene in vivo. In some cases, 
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there are also promising results relating to the efficacy of the treatments, including a 
survival advantage of modified cells, reduced viral load and an improvement in T 
cell numbers, which support further investigation of this new therapeutic technique. 
To help prevent mutagenic escape of HIV from the therapeutic transgene, vectors 
are being designed that express combinations of antiviral genes.  For example, a 
triple transgene vector encoding a chimeric TRIM5α, CCR5 shRNA and a TAR 
decoy has been tested in vitro (128). Some of these multi-transgene vectors are now 
in clinical trial. For instance a lentiviral vector carrying three transgenes, Tat/rev 
shRNA, TAR decoy and CCR5 ribozyme, has been used to modify autologous HSC 
(129). As well as in vitro viral restriction, the in vivo efficacy of these transgenes 
must now be demonstrated to determine how effective gene therapy could be for the 
treatment of HIV-1. 
 
Target Vector Results Reference 
Env Antisense targeting env, 
conditionally replicating LV 
vector into CD4
+
 T cells 
Some increase in CD4
+
 counts, vector 
mobilisation 
(120) 
Tat/rev, CCR5, 
TAR 
Tat/rev shRNA, TAR decoy, 
CCR5 ribozyme 
Low level marking for 2 years in multiple 
lineages 
(129) 
Rev Dominant negative Rev 
(huM10), RV vector in CD34
+
 
cells 
Marked cells dropped below detection 
after a few months, increased marking in 
one patient when viral load increased 
(130) 
Tat/rev Anti-Tat ribozyme, RV vector 
in CD4
+
 T cells 
Survival of marked cells for 4 years. No 
adverse effects 
(131) 
Rev/TAR Trans-dominant 
Rev/antisense TAR, RV vector 
in CD4
+
 T cells 
Long term survival of cells, survival 
advantage of marked cells in patient with 
high viremia 
(132) 
Fusion C46 fusion inhibitor, RV 
vector in T cells 
Long term, but low gene marking, 
increased CD4
+
 
(133) 
Tat/vpr Anti tat/vpr ribozyme (OZ1), 
RV vector in CD34
+
 cells 
No significant difference in viral load, but 
some other markers improved 
(134) 
CCR5 ZFN, AdV vector in T cells Modified cells detected in circulation and 
GALT 
(135) 
RRE decoy RRE decoy, RV vector into 
CD34
+
 cells 
Low level gene marking in periphery only 
for a few months. No safety problems 
(136, 137) 
Table 1.1 Examples of anti-HIV-1 clinical trials. 
 Information includes the viral target, the vector and cell type used, brief summary of results of the 
trial and reference for the trial. AdV-adenoviral, GALT-gut associated lymphoid tissue, LV-lentiviral, 
RRE-Rev response element, RV-retroviral, shRNA-short hairpin RNA, TAR-trans-activation 
response element, TCR-T cell receptor, ZFN-zinc finger nuclease.  
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1.4 Restriction factors of the innate immune system 
1.4.1 Antiretroviral restriction factors 
Higher organisms have evolved a complex immune system where the innate immune 
system acts quickly after infection to provide protection against pathogens, allowing 
time for the adaptive immune system to mount a response. The innate system 
includes interferon (IFN), pattern recognition receptor (PRR) and secreted soluble 
molecules such as toll-like receptors or complement. Adaptive immunity is more 
complex and found only in vertebrates and can take days to come into effect. It 
involves the activation and expansion of T and B lymphocytes and production of 
pathogen specific antibodies. Although innate immunity begins to control infection 
much sooner than the adaptive response, it still requires some signaling, often IFN 
mediated, which can take time to upregulate.  
One aspect of the innate immune system involves the expression of a variety of 
antiviral restriction factors. Unlike conventional immunity, this system does not 
involve signaling and relies on constitutive expression of a number of proteins that 
are able to act immediately upon viral infection, in the absence of any cell signaling 
or cell-cell interaction, providing the first line of defence against invading viruses 
(138). The expression of restriction factors is now far more widespread than initially 
thought and a wide range of mammals have now been shown to express these 
antiviral proteins.   
Retroviruses have evolved systems to avoid inhibition by these restriction factors in 
a species specific manner. Typically, HIV-1, HIV-2 and SIV are not significantly 
inhibited by restriction factors of their natural host species. Host restriction factors 
and retroviruses have co-evolved, each trying to gain advantage over the other, 
resulting in high levels of selective pressure as viruses evolve mechanisms to avoid 
inhibition by host restriction factors. Viral tropism is therefore often determined by 
the panel of restriction factors expressed by host cells and the target specificity of 
these factors. In fact it is the tropism of different retroviruses that has been a vital 
tool in the identification and study of these restriction factors.  
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Due to the extensive research that has been performed on retroviruses, most of the 
knowledge obtained on restriction factors is related to inhibition of these viruses.  
Four groups of proteins that fall into the category of antiviral restriction factors 
include APOBEC proteins, tetherin, SAMHD1 and Fv1/TRIM5α proteins. 
1.4.2 The APOBEC family 
The apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) 
family are capable of restricting HIV-1, the most efficient member being 
APOBEC3G. APOBEC3G is a cytidine deaminase and is thought to target HIV 
ssDNA (139, 140). Specificity for ssDNA, not double stranded or RNA-DNA 
hybrids, results in deamination predominantly of the minus strand DNA, which is 
synthesised first during reverse transcription and is the principle form of single 
stranded viral DNA in an infected cell. These mutations are then copied over to the 
plus strand DNA, ultimately resulting in a G to A mutation of the viral genome 
(141). 
APOBEC3G also inhibits Vif deficient HIV-1 in a deaminase independent way. 
Mutant protein in which the cytidine deaminase domain is no longer functional is 
still capable of causing significant restriction (142). The mechanisms of the cytidine 
deaminase independent restriction have not been fully elucidated, but are thought to 
target reverse transcription leading to reduced levels of viral DNA (143). There has 
been evidence that various processes during reverse transcription are affected, 
including interference with primer annealing (144, 145) and strand transfer (146). 
APOBEC3G is incorporated into Vif deficient virions through interactions with both 
Gag, specifically the NC (147), and viral RNA (148). Once the virion infects a new 
cell, APOBEC3G remains associated with the mature viral proteins and RNA to 
enable deamination during reverse transcription. 
The inhibitory effects of APOBEC3G and APOBEC3F were found to be 
counteracted by the viral Vif protein, restoring replication (149). Vif prevents 
incorporation of APOBEC3G into budding virions (150) and reduces APOBEC3G 
protein levels by interfering with translation and reducing its half-life (151). Loss of 
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protein is primarily a result of ubiquitin mediated degradation. Vif acts as an adaptor 
molecule, binding both APOBEC3G and an E3 ubiquitin ligase complex consisting 
of cullin-5, elongins B and C and Rbx1. This allows polyubiquitinylation of 
APOBEC3G leading to proteasomal degradation (152). Vif is also able to prevent 
APOBEC3G incorporation into virions in a proteasome independent manner, as 
shown by the exclusion of a degradation resistant APOBEC3G from budding virus 
particles (153). 
1.4.3 Tetherin 
Vpu was shown to be required for HIV-1 release from cells in a cell specific manner. 
In some cell lines, Vpu deficient virion particles were seen to accumulate at the cell 
surface and endosomal compartments. Accumulation at the endosome was due to 
endocytosis of membrane trapped virions and could be prevented by inhibition of 
membrane to early endosome transport. Viral particles accumulated at the cell 
membrane could be released by protease treatment, indicating a protein was 
responsible for this accumulation, rather than prevention of membrane scission (154, 
155) . In 2008, two groups identified tetherin, also called bone marrow stromal Ag 2 
(BST2), as the protein responsible for this restriction (156, 157).  
 
Tetherin is a type II membrane glycoprotein that inhibits the release of many 
enveloped viruses, including HIV-1. It functions as a general antiviral restriction 
factor without obvious species specificity, as it interacts with the host membrane 
rather than a viral factor. Originally identified on B cells, tetherin has now been 
shown to have a broad expression pattern. However, HIV-1 target cells, including 
CD4
+
 T cells, dendritic cells and macrophages, were not found to express tetherin 
(158). This casts doubt on the importance of the interaction between tetherin and 
HIV-1 in vivo, although as this group only examined healthy donors and cancer 
patients it is possible that there is upregulation after HIV-1 infection and type I IFN 
signaling. 
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The protein has an unusual structure as it is anchored at both ends to the plasma 
membrane via an N terminal transmembrane domain and a C terminal glycosyl-
phosphatidylinositiol anchor (159). Through insertion into the plasma membrane, 
tetherin is able to crosslink neighbouring virus particles and host cell membranes 
causing an accumulation of budding virions (160). 
HIV-1 has evolved a mechanism to avoid this restriction through its accessory 
protein Vpu. Vpu is an 81 amino acid phosphoprotein that is expressed from a 
bicistronic mRNA with the Env gene. Its transmembrane domain is known to 
multimerise, most likely in a pentamer, to form cation channels (161).   
Vpu is thought to abrogate the antiviral activity of tetherin through endosomal 
trafficking and subsequent lysosomal degradation. This process requires the host 
protein βTrCP (162, 163). In addition to this, Vpu can abolish tetherin mediated 
restriction without decreasing cellular levels of the protein, and this involves 
sequestering of tetherin in a perinuclear location that contains trans-Golgi network 
markers (164, 165). 
1.4.4 SAMHD1 
The most recently identified restriction factor is the sterile alpha motif and 
histidine/aspartic acid domain containing protein-1 (SAMHD1) (166, 167). 
SAMHD1 was originally identified as its mutation causes Aicardi-Goutières 
syndrome, an encephalopathy that manifests early in childhood and often leads to a 
variety of physical and neurological problems (168).  
SAMHD1 was subsequently determined to be an HIV-1 restriction factor and is 
responsible for the inability of HIV-1 to infect dendritic cells and its reduced 
infectivity in macrophages. It functions as a dNTP triphosphohydrolase (169) and 
has been shown to deplete dNTP levels sufficiently to prevent reverse transcription 
(170). However, HIV-2, SIVmac and SIVsm (sooty mangabey) counteract this 
restriction through expression of the accessory protein Vpx, which promotes 
proteasomal degradation of SAMHD1 (166, 167). 
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1.5 TRIM proteins 
1.5.1 Identification of TRIM5α as an antiretroviral restriction factor 
The final restriction factor to discuss was actually the first to be identified. Studies 
were carried out investigating the susceptibility of different strains of mice to the 
Friend strain of MLV. The responsible genes were named the Friend virus 
susceptibility (Fv) genes, and Fv1 in particular was studied further. Two main Fv1 
alleles were identified; Fv1
n
 and Fv1
b
, which were found to restrict B-tropic MLV 
(B-MLV) and N-tropic MLV (N-MLV) respectively. A third viral tropism, NB-
MLV was able to infect both strains of mice.  
The mode of restriction mediated by Fv1 was novel and interesting characteristics 
were observed. Fv1 restriction of MLV could be saturated by the addition of 
sufficient viral particles simultaneously or prior to infection. The virus particles 
could be non-infectious and genome deficient, as long as they were of the correct 
tropism (171). Fv1 targets MLV CA and the two strains of virus have an amino acid 
difference at position 110 in the CA, which determines their susceptibility to Fv1 
(172, 173). In addition to amino acid 110, surrounding residues in the CA also play a 
role in determining susceptibility to Fv1 (174). Protection from different MLV 
viruses of different tropisms was inherited dominantly. These observations 
suggested that Fv1 encoded a saturable factor that was able to restrict incoming virus 
recognised by its CA sequence. Once the Fv1 gene had been identified and cloned, it 
was found to be closely related to the gag gene of an endogenous retrovirus 
suggesting a retroviral origin (175).  
Fv1 mediates restriction early in infection, after reverse transcription and prior to 
integration, as identified by the presence of reverse transcripts, but lack of 
integration into the host genome (176, 177). Regions at the C and N terminus of the 
protein, and specific regions within the major homology region are required for 
restriction, although a large portion of the internal sequence is non-essential. 
Antiviral specificity is determined by sequences within the C terminal (178). The 
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protein functions as a dimer and requires dimerisation at the N terminal to restrict 
MLV (179). 
 
Pseudotyping with VSV-G provides MLV with a broad tropism and allowed the 
identification of another restriction factor in human cells, which was named 
resistance factor 1 (Ref1). Similar to Fv1, Ref1 can be saturated by high titres of 
restricted virus, but in contrast to Fv1, Ref1 restricts incoming virus before reverse 
transcription and reverse transcripts cannot be detected in non-permissive cells (180, 
181). These two restriction factors use different restriction mechanisms and when 
expressed in the same cell, compete for restriction of incoming MLV (182). The 
human Ref1 restriction factor was shown to restrict both N-MLV and equine 
infectious anaemia virus (EIAV) (183, 184). 
Studying restriction in primate cells found sensitivity to a set of retroviruses distinct 
to both human and murine cells. The simian restriction factor was named lentivirus 
susceptibility factor 1 (Lv1) and provided African green monkeys and rhesus 
macaques with a resistance to HIV-1. Lv1 had many functional similarities to Ref1; 
the reduction of viral reverse transcripts, the block to infection being most effective 
at low multiplicities of infection and saturation with large quantities of virus (185-
187). 
 
In 2004, the cytoplasmic body component TRIM5α was identified as the restriction 
factor responsible for the resistance of Old World monkeys to HIV-1 (188). Shortly 
after this discovery, TRIM5α was confirmed to be responsible for the restrictive 
activities previously accounted for by the restriction factors Ref1 and Lv1 (189, 
190). 
This TRIM protein family member caused a species specific block to retroviral 
infection as previously described. TRIM5α is typically ineffective against 
retroviruses exogenous to the host species, but often restricts those from other 
species, illustrating its important role in prevention of zoonotic transmission of 
retroviruses. For instance, TRIM5α from Rhesus macaque (rhTRIM5α) is a strong 
inhibitor of HIV-1, but not SIVmac, whereas in humans N-MLV and EIAV are 
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strongly restricted. Human TRIM5α (huTRIM5α) mediates mild restriction of HIV-2 
(191), but does not cause a significant inhibition to HIV-1. These species specific 
differences in restriction are attributed to CA sequence variation between viruses 
and subsequently, the ability of TRIM5α to recognise and bind the virus. Alteration 
of CA amino acid 110 will alter specificity of huTRIM5α between B- and N-MLV 
(192). There are even different restriction specificities within a species, for example 
in Rhesus macaques there are different TRIM5 alleles which have activity against 
different retroviruses. Throughout evolution selective pressure from viral infection 
has driven diversity in this gene (142, 193). Within humans, different TRIM5α 
polymorphisms or expression levels have little or no effect on HIV-1 infection or 
disease progression (194-196). 
Delivery of rhTRIM5α into human cells using lentiviral vectors as an ex vivo gene 
therapy has been proposed (197) but this method is likely to lead to problems with 
immune rejection as it is a foreign protein. However, huTRIM5α can be modified to 
provide specificity to HIV-1. Either transfer of a patch of rhTRIM5α B30.2 (198) or 
a single amino acid change at 332 in the human protein is sufficient to allow 
restriction of HIV-1 by huTRIM5α (199-201). Although HIV-1 is not susceptible to 
restriction by TRIM5α of some species, unlike for APOBEC and tetherin, the virus 
has not been able to evolve a mechanism to avoid the general restrictive effects of 
TRIM5α, making it a good therapeutic possibility. 
 
TRIM5α is a member of the large family of TRIM proteins, which has around 70 
human proteins with diverse roles. There are a similar number in mice, whereas in 
worms and flies there are approximately 20 and 10 members respectively, 
suggesting that the TRIM family has dramatically expanded throughout evolution 
(202). 
This family is characterised by its TRIpartite Motif (TRIM), which consists of a 
RING, B-box and coiled coil domains (RBCC). In addition to the RBCC domains, 
TRIM5α also includes a C terminal B30.2 or PRYSPRY domain. It is the B30.2 
domain that is responsible for binding of restricted virus CA and therefore the 
proteins specificity (200, 201, 203, 204). TRIM5 is alternatively spliced to produce 
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other isoforms, which are truncated from the C terminal. These include TRIM5β, 
TRIM5δ, TRIM5γ and TRIM5ε (205). The TRIM5δ and - γ isoforms, which lack the 
B30.2 domain, can act in a dominant negative fashion against TRIM5α by forming 
heteromultimers with TRIM5α, abolishing its antiretroviral activity (182, 192). 
These other isoforms may be involved in regulating TRIM5α activity. 
Subsequently, antiretroviral TRIM5α proteins have been identified in other non-
primate species, including rabbit (206), cattle (207, 208) and hare (209), that restrict 
various retroviruses in a species specific way. 
 
TRIM5 is ubiquitously expressed in all tissues throughout the human body, 
including stimulated, but not unstimulated peripheral blood lymphocytes which are 
the target of HIV (205, 210). Expression levels in many of these tissues are low, but 
TRIM5 expression is upregulated by IFN through a putative interferon-stimulated 
response element (ISRE) (211). As expression is IFN inducible, it supports the role 
of TRIM5 as an important factor in the innate immune system as IFNs have a key 
role in this system and inducing gene expression in response to viral infection. 
1.5.2 Protein structure of TRIM proteins 
1.5.2.1 The RING domain 
At the N terminus of the TRIM protein is the Really Interesting New Gene, or RING 
domain, which is a zinc finger binding domain present in a diverse range of different 
protein molecules. RING domains are typically 40-60 amino acids and are defined 
by the consensus sequence CX2CX(9–39)CX(1–3)HX(2–3)C/HX2CX(4–48)CX2C, 
with cystidine and histidine residues interacting with two zinc ions (212). 
RING domains have been shown to have E3 ubiquitin ligase activity and be 
involved in mediating specificity of E2 dependent ubiquitinylation and proteasomal 
degradation of proteins (213). Specifically, the RING domain of TRIM5α has been 
shown to be capable of self-ubiquitinylation, and can also be ubiquitinylated by 
another member of the TRIM family, TRIM21 (214). In addition to TRIM5α, E3 
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ubiquitin ligase activity has been shown for the RING domains of several other 
TRIM proteins, including TRIM11, TRIM21, TRIM22 and TRIM25 (215-218). 
The RING domain is required for rapid ubiquitinylation and proteasomal 
degradation (219). However, the role that the RING domain plays in antiviral 
activity of TRIM5α is unclear. Inhibition of degradation with proteasome inhibitors 
does not rescue viral infectivity (220-222), and truncated TRIM5α molecules with 
an absent RING domain experience only a partially reduced antiviral activity (223, 
224). 
1.5.2.2 The B Box 
Similar to the RING domain, the B-box is a zinc finger binding domain and is 
typically involved in protein-protein interactions. There are two different types of B-
box: B-box1 and B-box2. Although their sequences differ, their tertiary structures 
are similar to each other, and to the RING domain, suggesting a common ancestral 
domain. The presence of one or both B-box domains varies between different TRIM 
proteins. If a TRIM protein only contains one B-box, it is always B-box2, and if both 
are present, B-box1 precedes B-box2. Both TRIM5α and TRIM21 contain a B-box2 
(205). A B-box2 is made up of an α-helix and structured loop with two antiparallel β 
sheets. It also co-ordinates two zinc ions. 
Along with the RING domain, the B-Box is critical for rapid ubiquitinylation and 
proteasomal degradation (219). The B-Box 2 domain is also required for higher 
order multimerisation of TRIM5α (225, 226) and mutants lacking this domain do not 
restrict (204, 223). TRIM5α has been shown to assemble spontaneously into a 
hexagonal lattice from purified recombinant TRIM5-TRIM21 in vitro (227). 
However, formation was enhanced in the presence of HIV-1 CA assembled in vitro 
to mimic the viral core. Despite only a weak interaction between TRIM5α and 
retroviral CA monomers, the avidity between TRIM5α higher order structures and 
CA assembled in the core of a restricted virus is high, reflecting the importance of 
high order multimerisation (225).  
In addition to the B-Box, the L2 linker region located between the coiled coil and 
B30.2 domain is also required for this high order multimerisation, without which 
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TRIM5α loses its antiviral activity (228). This linker region is also required for 
cytoplasmic body formation. Sastri et al found that mutants lacking L2, and could 
not form cytoplasmic bodies, were unable to restrict virus. However, as L2 is also 
required for higher order multimerisation, it is thought that it is disruption of these 
structures, rather than cytoplasmic body formation, that abrogates restriction (228).  
1.5.2.3 The Coiled Coil 
In TRIM proteins, the B-box domain(s) is usually followed by a coiled coil domain, 
which is necessary and sufficient for homomultimerisation. Deletion of this domain 
results in a loss of the large aggregates normally seen with intact protein, to be 
replaced with diffuse localisation throughout the cell (205). 
In addition to the large multimers of TRIM5α that form, smaller multimers mediated 
by the coiled coil domain also form. It was originally thought that TRIM5α forms 
and functions as a trimer, but these experiments were limited by technical 
difficulties (229, 230). More recent biochemical analysis of purified recombinant 
protein consisting of TRIM5α with a TRIM21 RING domain shows TRIM5α 
actually forms dimers (231). Other studies have identified dimers and trimers, but 
more significant for restriction, higher order multimers, particularly hexamers, have 
been observed (232).  
The coiled coil is required for the binding of CA, along with the B30.2 domain, and 
contains residues that have been subject to selective pressure and can influence 
TRIM5α specificity against MLV. The RING and B-box are dispensable for this 
interaction (233, 234).  
1.5.2.4 The B30.2 domain 
There are different splice variants of TRIM5, but the longest TRIM5α includes a C 
terminal B30.2 domain that is responsible for the antiviral specificity of the protein 
(200, 201, 203, 224). SPRY domains are evolutionarily ancient and found in a 
diverse range of plants, animals and fungi, but the B30.2 domain has evolved more 
recently and is unique to vertebrates. B30.2 is made up of the evolutionary ancient 
SPRY domain, but has also incorporated a PRY domain (235). 
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TRIM5 and retroviruses have been co-evolving together for millions of years and 
this restriction factor may have played an important role in the control of spread of 
retroviruses within and between species (236). Regions within the B30.2 domain 
have been subject to high levels of selective pressure supporting its key role in 
antiviral specificity (237). Positive selection within this domain suggests co-
evolution of host restriction factors and viruses, with each providing selective 
pressure on the other to gain the advantage. The B30.2 is made up of two anti-
parallel β sheets, also with four loops that are located on one side of the B30.2 
domain and are hypothesised to interact with the viral CA (238). These loops are 
variable regions that exhibit substantial variation in both length and amino acid 
sequence, termed v1, v2, v3 and v4 (239). Variable regions v1-v3 determine the 
specificity of the TRIM5 antiviral activity.  
Deletion of the B30.2 domain results in a truncated protein that acts in a dominant 
negative fashion by dimerising with full length TRIM5α and abrogating its antiviral 
function (204, 223). 
 
TRIM5α is a modular protein and in some cases, it is possible for domains in the 
RBCC to be functionally replaced by those of other TRIM proteins. For instance, 
any of the RBCC domains of huTRIM5α can be functionally replaced by the 
corresponding domains of the paralogous proteins TRIM6 and TRIM34. Similarly, a 
chimeric protein generated by the substitution of the RING domain of rhTRIMα 
with that of huTRIM21, a more distant relative of TRIM5, retains its antiviral 
capabilities. However, substitution of the B-Box2 and flanking linker regions results 
in a protein which is unable to restrict viral infection. Therefore this domain is 
crucial for rhTRIM5α restriction of HIV-1 (240).  
1.5.3 Mechanism of TRIM5α restriction of HIV-1 
TRIM5α inhibits HIV-1 early in infection, as shown by the absence of reverse 
transcripts after viral entry (192). However, the exact process by which TRIM5α 
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restricts retroviruses has not been fully determined, although it is likely that TRIM5α 
mediates restrictive effects through several different mechanisms.  
 
TRIM5α recognises retroviruses when they enter cells via its B30.2 domain. 
However, the interaction between TRIM5α and CA has been difficult to 
characterise, indicating that it is a complex interaction and that recognition between 
two monomers is weak (241). TRIM5α initially forms dimers. Dimers can 
spontaneously form hexamers, but this is greatly enhanced in the presence of 
incoming viral CA. This mediates more efficient capsid binding with higher avidity 
and is required for efficient restriction. It is suggested that the hexameric structure of 
TRIM5α multimers allows multiple B30.2 domains to cover and interact with the 
incoming viral core with high avidity (227). 
Normally upon cell entry, the virus will undergo uncoating, which is a complex 
process that is not fully understood. Binding of TRIM5α in the cytoplasm can lead to 
accelerated and disrupted uncoating of the virus, preventing infection (233, 242-
244).  
TRIM5α can be ubiquitinylated, both by itself and other molecules (214), and 
degraded by the proteasome. The RING and B-box are required for proteasomal 
degradation of TRIM proteins. It is thought that this degradation is also carried out 
on the TRIM5α-virus complex, as there is proteasome-dependent degradation of 
TRIM5α upon infection of a restricted retrovirus (221). Inhibition of the proteasome 
results in formation of viral reverse transcripts and PICs in cells, but they are not 
detectable in the nucleus nor are there detectable 2-LTR circles. Therefore 
proteasome inhibition does not abrogate the antiviral activity of TRIM5α, but does 
rescue reverse transcription (220-222). This correlates with data that shows that 
proteasome inhibition or deletion of the RING domain does not abrogate antiviral 
activity and that TRIM5α mediates a proteasome independent antiviral activity prior 
to causing proteasome dependent destruction of both the virus and TRIM5. 
The proteasome independent inhibition is likely to be due to sequestering of the viral 
genome in either pre-existing aggregations of TRIM5, or by formation of new 
aggregates around virus particles. TRIM5α can also be seen to leave cytoplasmic 
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bodies to interact with nearby virus within the cytoplasm. This supports the notion 
that proteasomal degradation is needed for viral clearance, but is not necessary for 
restriction (245). These cytoplasmic bodies form when TRIM5α is overexpressed, 
but are also found at low levels of expression (205). TRIM5 varies between 
localisation in cytoplasmic bodies and more diffuse distribution throughout the 
cytoplasm (246). However, disruption of cytoplasmic bodies with geldanamycin, an 
Hsp90 inhibitor, does not prevent viral restriction, therefore their formation is not 
essential (247, 248). 
Recently human and Rhesus TRIM5α have been shown to shuttle between the 
cytoplasm and nucleus, and inhibition of CRM1 nuclear export machinery results in 
accumulation of TRIM5α in the nucleus. This was not seen in TRIM5α from cattle, 
New World monkeys or TRIMCyp. In the nucleus, TRIM5α co-localised with 
TRIM19 in nuclear domain 10 (ND10) structures (249). TRIM19 is thought to be 
involved in restriction of herpes simplex virus, so TRIM5 may be involved in this 
function. Accumulation of TRIM5α in the nucleus did not abrogate TRIM5 
mediated retroviral restriction, although it is likely that residual cytoplasmic protein 
or newly synthesised TRIM is responsible for restriction. The importance of nuclear 
shuttling of TRIM5α is not known, and may be involved in as of yet unrecognized 
functions. 
 
In addition to CA recognition and interaction with incoming virus, TRIM5α has 
been identified as playing a role in cell signaling in innate immunity. Independent of 
the B30.2 domain responsible for CA recognition, TRIM5α affects NFκB signaling 
through two different pathways, and the involvement of TRIM5 varies between 
species. Human TRIM5α and the mouse paralog TRIM30 downregulate NFκB 
signaling through proteasome independent degradation of TAB2, an adaptor protein 
upstream of NFκB. In contrast, human and Rhesus TRIM5α are able to activate 
NFκB expression. The relative activity of these two opposing effects upon NFκB by 
the human protein are thought to depend upon TRIM5α levels (250). TRIM30 also 
interacts with the TAK1-TAB2-TAB3 complex. It acts downstream of toll-like 
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receptor (TLR) activation to promote TAB2 and TAB3 degradation causing 
downregulation of NFκB signaling (251). 
TRIM5α activates NFκB signaling in conjunction with UBC13-UEV1A, an 
ubiquitin-conjugating enzyme. Together they assemble unattached K63-linked 
ubiquitin chains that activate the TAK1 kinase complex. TAK1 subsequently 
stimulates AP-1 and NFΚB transcription factors involved in innate immune signaling 
(252). This mechanism for NFκB signaling is similar to that mediated by TRAF6, a 
RING containing E3 ubiquitin ligase, which also synthesises K63-linked ubiquitin 
chains which activate IKK and TAK1 and subsequently NFκB (253, 254).  
The formation of ubiquitin chains and activation of NFκB signaling is significantly 
enhanced upon CA recognition. Prevention of formation of these chains through 
knockdown of UBC13 or UEV1A abrogates huTRIM5α restriction of susceptible 
retroviruses, such as EIAV. Through this function, TRIM5α and TRIM5Cyp act as a 
pattern recognition receptors as recognition of a restricted retroviral CA enhances 
the activation of NFκB signaling and innate immune response (252).  
1.5.4 TRIM21 
In humans there are a large number of TRIM proteins and many members of this 
protein family have been shown to play an important role in innate immunity. 
Screening the TRIM protein family has identified their role in various aspects of 
different retroviral lifecycles (255). Also, many of the proteins are IFN inducible, 
supporting the evidence that they play a role in innate immunity (256). 
The defining characteristic of the family is the RBCC motif at the N terminal, with 
the main differences in protein structure residing in the C terminal domains. 
However, the conserved RBCC domains are of interest as they are often responsible 
for the protein’s function, in particular the RING domain. The E3 ubiquitin ligase 
activity of the TRIM RING domain is often crucial for the general function and 
antiviral activity of the protein. 
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One member of the TRIM family which has been shown to play an important role in 
immunity is TRIM21 or Ro52/SS-A. Excluding the TRIM5 paralogs that are located 
in the same gene cluster (TRIM6, 22 and 34) (205), the most closely related protein 
to TRIM5 is TRIM21 (239). The TRIM21 gene is located in the same cluster as 
TRIM5 (11p15) (205) and the proteins have the same RING, B-box2, coiled coil and 
B30.2 domain structure (202).  
TRIM21 was until recently most commonly known as the autoantigen in various 
autoimmune diseases, including Sjögrens disease and systemic lupus erythematosus 
(SLE) (257). Anti-TRIM21 antibodies are used as a diagnostic for such diseases, and 
can act as an indicator of disease progression. 
TRIM21 is ubiquitously expressed in adult cells and forms cytoplasmic bodies 
within cells (205). These cytoplasmic bodies are highly motile, and despite the 
similarities, are distinct to those of TRIM5α (258). TRIM21 forms trimers (259). 
However the technique used to identify this could be susceptible to the same 
inaccurate reading as with TRIM5α, which then turned out to function and bind CA 
as a dimer (231). Other groups using alternative methodologies have suggested that 
TRIM21 forms dimers (230, 260, 261). TRIM21 has low background levels of 
expression, but like TRIM5 is upregulated upon IFNγ stimulation, suggesting it 
plays a role in immune response (262).  
 
As well as the interaction with autoantibodies, TRIM21 also binds IgG heavy chains 
with high affinity in mammalian cells (263). TRIM21 binds IgG via two binding 
pockets within its B30.2 domain (259, 264) through a novel mechanism, which was 
structurally and kinetically highly conserved between species (265).  
It was unexpected that an intracellular protein would bind antibodies with such a 
high affinity, driving speculation that TRIM21 functioned as a receptor for 
internalised opsonised pathogens. Recently, the mechanism that TRIM21 mediates 
was revealed, and its role in inhibiting infection of adenovirus was reported. This 
confirmed the importance of TRIM21 as an intracellular IgG receptor (266). Once 
antibodies have recognised and opsonised virus, the complex enters cells and the  
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IgG domain is bound by TRIM21. TRIM21 targets this viral complex for 
proteasomal degradation via its E3 ubiquitin ligase domain, most likely through 
autoubiquitinylation (266). TRIM21 therefore is involved in a novel antiviral 
mechanism that bridges both the innate and adaptive immune systems. 
 
TRIM21 plays an additional role by its involvement in IFN signaling, which is vital 
to the innate immune response against both viruses and bacteria. The family of IFN 
regulatory factors (IRF) transcription factors play an important role in IFN 
expression following pathogen recognition. IRF1, 3, 7, and 9 have all been 
suggested to play a role in type I IFN (α/β) gene expression. 
IRF3 is an important transcription factor involved in IFN production. It is 
constitutively expressed and involved in the initial expression of IFN following 
infection. In vitro experiments have produced conflicting results as to whether 
TRIM21 causes degradation of IRF3, or whether is it critical for its sustained 
activation (267, 268). TRIM21 interferes with the interaction between Pin1 and 
IRF3, preventing IRF3 ubiquitinylation and degradation. B30.2 is essential for this 
function, but the RING domain is dispensable, suggesting that ubiquitination is not 
required. Stabilisation of IRF3 promotes an antiviral response by maintaining IFN 
signaling (268). Alternative results suggest that TRIM21 interaction with IRF3 via 
its B30.2 domain, leads to its ubiquitinylation and proteasomal degradation, 
restricting downstream signaling via IFNβ. This can be prevented by proteasome 
inhibitors or depletion of TRIM21 using shRNA. This action requires both the RING 
and the B30.2 domains (267). It is still unclear which mechanisms TRIM21 mediates 
in vivo. 
Additional evidence supporting the involvement of TRIM21 in an IFN negative 
feedback loop in vitro shows that it is able to ubiquitinylate IRF7, which has a 
similar structure to IRF3. This targets IRF7 for proteasomal degradation preventing 
prolonged immune activation via the IFNα pathway (269, 270). 
E3 ligases can also play a role in processes independent of proteasomal degradation, 
including transcriptional regulation. For instance TRIM21 ubiquitinylates IRF8, 
which is a transcription factor involved in IFNγ mediated expression of pro-
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inflammatory cytokines, including IL-12p40 and type I IFNs. Rather than promoting 
its degradation, TRIM21 mediated ubiquitinylation leads to enhanced IL-12p40 
release via IRF8. Again, the B30.2 domain of TRIM21 is critical for this interaction 
with IRF8 (271). 
TRIM21 expression is also upregulated by IFN (262) meaning that it could be 
involved in an IFN feedback loop when combined with its actions on different IRFs. 
 
The role of TRIM21 was further investigated by production of TRIM21 knockout 
mice. Two groups independently produced mice using GFP to replace TRIM21 
exons, allowing study of the TRIM21 expression pattern. TRIM21 was found to be 
broadly expressed, with particularly high expression in the lymphoid compartment 
of spleen, lymph node and thymus, with little expression found in non-immune 
tissue (272, 273). Despite the similarities in expression pattern, the two studies 
produced mice with different phenotypes, the reasons for which are not clear. 
Yoshimi et al found that knockdown of TRIM21 did not affect viability, growth or 
fertility, and development of the immune system occurred as normal. Embryonic 
fibroblasts were seen to have increased pro-inflammatory cytokine production 
through TLR induced NFκB signaling suggesting it plays a role in modulating 
signaling (273). Subsequently, TRIM21 was shown to negatively regulate NFκB 
signaling through monoubiquitinylating IKKβ, targeting it for autophagosomal 
degradation (274, 275). Upregulation of related TRIM molecules was also seen in 
embryonic fibroblasts, suggesting compensation of TRIM21 by related proteins 
TRIM12, -30 and -34. There was reduced ubiquitinylation of IRF3 and IRF8 in 
knockout mice, but this did not lead to an alteration in expression of IFN induced 
genes.  
This phenotype was in contrast to that seen in the other TRIM21 knockout generated 
by Espinosa et al (272). Although generally there appeared to be no differences 
between wild type and knockout mice, after ear notching knockout mice developed 
severe dermatitis around the wound. This led to uncontrolled inflammation and 
development of systemic autoimmunity mediated through the IL-23-Th17 pathway. 
IRF5 was also identified as being ubiquitinylated and degraded by TRIM21 (272). 
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The reasons for these differences are not known, but it is though that the different 
gene knockout strategies used could be responsible. Yoshimi replaced TRIM21 
exons 3-5, which included the translational start site, with GFP resulting in 
eradication of TRIM21 transcripts. Espinosa et al replaced exons 5-8 with GFP, 
which theoretically could lead to production of a truncated protein encoded by exons 
1-4. This truncated protein may interfere with normal TRIM21 function and act in a 
dominant negative fashion (273). 
1.6 Cyclophilins 
1.6.1 The cyclophilin family 
Another protein that interacts with HIV-1 and plays an important role in its lifecycle 
is the peptidyl-prolyl isomerase (PPIase), cyclophilin A (CypA). Proline residues in 
proteins can exist in either a cis or trans conformation, and the intrinsic switch 
between the two forms is very slow, unless catalysed by PPIases. These enzymes 
can be divided into four structurally distinct families called cyclophilins (Cyps), 
FK506-binding proteins (FKBPs), the parvulins and Ser/Thr phosphatase 2A 
activator (PTPA) (276). PPIases are a conserved family of proteins found in all 
bacteria and eukaryotes. This high level of conservation suggests that they play a 
role in a fundamental process conserved between species. 
Humans express at least 17 Cyps, including proteins that contain cyclophilin-like 
domains. They vary in size and some contain additional domains to the Cyp moiety. 
The smallest is the 18kD CypA and the largest is the nuclear pore protein Nup358, 
also called RanBP2, which in addition to its Cyp domain includes Leu-rich, zinc 
finger and Ran-binding domains. 
Particular interest has been shown towards cyclophilins as they interact with 
cyclosporine A (CsA), a fungal metabolite that is used as an immunosuppressive 
drug following allogeneic transplantation (277). CypA is the predominant 
cyclophilin involved in CsA mediated immunosuppression, as CypA knockout mice 
require greatly elevated concentrations of the drug to illicit an effect (278).  
56 
 
CsA interacts with the binding pocket in CypA, interfering with substrate binding 
substrates and preventing PPIase activity. This CypA-CsA complex also inhibits 
calcineurin, a calcium activated serine/threonine phosphatase (279). Calcineurin is 
responsible for dephosphorylation of the nuclear factor of activated T cell (NFAT) 
family of transcription factors downstream of the TCR involved in T cell activation 
(280, 281). Once dephosphorylated, the NFAT transcription factors become 
activated and are translocated to the nucleus. Inhibition of calcineurin prevents 
NFAT dephosphorylation and consequently prevents signaling downstream of the 
TCR, such as cytokine expression. This restricts T cell activity, preventing organ 
rejection after transplant. This function is independent of the PPIase activity of 
CypA. 
 
CypA is a widely expressed, highly conserved protein found in both the cytosol 
(282) and nucleus (283). It is a globular protein consisting of a β barrel made up of 
eight anti-parallel β sheets, capped at either end by an α helix. A hydrophobic pocket 
forms the binding site and catalytic site for proline peptides (284). 
Different natural functions of Cyps have been proposed. They are thought to be 
involved in the correct folding of a range of proteins as cis/trans isomerisation is 
often the rate limiting step in protein folding, with the trans isomer the energetically 
favoured state. Cyps have been shown to mediate folding of a range of proteins, 
including collagen (285), carbonic anhydrase (286) and ribonuclease T1 (287). 
Independently of their PPIase activity, they have been shown to act as protein 
chaperones. They prevent aggregation of incorrectly folded proteins leading to an 
increased yield of correct folded protein, in addition to catalysing protein folding 
through PPIase activity (286, 288). However, these activities have only been 
observed in vitro. 
Another proposed role of Cyps is in cell signaling, and this is supported by in vivo 
data. CypA knockout mice have normal development and lifespan, but some mice 
develop spontaneous allergic disease driven by Th2 cells. CypA downregulates Th2 
cytokine expression by interacting with the IL-2 tyrosine kinase, Itk. CypA interacts 
with a proline residue in the SH2 domain of Itk, which acts a molecular switch by 
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promoting homodimerisation of Itk, preventing it from mediating downstream 
signaling (289).  
1.6.2 Role of cyclophilins in the HIV-1 lifecycle 
CypA is probably the most extensively studied PPIase due to its ability to interact 
with HIV-1, and the key role that it plays in the virus lifecycle. CypA and B were 
found to bind to HIV-1 Gag protein (290), although only the interaction with CypA 
has been recorded in vivo. CypB is localised to the endoplasmic reticulum and is not 
thought to have the opportunity to interact with either incoming or outgoing Gag 
(291). The active site of CypA binds to the G89-P90 peptide bond located on a nine 
amino acid flexible loop (P85-P93) in the N terminus of the CA, and catalyses 
cis/trans isomerisation of the bond (292, 293).  Nuclear magnetic resonance studies 
show that this bond can be found in either the cis (14%) or the trans (86%) 
conformations (294). G89-P90 is the bond primarily responsible for CypA binding, 
and mutation of either G89 or P90 will abrogate CypA binding. The surrounding 
residues P85, V86, H87, A88, P93 are also involved in binding (295).  
The interaction between CA and CypA results in its incorporation into newly 
synthesised HIV-1 virions at a ratio of ten CA molecules to one CypA. Incorporation 
can be abrogated by treatment of producer cells with CsA, mutating the G89-P90 
proline peptide bond within the CA or knockdown of the CypA gene, leading to a 
block in HIV-1 infection early after cell entry (88, 89, 295, 296). Despite its 
inclusion in virions, the presence of CypA in the target cell, rather than in the virus 
producing cell, is required for infectivity (297, 298). The relevance of virion 
incorporated CypA has not been elucidated. However, treatment of producer cells 
with CsA decreases infectivity of virions in a CypA independent manner, even when 
producing G89V mutant virions that do not bind CypA (297). Binding of CypA is 
not a conserved ability between all lentiviruses, but HIV-1, SIVagm and FIV have 
been shown to be targeted by CypA. 
Although it is now known that it is CypA in the target cell that influences infection, 
the role that the enzyme plays in host cells is not known. CypA acts upon incoming 
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HIV-1 particles soon after entry and before reverse transcription, at the same time as 
TRIM5α restriction in non-human primates occurs (299). It is thought that CypA 
binding to incoming HIV-1 CA protects the virus from restriction and that altering 
the isomerisation state of the proline bond may make the CA more recognisable to 
restriction factors such as TRIM5α. This is supported by the fact that CypA causes a 
range of effects on infectivity, both cell type and species specific, indicating 
interaction with other proteins and not solely on CypA assisting viral uncoating 
(300). Disruption of the CypA-CA interaction through CsA treatment or knock down 
of CypA by shRNA leads to HIV-1 restriction in human cells independently of 
TRIM5α (301). 
 
Generally binding of CypA to incoming HIV-1 CA is required for proper infectivity. 
However, it is now known that the interaction between CA and CypA is much more 
complex. 
Culture of HIV-1 in CD4
+
 HeLa cells in the presence of CsA results in the evolution 
of viral strains bearing mutations within the CypA binding loop of Gag; A92E and 
G94D. Although these mutants retain the ability to bind CypA, unlike wild type 
HIV-1 they are CsA dependent. In this instance, CA-CypA interactions appear to be 
detrimental to virus infectivity. Disruption of the CA-CypA interaction with CsA, 
knockdown of CypA or additional mutations that prevent CypA binding, rescue viral 
infection. Removal of CsA from culture results in reversion back to the wild type, 
CsA sensitive phenotype (302, 303). These CA mutants are therefore susceptible to 
CypA mediated restriction. The mechanism is not known, but it occurs after nuclear 
entry and before integration, as shown by the increased buildup of 2-LTR circles. 
This restriction is enhanced by cell cycle arrest (304-306).  
An important feature of the HIV-1 lifecycle is the ability to infect non-dividing cells. 
The factors responsible for this have still not been established, but CA has been 
suggested to play a role. Substitution of HIV CA with MLV CA or introduction of 
single amino acid mutations in the CA resulted in virus that showed reduced 
infectivity in arrested cells (41, 43). The enhancement of CypA restriction of CA 
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mutants upon cell cycle arrest provides further evidence of the involvement of CA in 
infection of non-dividing cells. 
Interestingly, the CsA dependence of these CA mutants is only seen in infection of 
particular cell lines, for instance HeLa and H9 cells. Jurkat, human osteosarcoma 
(HOS) and TE671 cells are able to support replication of these mutants even in the 
absence of CsA (298).  
One proposed explanation for the variability seen between cells of the effects of 
CypA and CsA on infection is thought to be due to different CypA expression levels 
in cells. HeLa cells have higher levels of CypA than Jurkat and TE671 cells. CA 
mutants are CsA dependent in HeLa cells, which is thought to be due to the high 
CypA expression levels. CypA has been proposed to be involved in the regulation of 
CA uncoating (307) and may target the mutated CA more efficiently leading to 
disruption of normal uncoating. Infection could be restored to wild type levels in 
HeLa cells treated with CsA or by siRNA knockdown of CypA. This indicates that 
the block to infection is CypA dependent. Increasing CypA levels in TE671 cells 
results in the same restriction pattern seen in HeLa cells (306). 
However, CypA levels alone are not able to explain the biphasic response to CsA 
dose seen in viral infection by primary isolates. In cells with similar CypA 
expression levels increasing CsA dose may or may not cause an increase in 
infectivity. This implies the involvement of other factors in addition to CypA. 
Similarly, TRIM5α levels and CA polymorphisms alone cannot explain the pattern 
of inhibition seen by treatment of cells with high doses of CsA. This suggests that 
there may be two factors with opposing effects within a cell that are influenced by 
the CA-CypA interaction. The effect that a particular dose of CsA has on infectivity 
depends upon the relative levels of these factors within the particular cell type (308). 
There could be a host restriction factor that is able to target the CA-CypA 
interaction. For instance in heterokaryons of CsA dependent and independent cells, 
the dependence is conferred between cells, supporting the hypothesis of a dominant 
cellular restriction that targets CA-CypA (309). 
Inhibition of CA-CypA interactions results in a virus strain specific effect and can 
cause an increase, decrease or no change in infectivity. Disruption of CA-CypA 
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interaction generally caused an increase in the susceptibility of HIV-1 strains to 
huTRIM5α restriction, but this effect is both strain specific and TRIM5α allele 
specific (310). 
Although the presence of CypA in target cells is generally required for HIV-1 
infection in human cells, its role is species specific. In many non-human primate 
cells the CypA-CA interaction actually enhances TRIM5α mediated restriction. This 
is possibly by CypA mediated isomerisation that may make the viral CA more 
efficiently bound by TRIM5α (or unknown restriction factors) (311, 312) or by 
stabilising the CA core and increasing the time for recognition by TRIM5α. 
However, even in the absence of CypA or when disrupting the CypA-CA interaction 
using the G89V mutation, TRIM5α is still able to restrict HIV-1 in Old World 
monkey cells to some extent (233).  
 
Mutations in gag sequence and subsequent interactions with host factors, including 
TRIM5 and CypA, can cause significant effects in viral fitness and greater 
understanding of these interactions could allow exploitation of these systems in the 
future in antiviral therapies. 
1.6.3 TRIMCyp fusion proteins 
The species specific antiviral activity of TRIM5α confers resistance to HIV-1 in Old 
World monkeys and SIVmac in New World monkeys. Despite it being common 
amongst Old World monkeys for TRIM5α to confer resistance to HIV-1, most New 
World monkey cells are susceptible to infection by this virus (313). An exception is 
the New World owl monkey, of the genus Aeotus, due to expression of a fusion 
protein between TRIM5 and CypA. This has arisen from the LINE-1 (L1) mediated 
retrotransposition of a CypA cDNA into the TRIM5 intron 7 resulting in an in-frame 
fusion between exons 2 to 7 of TRIM5 and an entire CypA cDNA. CypA replaces 
the B30.2 domain that is encoded by exon 8, and is linked to the RBCC domains of 
TRIM5 via 11 amino acids encoded by the CypA 5’ UTR. Owl monkeys are 
homozygous for this altered gene and do not have any other TRIM5 alleles. The owl 
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monkey TRIM5-CyclophilinA (omTRIM5Cyp) fusion protein is a strong inhibitor 
of HIV-1, due to the ability of CypA to bind HIV-1 CA and recruit the TRIM5 
RBCC domains, and is responsible for the resistance of owl monkey cells to this 
virus. Inhibition can be overcome by treatment with CsA or the use of G89V HIV-1 
mutants (314, 315). omTRIM5Cyp also restricts FIV and SIVagm, but leaves cells 
from this species susceptible to SIVmac (316).  
 
There has been a second incident of retrotransposition of CypA into TRIM5 in Old 
World monkey macaques, including rhesus macaques (Macaca mulatta), pig-tailed 
macaques (Macaca nemestrina) and crab eating macaques (Macaca fascicularis) 
which, due to the different location of the Cyp DNA in the TRIM5 gene, is most 
likely to have occurred independently of the owl monkey event (231, 317-319). The 
resultant protein is encoded by exons 2 to 6 of TRIM5, with the CypA cDNA 
replacing exons 7 and 8, in contrast to the owl monkey fusion that is encoded by 
exons 2 to 7 of TRIM5 and the CypA cDNA. The antiviral specificity of this fusion 
protein is also distinct to the owl monkey, with the rhesus TRIM5Cyp being a strong 
inhibitor of HIV-2, HIV-1 group O and FIV, but not HIV-1 group M. This 
difference in restriction specificity is due to variations in the Cyp domain of 
rhTRIM5Cyp compared to that of the genomic Cyp, altering the configuration of the 
active site loop (320). Furthermore, TRIM5Cyp alleles from different macaque 
species also have diverse antiviral specificities due to additional mutations in their 
Cyp domains (321). 
The proline-rich CypA binding loop is highly conserved amongst primate 
lentiviruses, as well as FIV and EIAV (316), suggesting that it plays an important 
role in a conserved function. This would reduce the probability of the development 
of TRIM5Cyp resistant escape mutants. 
 
Despite the differences in specificity of the macaque and owl monkey TRIM5Cyp 
proteins, the mechanism of restriction is similar, causing a block in infection before 
reverse transcription which can be abrogated by CsA treatment or mutation of the 
TRIMCyp binding site on the viral CA. As with TRIM5α, the mechanism of 
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antiviral restriction has not been fully confirmed, but it is also likely to function 
through multiple actions. Restriction occurs rapidly after viral entry into the cell 
before reverse transcription, and does not require ubiquitin mediated proteasomal 
degradation or cytoplasmic body formation. TRIMCyp does form cytoplasmic 
bodies, although this is not essential for restriction (247). Deletion of the RING 
domain causes a reduction in restriction, and deletion of the RING and B-Box2 
domains eliminates restriction (316) implying that they are important for efficient 
inhibition. 
Like TRIM5, TRIM5Cyp forms multimers, and dimers, trimers and hexamers have 
all been identified. Multimerisation is mediated by the coiled coil domain, and this 
domain alone is sufficient to interact with full length TRIM5Cyp. This interaction 
means that mutated TRIM5Cyp proteins can elicit a dominant negative effect on 
native TRIM5Cyp in owl monkey cells (316)
,
(232). The L2 region, which is critical 
for the higher order multimerisation and therefore antiviral activity of TRIM5α 
(228), is present in all naturally occurring primate TRIM5Cyp proteins. 
Like TRIM5α, TRIM5Cyp has been shown to disrupt CA cylinders in vitro, 
suggesting that at least one mechanism of antiviral activity is through interference 
with uncoating (243). 
 
Human (322) and feline (323) TRIM5Cyp fusion proteins have been generated and 
are able to restrict HIV and both HIV and FIV respectively. Human TRIM5Cyp was 
able to restrict HIV-1 at levels comparable to the owl monkey fusion protein when 
expressed in cell lines and primary T cells and macrophages. It was also able to 
provide robust restriction of HIV-1 in a humanised mouse model of HIV-1 (322). 
Also TRIMCyp fusion proteins have been generated using alternative TRIM proteins 
to TRIM5, but that have the same domain structure (TRIM1, 18 and 19) (324) and 
Cyp has been fused to Fv1 to produce an inhibitor of HIV-1 (325). 
These data suggest that fusion of CypA to the effector domain of restriction factors 
mediates recruitment to the virus through CA binding and is an effective method for 
the generation of HIV-1 restriction factors. 
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1.7 Targeting CCR5, an HIV-1 co-receptor 
1.7.1 Identification of CCR5 as an HIV-1 co-receptor 
In addition to the primary receptor CD4, HIV-1 requires the presence of a co-
receptor to allow virus entry into a cell. Two co-receptors have been identified; 
CCR5 (5-9)  and CXCR4 (10), which are used by R5 tropic and X4 tropics HIV-1 
strains respectively. CCR5 and CXCR4 tropic strains were initially identified by the 
cell type which they were able to infect and consequently were named macrophage 
tropic and T cell tropic respectively. Dual tropic strains were identified as being able 
to replicate in both cell types. 
 
Both CCR5 and CXCR4 are structurally similar chemokine receptors belonging to 
the superfamily of G protein coupled receptors and expressed on haematopoietic 
cells. Chemokines bind these receptors and activate intracellular signaling pathways 
involved in a variety of different cellular functions, particularly chemotaxis and cell 
migration and recruitment to sites of inflammation. 
CCR5 is predominantly expressed on macrophages and particular subsets of CD4
+
 T 
cells, typically those with a memory phenotype (326), and plays a role in 
haematopoiesis and inflammation. The natural ligands for CCR5 include RANTES, 
MIP-1α and MIP-1β and they can reduce infection by R5 tropic strains by competing 
with HIV-1 for the co-receptor and causing internalisation of the receptor, reducing 
the opportunity for viral binding (327). CCR5-tropic (R5) HIV-1 strains are the most 
common, are primarily responsible for viral transmission and are the predominant 
strain during initial infection (328). 
CXCR4 is highly expressed on both CD4
+
 and CD8
+
 T cells, with around 90% of 
CD4
+
 cells also expressing CXCR4. In addition, CXCR4 is also expressed on 
haematopoietic stem/progenitor cells and, with its ligand SDF-1α, plays an 
important role in their migration and haematopoiesis.  
X4 HIV-1 strains become more prevalent throughout infection, typically at the onset 
of disease symptoms (111). It is debatable whether these strains are co-transmitted 
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with R5 viruses in the initial infection and then remain latent or suppressed until 
immunity wanes. Another theory is that R5 tropic strains evolve to use different co-
receptors, from CCR5, through a dual tropic stage before developing a strong 
affinity to CXCR4 in later stage disease. After their appearance there is often rapid 
loss in T cells, particularly naïve cells, targeted due to their high levels of CXCR4 
expression (329). 
In vitro evidence suggests that some HIV-1 strains can use other seven 
transmembrane receptors in placement of CCR5 and CXCR4 alongside CD4, such 
as CCR2 (8), CCR3 (6), CCR8 (330), BOB and Bonzo (331). However, there is 
insufficient evidence to fully appreciate the role that these additional receptors play 
in vivo. 
 
A small population of individuals who, despite repeated exposure to HIV-1, did not 
develop infection were found to be homozygous for a 32 base pair deletion (Δ32) in 
the CCR5 gene. This deletion results in a frame shift and expression of a truncated 
form of the receptor (332, 333). Absence of CCR5 from the cell surface means that 
R5 strains of HIV-1 are unable to infect target cells. Also the truncated form of the 
protein is thought to enhance HIV-1 resistance by sequestering CXCR4 from the cell 
surface, reducing infection by X4 virus in addition to there being no entry via CCR5 
(334). Although it is rare, Δ32 homozygotes can still become infected with HIV-1, 
either by X4- or dual-tropic strains of virus. 
CCR5 Δ32 heterozygotes express reduced levels of cell surface CCR5 (326), but this 
does not provide resistance to infection. However there is evidence to show that their 
loss of CD4
+
 cells is slower and onset to AIDS is later compared to those with the 
wild type genotype (335, 336). 
Importantly, individuals homozygous for the Δ32 mutation appear to have no 
defective phenotype due to this mutation, indicating redundancy in the role of 
CCR5. However, reports have suggested that CCR5 Δ32 homozygotes have an 
increased susceptibility to West Nile virus (337) and tickbourne encephalitis virus 
(338). Despite this, CCR5 remains a desirable target in anti-HIV therapy to mimic 
this naturally occurring protection against infection. 
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Recently substantial support for the theory of targeting CCR5 as an anti-HIV therapy 
has emerged from the allogenic transplant setting. An HIV-1 infected man 
developed acute myeloid leukaemia and received an allogenic transplantation of 
CD34
+
 peripheral blood stem cells from an HLA-identical donor homozygous for 
the Δ32 CCR5 mutation (339). The patient suffered relapse of the leukaemia nearly 
one year later so received a second transplant from the same donor, resulting in 
complete remission of leukaemia. He also discontinued HAART at this time, which 
on previous occasions had led to a rapid viral rebound. However, following the 
second stem cell transplantation, HIV has been undetectable for more than 3 years 
without any administration of HAART (339, 340). Interestingly, although the patient 
had X4 tropic strains of virus before the transplant, these remained quiescent 
following the transplant. It is not known why these strains of virus did not continue 
replicating despite CXCR4 expressing target cells still remaining. It is possible that 
either the level of virus or number of target cells following transplantation were too 
low to facilitate viral rebound. 
Allogenic transplant, which requires myeloblation and immune suppression, is not a 
viable option for wider treatment of HIV-1. In addition, the likelihood of obtaining 
an HLA matched, Δ32 homozygote donor is very low, with only around 1% of the 
Caucasian population being of this genotype. 
Although only a single case, this successful treatment of an HIV-1 patient is the first 
documented functional cure and has confirmed the validity of CCR5 as a potential 
target in anti-HIV therapy. It also shows that delivery of an HIV-1 resistant 
population of cells to an infected individual can lead to repopulation of the immune 
system and apparent eradication of infection. There are many different groups 
working on various methods to disrupt CCR5 expression to prevent HIV-1 infection 
of cells. Amongst these, include the use of shRNA (341), ribozymes (342), 
intrabodies (343) and drugs, such as Maraviroc (344). One method that shows 
particular promise is the use of zinc finger nucleases (ZFNs) to specifically target 
and disrupt the CCR5 gene. 
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1.7.2 Generation of zinc finger nucleases (ZFNs) 
ZFNs are chimeric nuclease proteins that are engineered to target a specific DNA 
sequence and induce a double stranded break (DSB). They are synthesised by 
assembling Cys2His2 zinc finger (ZF) DNA binding domains to the catalytic domain 
of FokI, a non-specific endonuclease (345). The ZFs are proteins motifs that consist 
of an α helix and an antiparallel β sheet folded around a zinc ion, which bind DNA 
by insertion of the α helix into the DNA major groove. Three or four ZFs, which 
each typically bind three base pairs of DNA, are combined in each ZFN resulting in 
a 9-12 nucleotide recognition site (346). This string of ZFs is fused to a FokI 
monomer, which must dimerise to function and cause a DSB (347). Therefore two 
ZFNs are required to bind on opposite strands of DNA and with correct spacing to 
allow FokI dimerisation and subsequent double strand DNA cleavage between the 
two ZFNs. Dimerisation means that the total nucleotide recognition site is 18-24 
nucleotides long, providing high specificity. The FokI domains have been modified 
so that they can only function as heterodimers (348). Preventing homodimerisation 
further improves specificity of the ZFNs, as they will only cleave DNA when 
correctly paired. Adjusting the spacing between the two binding sites and linker 
length in the ZFN between ZF and FokI affects the efficiency of cleavage (349).  
 
For this technology to be an effective therapy applicable to different diseases, ZFNs 
must be able to target a range of loci. The modular assembly of ZFNs has enabled 
them to be designed to target a large number of genomic sequences and 
theoretically, a ZFN site can be located approximately every 150bp within the 
genome. 
ZF motifs recognise and bind a 3bp DNA sequence, and the most simple method of 
generating ZFNs with a particular target site is modular assembly, by which ZFs 
with a known target sequence are joined together. However, as the binding 
specificity of each ZF is not independent of its neighbours, the target site of a string 
of ZFs does not simply match the sequence of the individual motifs. Therefore there 
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is only a low success rate of approximately 6% in producing ZFN pairs using this 
method, and high levels of associated off target toxicity (350). 
A more advanced method termed context dependent or sequential selection takes 
into account the influence of neighbouring ZFs and its position within the ZFN. The 
ZFs are selected one by one, allowing optimisation of binding of each ZF in the 
context of it neighbour (351). However, this method is labour intensive as it requires 
screening of each ZF motif and is therefore not practical for most laboratories, 
although it does generally result in highly specific ZFNs (351, 352). 
Sangamo, a biopharmaceutical company which is a leader in the field of ZFN 
technology, uses a library of ZF protein pairs and combines these to produce a four 
fingered protein, using algorithms to predict the interaction between them and how 
this may influence binding specificity. Both the library and the algorithms used are 
exclusive to Sangamo and therefore cannot be utilised by other researchers to design 
novel ZFNs. 
In contrast, a publically available source developed by the Zinc Finger Consortium, 
a collaboration between different academic laboratories, allows production of ZFNs 
using Oligomerised Pool Engineering (OPEN) technology (353). This consists of a 
library made up of different pools each containing fingers which bind to a particular 
DNA triplet depending on where in the string of ZFs they are found. OPEN requires 
192 pools; 64 different possible DNA triplets, targeted by a ZF in three possible 
different positions within the ZFN. ZF motifs are then selected from these different 
pools and tested for specificity in a bacterial two-hybrid (B2H) system. Again, this 
method of ZFN assembly provides more specific and therefore less toxic proteins 
than modular assembly (353). 
Whichever method is used to design ZFNs, it is important that the specificity is 
confirmed. The location and frequency of off target cleavage must be identified, and 
the subsequent toxicity on modified cells measured for the most efficient effect. 
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1.7.3 ZFNs as a tool for gene therapy 
Once a genomic locus has been targeted by a pair of ZFNs and a DSB introduced, it 
can be repaired by two different mechanisms; non-homologous end joining (NHEJ) 
or homology directed repair (HDR), both of which are useful in different gene 
therapy scenarios.  
NHEJ is the predominant repair mechanism and is more common at the G1 phase 
when sister chromatids are not present to provide a template for repair. After 
initiation of the DSB, the heterodimer Ku binds to the DNA ends and enhances 
recruitment of nucleases, polymerases and ligases required for NHEJ, including 
DNA-dependent protein kinase (DNA-PKcs) (354). Artemis forms a complex with 
DNA-PKcs, allowing its phosphorylation and subsequent activation. The Artemis-
DNA-PKcs complex has a range of endonuclease activities, which allows cleavage 
of damaged DNA ends (355). Polymerases bind the Ku-DNA complex and are 
responsible for DNA extension, which is often required to create homology between 
the DNA ends. The XLF-XRCC4-DNA ligase IV complex is recruited by Ku and 
ligates DNA ends to restore the chromosome structure at a DSB (356). 
The enzymes involved in NHEJ have a high degree of flexibility in their function, 
allowing repair of a diverse range of DNA ends, and resulting in a variety of 
different DNA sequences. NHEJ typically leads to the formation of mutations in the 
original wild type DNA sequence by insertions or deletions (InDels). These 
mutations frequently result in disruption of the reading frame and production of a 
truncated, non-functional protein.  
This method would be effective in the case of HIV-1 treatment, where knockout of 
CCR5 would produce cells that are resistant to infection by R5 tropic HIV-1 strains. 
Only transient expression of the ZFN pair would be required to produce a permanent 
knockout of the gene, which would be passed on to daughter cells. 
 
The second repair mechanism, HDR, is a less frequent, but more accurate method 
for repairing DSB and utilises a homologous DNA sequence as a template for repair. 
This mechanism is most common at the S and G2 phases, when sister chromatids are 
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available to act as a repair template, resulting in maintenance of the correct 
sequence.  
When a DSB has occurred, the MRN (Mre11/Rad50/Nbs1) complex assembles at 
either end of the DNA keeping the two DNA ends in close contact (357). It also 
activates the protein kinase ATM (ataxia telangiectasia mutated), which in turn 
phosphorylates and activates other molecules involved in DNA repair (358). DNA 
resection of the 5’ end forms a 3’ ssDNA overhang to which the recombinase Rad51 
is recruited by an array of accessory proteins, including direct interaction with 
BRCA2 (359). This results in a nucleoprotein filament of Rad51 multimers. Rad51 
assembly, rearrangement and disassembly is responsible for the interaction of the 
ssDNA with a homologous dsDNA template; typically the sister chromatid or, if it is 
present, a donor DNA template.  
Once a suitable template has been found, the Rad51 filament is able to insert into the 
dsDNA in a process called strand invasion. This strand invasion forms a 
displacement (D) loop intermediate and extension of the invading ssDNA is carried 
out by a DNA polymerase. In the synthesis dependent strand annealing model, after 
extension, the invading strand is displaced and anneals to the second end of the 
DSB. Alternatively, during extension, the D loop can anneal to the second ssDNA 
end of the DSB to provide another template for extension and leading to the 
formation of two Holliday junctions. Various endonucleases can resolve the 
Holliday junctions, and subsequent ligation of the DNA ends results in either 
crossover or non-crossover DNA products (reviewed in (360)) (Figure 1.2). 
HDR can be exploited in therapy by providing a homologous DNA sequence termed 
the donor template to function as a template for repair. Provision of a high 
concentration of this donor template can increase the frequency of HDR over NHEJ 
(361). The template would consist of the sequence to be integrated flanked by DNA 
sequence homologous to that at the site of the break. This template can then be used 
to allow either correction of a mutation within the targeted gene or insertion of a 
novel transgene at this specific locus.  
One particular example which has shown great promise for this technology is the 
treatment of a mouse model of haemophilia (362). Haemophilia is caused by 
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mutations in the blood coagulation factor IX, which is encoded by the F9 gene. 
ZFNs targeting intron 1 of F9 and a donor template encoding exons 2-8 of F9 were 
delivered using adeno-associated virus (AAV) vectors into a newborn haemophilia 
mouse model and resulted in a clear improvement in clotting.  
 
Site specific integration is highly desirable in gene therapy, but using homologous 
recombination alone is far too inefficient to be used therapeutically. However, using 
ZFNs to introduce a DSB greatly increases the efficiency of homologous 
recombination to allow gene targeting. Proof of principle of this was first shown by 
introduction of a DSB using the endonuclease I-SceI, which has an 18bp recognition 
sequence and therefore cuts infrequently within a genome.  Depending upon the cell 
type, introduction of a DSB increased the efficiency of homologous recombination 
50-100 fold (363, 364).  
Using this theory, ZFNs have been designed to target specific sequences and 
introduce a DSB at a desired location for integration by HDR. As well as ZFNs, 
other sequence specific nucleases, namely meganucleases and TALE nucleases 
(TALENs) have also been designed for this purpose. Transcription activator-like 
effectors (TALEs) are transcriptional activators derived from the plant bacterial 
pathogen, Xanthomonas. Each TALE specifically binds a single nucleotide via a 
central repeat domain of 30-35 amino acids, specifically a two amino acid motif 
named the repeat variable diresidue (365). As with ZFs, a series of TALEs combined 
to guide DNA binding specificity can be fused to the FokI endonuclease to form 
TALENs. These TALENs must also function in pairs with correct DNA binding and 
spacing to allow dimerisation of FokI and induction of a DSB (366, 367). 
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Figure 1.3 Mechanism of repair by homology directed repair after double strand break by zinc 
finger nucleases 
Zinc finger nucleases bind opposing strands of DNA (A), allowing FokI heterodimerisation and 
induction of a double strand break (B). End resection results in 3’ ssDNA overhangs on which 
filaments of Rad51 recombinase (green circles) accumulate (C). These filaments recognise and 
capture homologous duplex DNA, forming a D loop intermediate. The 3’ end of the invading strand 
is extended by DNA polymerase using the duplex DNA as a template (D). The D loop can capture the 
second 3’ end of the DSB, allowing DNA polymerisation and forming two Holliday junctions (E). 
The Holliday junctions can be resolved in two distinct ways, resulting in either non-crossover (i) or 
crossover (ii) products.  
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Site specific integration has advantages over random integration as transgenes could 
be inserted at a safe harbour site where they would not affect gene expression of 
neighbouring genes. Similarly, transgene expression would be protected from 
silencing or influence from surrounding genes which can be a problem with 
randomly integrating vectors causing issues with sustained treatment of a disease  
(368). Importantly, integration at a safe harbour would also avoid insertional 
mutagenesis, the problems of which have been demonstrated in clinical trials and 
discussed in section 1.3. Therefore, site specific integration using ZFNs is highly 
desirable in gene therapy. Although there has been significant development of 
lentiviral vectors to replace gamma retroviral vectors due to their safer integration 
profile, site specific integration using ZFNs is still highly desirable in gene therapy. 
 
The CCR5 locus has attracted interest as a safe harbour because insertion at this site 
and consequent loss of expression does not cause serious side effects, as 
demonstrated with the naturally occurring Δ32 mutation. However, a significant 
benefit associated with this mutation is that Δ32 homozygotes have a strong 
resistance to HIV-1 infection, therefore making CCR5 specific ZFNs an attractive 
possibility for gene therapy against HIV-1.  
Sangamo have developed a pair of obligate heterodimeric ZFNs to target and 
knockout CCR5 expression. In preclinical in vitro studies, delivery of these ZFNs 
into T cells using the Ad5/35 adenoviral vector led to CCR5 knockout in 40-60% of 
cells. These cells were transplanted into immunodeficient non-obese diabetic 
(NOD)/SCID/IL-2r γ chain (NSG) mice which were subsequently infected with R5 
tropic HIV-1. ZFN treated mice had higher CD4
+
 T cell counts and lower viral loads 
than control mice receiving wild type CD4
+
 T cells (369). This data led to testing of 
the ZFNs in two phase I clinical trials, in which HIV patient CD4
+
 T cells were 
modified with ZFNs. Preliminary data from these trials have so far been promising, 
showing no adverse effects in response to the procedure and an increased CD4 count 
(135). Alongside this, these ZFNs have been further tested by modification of HSCs. 
Modified haematopoietic progenitor cells were transplanted into NSG mice where 
they gave rise to multi-lineage progeny. Mice were infected with R5 tropic HIV-1, 
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and in those which received ZFN modified cells there was a lower viral load and an 
expansion of CCR5
-
 cells. Mice engrafted with wild type HSCs suffered a 
significant loss of CD4
+
 T cells after HIV infection (370).  
This data further supports the theory of targeting HSCs through gene therapy to 
provide HIV-1 resistance in multiple cell types and repopulate the host immune 
system. 
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1.8 Project aims 
Gene therapy offers potential for a single long term treatment of HIV-1, eliminating 
the requirement of intensive drug regimens. Numerous different anti-HIV-1 
transgenes have been proposed for modification of T cells or HSCs to inhibit HIV-1 
infection. 
The aim of this project is to investigate possible gene therapy strategies against HIV 
as follows: 
 Generate humanised TRIM5Cyp proteins based upon the naturally occurring 
TRIM5Cyp lentiviral restriction factors found in primates 
 Compare TRIM5Cyp with the alternative TRIM21Cyp generated by 
replacement of the TRIM5 RBCC motif with the corresponding domains of 
TRIM21 
 Characterise the effects of TRIMCyp expression on endogenous TRIM 
antiviral function 
 Combine TRIMCyp proteins with CCR5 specific ZFNs using non-integrating 
lentiviral vectors to exploit this site as a safe harbour, and for CCR5 
knockout 
 Investigate the use of these strategies in anti-HIV gene therapy by expressing 
TRIMCyp proteins from lentiviral vectors in susceptible cell populations and 
measuring restriction of HIV-1 
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2 Materials and Methods 
2.1 Materials 
Unless otherwise stated, all cell culture reagents were supplied by Gibco BRL 
(Invitrogen) and all general chemicals by Sigma-Aldrich. Enzymes for molecular 
cloning were supplied by Promega and primers by Invitrogen. DNA sequencing 
reactions were performed by Eurofins MWG Operon. 
2.1.1 General reagents  
1kb Plus DNA ladder     Invitrogen 
Agarose      Melford 
Ampicillin      Sigma-Aldrich 
Cyclosporine      Sandoz Pharmaceuticals 
dNTPs       Applied Biosciences 
Ficoll       GE Healthcare 
FuGene-6      Roche 
Interferon-α      SP Labo, Heist-op-den-Berg 
Interferon-β      Merck Serono 
Interleukin-2 (IL-2)     Proleukin, Chiron 
Kanamycin      Sigma-Aldrich 
LIVE/DEAD fixable blue dead cell stain   Invitrogen 
MES SDS Running buffer (20x)   Invitrogen 
NuPAGE 4-12% Bis-Tris gels   Invitrogen 
NuPAGE Transfer buffer (20x)   Invitrogen 
Proteinase K      Applied Biosciences 
SeeBlue
®
 Plus2 Protein standard   Invitrogen 
T7 Endonuclease I     New England Biolabs 
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2.1.2 Buffers 
10 x TAE: 400mM Tris-acetate, 10mM EDTA in H2O 
DNA loading buffer: 50% Glycerol, 0.4% Orange G 
DNA lysis buffer: 1mg/ml Proteinase K, 0.5% NP40, 0.5% Tween 20 in TE 
Laemmli buffer: 60mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue 
Transformation buffer: 55mM MnCl2·4H2O, 15mM CaCl2·2H2O, 250mM KCl, 
10mM PIPES in H2O 
2.1.3 Antibodies 
AB1424 Anti-HA    Abcam 
A1978  Anti-β-actin    Sigma-Aldrich   
BML-SA296 Rabbit Anti-Cyclophilin A  Enzo Lifesciences 
NXA931 Sheep HRP-linked Anti-Mouse GE Healthcare 
NA934 Donkey HRP-linked Anti-Rabbit GE Healthcare 
557755 APC-Cy7 Mouse Anti-Human  BD Pharmingen 
   CD195 
555349 APC Mouse Anti-Human CD4   BD Pharmingen 
AB1056 Goat Anti-Adenovirus  Millipore 
TC31-             Anti-Adenovirus type 5 hexon Developmental studies 
9C12.C9 hybridoma bank  
2.1.4 Kits 
Geneamp
®
 RNA PCR core kit   Applied Biosciences 
HIV-1 p24 antigen ELISA    ZeptoMetrix 
In vitro toxicology assay kit (MTT  based)  Sigma-Aldrich 
Plasmid preparation (mini/maxi)   Qiagen 
QiaQuik Gel Extraction    Qiagen  
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QiaQuik PCR Purification    Qiagen 
TOPO TA cloning kit     Invitrogen 
2.1.5 Cells 
Bacteria 
One Shot Stbl3 E. coli    Invitrogen 
Genotype: F- mcrB mrr hsdS20 (rB
-
, mB
-
 ) recA13 supE44 ara-14 galK2 lacY1 
proA2 rpsL20 (Str ) xyl-5 λ- leu mtl-1r 
One Shot TOP10 E. coli    Invitrogen 
Genotype: F
- 
mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 
araD139 Δ(ara-leu) 7697 galU galK rpsL (Str
R
) endA1 nupG λ- 
Mammalian cell lines 
CRFK    Crandell-Reese feline kidney cells. 
GHOST   CD4 transformed human osteosarcoma cells (HOS-
CD4) expressing chemokines, either CCR5 or CCR5 and CXCR4 (371). Obtained 
from NIBSC 
HEK293T    Human embryonic kidney cell line 
HeLa     Human cervix epithelial carcinoma cell line 
Jurkat.CD4-CCR5   Human T cell line (CD4 positive) stably transfected 
with CCR5. Obtained from NIBSC 
TE671    Human rhabdomyosarcoma cell line. 
2.1.6 Media 
Bacteria 
LB Broth: 1% tryptone, 0.5% yeast extract, 1% NaCl 
LB Agar: As above with the addition of 1.5% agar 
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Mammalian cells 
All cell culture media were from Gibco BRL, Invitrogen unless otherwise stated. 
Foetal calf serum (FCS)     Sigma-Aldrich 
Human AB serum     Lonza 
X-Vivo-10      Lonza 
Dynabeads 
®
 Anti-CD3/anti-CD28 beads  Invitrogen 
G418 (500µg/ml)     Source Bioscience 
Puromycin (1µg/ml)     Sigma-Aldrich 
Hygromycin (100µg/ml)    Invitrogen 
2.1.7 Quantitative real time PCR 
Platinum qPCR SuperMix UDG with ROX  Invitrogen 
Primers      Invitrogen 
Probes       MWG 
 
Human β actin forward TCACCCACACTGTGCCCATCTACGA 
Human β actin reverse CAGCGGAACCGCTCATTGCCAATGG 
Human β actin probe FAM-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA 
WPRE forward TGGATTCTGCGCGGGA 
WPRE reverse GAAGGAAGGTCCGCTGGATT 
WPRE probe FAM-CTTCTGCTACGTCCCTTCGGCCCT-TAMRA 
Table 2.1 Table of primers and probes used for quantitative polymerase chain reaction 
 
Human TRIM5 (Hs01552552_g1)   Applied Biosystems 
Human TRIM21 (Hs00989233_g1)  Applied Biosystems 
Human GAPDH (Hs99999905_m1)  Applied Biosystems 
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2.1.8 PCR primers 
Pfu DNA polymerase     Promega 
Go Taq DNA polymerase    Promega 
Primers      Invitrogen 
 
Primer 
Name 
Primer sequence  
TS141 GCATGCGGCCGCCATGGTCAACCCCACCGTGTTCTTCG Fw CypA, adds NotI 
TS142 GCATGTCGACTTATTCGAGTTGTCCACAGTCAGC Rv CypA, adds SalI 
TS58 ATGCCAATTGATGGCTTCTGGAATCCTGGTTAATGTAAAG
G 
Fw TRIM5, adds MfeI 
TS201 AGCTGCGGCCGCGTTTGGAGCCACTGTCACATCAACCCAG Rv TRIM5 aa306, adds 
NotI 
TS202 AGCTGCGGCCGCCCAGTAGCGTCGGACATCTGTCAGCTC Rv TRIM5 aa298, adds 
NotI 
TS203 AGCTGCGGCCGCCACTTCTAGCATTCCTTTCAGATCAGG Rv TRIM5 aa287, adds 
NotI 
TS209 ATGCGGATCCACCATGGCTTCTGGAATCCTGGTTAATG Fw TRIM5, adds 
BamHI 
TS187 GCATGGATCCTTATTCGAGTTGTCCACAGTCAGCAATGGT
G 
Rv CypA, adds BamHI 
TS154 AGCTGCGGCCGCTGTCCTCAGCATCTTCTTCAGCCCTGGC
AC 
Fw TRIM21, adds 
MfeI 
TS43 CAGTGAATTCATGGCTTCAGCAGCACGCTTGACAATGATG Rv TRIM21, adds NotI 
ZFN1 CAGCTCGAGCCTGCAGGGTATGGACTACAA Adds SbfI and XhoI 
ZFN2 GCTGATCAGCGGGTTTAAACGGGCCCTCT Adds an XhoI 
T21Cfw AGAAGATGCCACAGCAGCGCC Fw TRIM21CypCO 
T21Crv GTTGGTGTTGGGTCCGGCGT Rv TRIM21CypCO 
PGKfw TGAAGAATGTGCGAGACCCAGG Fw PGK 
8-CCR5 CCCCATAGCAAGACAAAGACCTGT Rv CCR5 
9-CCR5 CACTTTTTATTTATGCACAGGGTGGA Fw CCR5 for T7 assay 
10-CCR5 GATGATTCCTGGGAGAGACGC Rv CCR5 for T7 assay 
Table 2.2 Table of primers used in this study 
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2.1.9 Parental plasmids 
pEXN: derivative of the Moloney MLV retroviral vector pLNCX2 containing a HA 
tag (372). 
pLNT/SFFV-MCS-WPRE: self-inactivating (SIN) second generation lentiviral 
backbone derived from pHR plasmid. It includes a SFFV promoter followed by a 
multiple cloning site and Woodchuck hepatitis virus post transcriptional regulatory 
element (WPRE). 
pLNT/SIEW: (SFFV-IRES-eGFP-WPRE) lentiviral vector with the same backbone 
as pLNT/SFFV-MCS-WPRE, with an IRES-eGFP inserted at the multiple cloning 
site (373). 
pVax/CMV-ZFNEL: expression plasmid encoding the left CCR5 ZFN, ZFNEL, 
under control of the CMV promoter. Provided by Sangamo. 
pVax/CMV-ZFNKK: expression plasmid encoding the right CCR5 ZFN, ZFNKK, 
under control of the CMV promoter. Provided by Sangamo. 
pCR4/CCR5 BglI donor: TOPO plasmid with CCR5 genomic sequence containing 
BglI site for cloning ZFN donor template. Provided by Sangamo. 
pCR4/CCR5 GFP donor: TOPO plasmid with CCR5 genomic sequence flanking 
GFP. Provided by Sangamo. 
pMA/TRIM21CypCO: Codon optimised TRIM21Cyp synthesised by Geneart 
(Regensburg, Germany) using their in-house GeneOptimizer® software. 
2.1.10 Generated plasmids 
pEXN/Cyp  
Human cyclophilin A was amplified from HeLa cell cDNA using primers TS141 
and TS142. The PCR product was cloned into pEXN between NotI and SalI. 
Provided by Dr. Torsten Schaller 
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pEXN/TRIM5Cyp 
Three human TRIM5 RBCC motif fragments were amplified by PCR using primer 
TS58 with TS201, TS202 or TS203. Human TRIM5 in pEXN was provided by Dr. 
Torsten Schaller and used as the template. The number of the final amino acid of the 
TRIM5 RBCC sequence is denoted in the name of the resultant TRIMCyp fusion 
protein construct i.e. 306, 298 and 287 (Figure 3.1). 
The PCR product was ligated between EcoRI and NotI of pEXN/CypA (provided by 
Dr. Torsten Schaller). This produced three different TRIM5Cyp constructs of 
increasing lengths. The resulting plasmid was named pEXN-TRIM5Cyp (Figure 
3.2).  
 
pLNT/S-TRIMCyp-IEW 
TRIM5Cyp constructs were amplified from the EXN vector by PCR using primers 
TS209 and TS187, and cloned into the BamHI site of pLNT/SIEW to produce the 
plasmid pLNT/S-TRIM5Cyp-IEW (Figure 3.5). pLNT/SIEW expressed just GFP 
and served as an empty vector control. 
The TRIM21Cyp fusion construct was originally generated by fusing the first 284 
amino acids of human TRIM21 amplified by primers TS154 and TS43 with human 
CypA with a NotI site in between the two genes. This construct was supplied by Dr. 
Torsten Schaller in the lentiviral plasmid, pSFXUC. The entire construct was 
removed by digestion with BamHI before ligation into pLNT/-SIEW at the BamHI 
site. The resulting plasmid was named pLNT/S-TRIM21Cyp-IEW (Figure 3.5). 
 
pLNT/SFFV-TRIMCyp-WPRE: To produce lentiviral vectors without eGFP, 
TRIMCyp from pLNT/S-TRIM5Cyp-IEW was removed using BamHI and inserted 
into pLNT/SFFV-MCS-WPRE at BamHI. The resulting plasmid was named 
pLNT/SFFV-TRIMCyp-WPRE. 
 
pLNT/SFFV-ZFNEL-WPRE 
The ZFNEL gene was amplified from the Sangamo pVax plasmid by PCR using 
primers ZFN1 and ZFN2. The purified PCR product was ligated into the recipient 
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lentiviral backbone, pLNT/SFFV-MCS-WPRE at XhoI. The final plasmid was 
named pLNT/SFFV-ZFNEL-WPRE (Figure 6.1). 
 
pLNT/SFFV-ZFNKK-WPRE 
The pVax/CMV-ZFNKK plasmid was cut with EcoRI and the DNA overhangs filled 
in before digestion with XhoI. The recipient lentiviral backbone, pLNT-SFFV-MCS-
WPRE was cut with BamHI and blunt ended using DNA polymerase I Large 
(Klenow) fragment and then cut with XhoI. The two DNA molecules were ligated 
together to produce pLNT/SFFV-ZFNKK-WPRE (Figure 6.1). 
 
pLNT/CCR5-PGK-GFP 
The CCR5 donor expression plasmid from Sangamo was digested with NsiI and 
NheI to remove a fragment consisting of PGK-GFP. The ends were filled in using 
DNA polymerase I Large (Klenow) fragment. The recipient lentiviral plasmid 
pLNT/SFFV-MCS-WPRE was digested with XhoI and EcoRI to remove SFFV and 
the ends filled in before 5’ dephosphorylation using shrimp alkaline phosphatase 
(SAP). The PGK-GFP fragment was ligated into the lentiviral backbone. The final 
donor plasmid was named pLNT/CCR5-PGK-GFP (Figure 6.1). 
 
pLNT/CCR5-PGK-TRIM21CypCO 
A plasmid was synthesised by Geneart which consisted of PGK-driving expression 
of a codon optimised TRIM21Cyp transgene, T21CypCO. This plasmid was 
digested with BglI to yield the fragment PGK-T21CypCO. The Sangamo CCR5 
donor TOPO plasmid, CCR5-BglI, was digested with BglI, dephosphorylated with 
SAP and was ligated to PGK-T21CypCO. The CCR5 flanked PGK-T21CypCO was 
removed from the plasmid by digestion with NsiI and NheI. The recipient plasmid, 
pLNT/SFFV-MCS-WPRE, was prepared by digestion with EcoRI and XhoI to 
remove SFFV, filling in the 5’ DNA overhangs and dephosphorylation with SAP. 
The lentiviral backbone and CCR5 flanked PGK-T21CypCO were ligated together 
to produce the final plasmid, pLNT/CCR5-PGK-T21CypCO (Figure 6.1).  
83 
 
2.2 Methods 
2.2.1 Growth and maintenance of E. coli 
Escherichia coli (E. coli) were grown in LB broth at 37°C with agitation at 250 rpm 
or streaked out on LB agar plates (1.5% bacto agar). For selection of transformed E. 
coli the same media supplemented with 50µg/ml ampicillin or 50µg/ml kanamycin 
was used. Bacterial cultures were stored at -80°C in LB broth containing 15% (v/v) 
glycerol.  
2.2.2 Production of chemically competent Stbl3 E. coli 
Chemically competent E. coli were prepared using the Innoue method (374). Stbl3 
E. coli were streaked out on a LB agar plate with no antibiotics and grown 
overnight. A single colony was used to inoculate 25ml of LB broth and grown for 8 
hours at 37ºC with shaking. 2-10ml of this starter culture was used in inoculate 
250ml LB and grown at room temperature until the OD600 reached 0.55. The culture 
was placed in ice for 10 minutes before harvesting the cells by centrifugation at 
2500g for 10 minutes at 4ºC. The bacteria were resuspended in 80ml ice cold 
transformation buffer and then pelleted again at 2500g for 10 minutes at 4ºC. The 
cells were resuspended in 20ml ice cold transformation buffer and DMSO added to a 
final concentration of 7%. 100µl aliquots were frozen at -80ºC  
2.2.3 Transformation of chemically competent E. coli 
One vial of Stbl3 E. coli was thawed on ice and DNA was added, mixed gently and 
incubated on ice for 30 minutes. Cells were heat-shocked at 42°C for 45 seconds and 
cooled on ice for 2 minutes. 250µl of LB broth was added and the cells were 
incubated for 1 hour at 37°C with shaking. Cells were plated out on LB agar plates 
with the appropriate selection antibiotic and cultured overnight at 37ºC. 
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2.2.4 Plasmid DNA preparation 
E. coli containing plasmid was grown overnight in LB broth with the appropriate 
antibiotic. Plasmid was extracted by alkaline lysis using Qiagen Miniprep or 
Maxiprep kits according to manufacturer’s instructions. DNA concentration was 
measured using a Nanodrop ND-1000 spectrophotometer at a wavelength of 260nm. 
2.2.5 Restriction endonuclease digests 
DNA was digested in a final volume of 20µl containing 1x buffer (supplied by 
manufacturer), 0.1mg/ml BSA and one or two restriction enzymes (<10% final 
volume). The reaction was incubated for 4 hours at 37°C. 
2.2.6 Filling in of 5’ DNA overhangs 
5’ DNA overhangs generated by restriction enzyme digests were filled in using 
DNA polymerase I Large (Klenow) fragment. DNA was mixed with 1 unit (U) of 
enzyme per microgram of DNA, 1x buffer (supplied by Promega) and 40µM of each 
dNTP. The reaction was incubated at room temperature for 10 minutes, and stopped 
by heat inactivation of the enzyme for 10 minutes at 75°C. 
2.2.7 Dephosphorylation of 5’ phosphate groups from DNA 
5’ phosphate groups from DNA were removed prior to ligation to prevent re-ligation 
of linearised vector DNA with compatible ends. Thermosensitive alkaline 
phosphatase was added at 1U per microgram of DNA directly to restriction 
reactions. The reaction was incubated for 15 minutes at 37°C, and the enzyme 
inactivated at 75°C for 10 minutes. 
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2.2.8 DNA Ligation 
Insert DNA was ligated into plasmid backbone in approximately 3:1 molar ratio 
using 1U of T4 DNA ligase and 1x T4 DNA ligase buffer (supplied by 
manufacturer) in a final reaction volume of 20µl. Reactions were incubated 
overnight at either 4°C or 16°C for sticky ends or blunt ends respectively and were 
then transformed into chemically competent Stbl3 E. coli. 
2.2.9 Agarose gel electrophoresis and purification of DNA fragments 
DNA fragments were resolved on a 1% agarose gel in 1x TAE buffer. Agarose was 
dissolved in TAE by heating and ethidium bromide was added to a final 
concentration of 0.5µg/ml before being allowed to set. Samples were mixed with 
DNA loading buffer before being loaded onto the gel alongside 1kb Plus DNA 
ladder. Fragments were separated by electrophoresis at 100-150V in 1x TAE and 
visualised under UV light using a UviDoc gel documentation system. DNA 
fragments were excised from the gel using a scalpel under UV light and purified 
using a Qiaquik gel extraction kit. 
2.2.10 PCR cloning 
100ng DNA was used as a template and mixed on ice with 1x PFU buffer supplied 
by the manufacturer, 1µM each primer, 250µM each dNTP, 2U Pfu DNA 
polymerase in 50µl volume. Initial denaturation was performed at 94ºC for 5 
minutes, then 35 amplification cycles were carried out- denaturation at 94ºC for 30s, 
primer annealing at between 53 and 60ºC (depending upon primers used) for 30s, 
extension at 72ºC for 1 minute/kb, and a final extension step of 7 minutes at 72ºC. 
2.2.11 Genomic DNA extraction 
20µl of DNA lysis buffer was added to approximately 1x10
5
 cells and incubated at 
56ºC for 2 hours, then 95ºC for 5minutes. 180µl H2O was added and the sample 
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spun in a bench top centrifuge at 13 000rpm for 3minutes. The supernatant 
containing DNA was removed and stored at -20ºC. 
2.2.12 Identification of integration of PGK-TRIMCyp at the CCR5 locus 
by PCR 
Primers spanning the TRIM21 and Cyp junction (T21Cfw and T21Crv) were used to 
amplify the TRIM21CypCO transgene in GHOST clones. This reaction would detect 
the transgene after integration at any locus. 100ng template DNA was mixed with 
1xTaq polymerase buffer, 1mM MgCl2, 1µM each primer, 250µM each dNTP, 
1.25U Taq polymerase in a total of 50µl. Denaturation was performed at 94ºC for 5 
minutes, followed by 35 amplification cycles of denaturation at 94ºC for 1 minute, 
primer annealing at between at 50ºC for 30s, extension at 72ºC for 1 minute, and a 
final extension step of 10 minutes at 72ºC. The correct TRIM21Cyp product was 
486bp. 
 
PCR was used to amplify the junction between the TRIM21CypCO transgene and 
the CCR5 gene in GHOST clones. One primer bound within the PGK promoter of 
the insert (PGKfw), and the other to the endogenous CCR5 sequence (8-CCR5). 
Therefore, this PCR would only detect inserts at the correct site of integration within 
the CCR5 gene, producing a PCR product of 1507bp. 
100ng template DNA was mixed with 1xTaq polymerase buffer, 3% DMSO, 1mM 
MgCl2, 1µM each primer, 250µM each dNTP, 1.25U Taq polymerase in a total of 
50µl. Samples were amplified using the following touchdown PCR conditions: 95ºC 
for 5 minutes, 17 cycles of 95ºC for 30s, 68ºC for 30s and 72ºC for 2 minutes 30s, 
then 25 cycles of 95ºC for 30s, 60ºC for 30s and 72ºC for 2 minutes 30s, then 6 
cycles of 95ºC for 30s, 59ºC for 30s and 72ºC for 2 minutes 30s, then 6 cycles of 
95ºC for 30s, 58ºC for 30s and 72ºC for 2 minutes 30s then a final extension of 72ºC 
for 10 minutes. 
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2.2.13 TOPO cloning  
Gel extracted and purified PCR product was ligated into the pCR
®
4-TOPO
®
 plasmid 
following manufacturers guidelines, which involved incubation of DNA with salt 
solution, water and vector for 5 minutes at room temperature. The resultant plasmid 
was used to transform One Shot TOP10 E. coli by heat shock, which were then 
plated onto ampicillin LB agar plates. DNA was extracted from colonies and the 
insert sequenced. 
2.2.14 T7 endonuclease assay 
The CCR5 ZFN target site was amplified by PCR using primers 9-CCR5 and 10-
CCR5 and the 498bp product resolved by electrophoresis through an agarose gel. 
The relevant band was excised and purified by a QiaQuik gel extraction kit. 
Approximately 100ng DNA was denatured for 10 minutes at 98ºC in a total volume 
of 11.2µl containing 1x buffer 2 (supplied by manufacturer) and cooled to allow re-
annealing. T7 endonuclease I recognises and cleaves mismatched double stranded 
DNA formed when NHEJ DNA containing mutations re-anneals with the native 
sequence. Therefore DNA was digested using 5U T7 endonuclease for 30 minutes at 
37ºC to cleave mismatched DNA producing two products of approximately 200 and 
300bp. DNA was visualised on a 1.5% agarose gel with 0.5µg/ml ethidium bromide 
under UV light. 
2.2.15 Quantitative real time PCR (qPCR) 
Approximately 100ng of genomic DNA was used as a template for each reaction. 
Reactions were performed in triplicate in a total volume of 25µl containing 0.9µM 
of both forward and reverse primers, 0.2µM fluorescently labeled probe and 1x 
master mix. WPRE primers and probes were used to detect integrated copies of 
lentiviral vector, and β-actin primers and probes were used to quantify cell number. 
For each reaction 1 cycle of 50ºC for 2 minutes, 1 cycle of 95ºC for 10 minutes, 40 
cycles of 95°C for 15s and 60°C for 1 minute were performed using an ABI Prism 
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7000 sequence detection system (Applied Biosystems). Samples were compared to a 
standard curve generated by serially diluted plasmid stocks. 
2.2.16 Total RNA isolation and reverse transcription 
0.5ml Tri-reagent and 0.1ml chloroform were added to cell pellets, shaken and 
centrifuged at 13000rpm for 15 minutes. 0.2ml of the upper aqueous phase was 
added to 0.2ml isopropanol and incubated at -20ºC for 4 hours. Following this, RNA 
was pelleted by centrifugation at 13000rpm in a bench top centrifuge for 10 minutes. 
The supernatant was removed and pellet washed in 1ml 70% ethanol before air 
drying and resuspension in 10µl H2O. 
Reverse transcription was performed on RNA samples using the Geneamp
®
 RNA 
PCR core kit. 2.85µl sample, 1x buffer, 5.5mM MgCl2, 250µM each dNTP, 1.25µM 
random hexamers, 12.5U RT, and 4U RNAse inhibitor were incubated at 25ºC for 
10 minutes, 48ºC for 30 minutes and 95ºC for 5 minutes. The resultant cDNA was 
used as a template for real time reverse transcription PCR (RT-PCR) using 
primer/probe sets for TRIM5 or TRIM21 normalised to the GAPDH housekeeping 
gene. For each reaction 1 cycle of 50ºC for 2 minutes, 1 cycle of 95ºC for 10 
minutes, 40 cycles of 95°C for 15s and 60°C for 1 minute were performed using an 
ABI Prism 7000 sequence detection system (Applied Biosystems). The relative 
expression level was calculated using the 2
-ΔΔCt 
method, assuming amplification 
efficiencies of TRIM and GAPDH were similar, using the formula: 
ΔΔCt=ΔCtsample - ΔCtreference 
2.2.17 Western blotting 
1x10
6
 cells were lysed by addition of 100µl Laemmli buffer and heating at 100ºC for 
10 minutes. Samples were centrifuged in a bench top centrifuge for 3 minutes at 
13000rpm. Samples and SeeBlue Plus2 Prestained Standard were separated by 
electrophoresis through a 4-12% Bis-Tris NuPAGE gel and 1x MES buffer at 200V 
for 45 minutes. Protein was then transferred onto Immobilon-P PVDF membrane 
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using an X-Cell II Blot module and 2x NuPAGE transfer buffer, 10% methanol at 
18V for 45 minutes. The membrane was blocked in 4% milk powder in PBST (PBS 
containing 0.05% (v/v) Tween-20) for 1 hour at room temperature, and then primary 
antibody was added at 1:1000 for anti-HA tag or 1:5000 for anti-Cyclophilin and 
incubated at room temperature overnight. The membrane was washed three times in 
PBST before addition of horse-radish peroxidase conjugated secondary antibody 
diluted 1:2000 in 4% milk in PBST for 1 hour. The membrane was washed three 
times in PBST and bands visualised using Pierce ECL detection kit and UviChemi 
chemiluminescence detection system.  
2.2.18 p24 ELISA 
ELISA was used to measure the levels of HIV-1 p24 in culture supernatant after 
infection with HIV-1 or for physical titration of lentiviral vector. Samples were 
diluted appropriately in fresh complete medium. The assay was performed on these 
samples according to manufacturer’s instructions. Briefly, samples were lysed and 
added to wells coated with anti-p24 antibody in duplicate alongside serial dilutions 
of p24 antigen standards supplied by the manufacturer. The plate was incubated at 
4ºC overnight before washing and incubation with biotin conjugated anti-p24 
antibody for 1 hour at 37ºC. After further washing, streptavidin-peroxidase solution 
was incubated on the plate for 30 minutes at 37ºC, colour developed by the addition 
of substrate at room temperature and the reaction stopped with stop solution. The 
absorbance was read at 450nm using a FLUOstar OPTIMA (BMG Labtech, 
Offenburg, Germany) and the concentration of p24 calculated using the p24 antigen 
standards. 
2.2.19 MTT assay 
In vitro cell viability was measured using the In vitro toxicology assay kit, based 
upon (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT, 
according to manufacturer’s instructions. Briefly, MTT was added to cells in a 96 
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well plate in an amount equal to 10% of the culture medium volume. Cells were 
incubated at 37ºC for 2-4 hours to allow the formation of formazan crystals, which 
were then dissolved in MTT solubilisation solution provided with the kit. 
Absorbance was measured at 595nm using a FLUOstar OPTIMA (BMG Labtech, 
Offenburg, Germany). 
2.2.20 Propagation and storage of mammalian cell lines 
Adherent cell lines were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing GlutaMAX supplemented with 10% (v/v) FCS and 1% (v/v) 
penicillin/streptomycin (referred to as complete DMEM). Cells were passaged when 
80-90% confluent by washing in Dulbecco’s phosphate buffered saline (PBS) then 
incubating with trypsin/EDTA until cells became detached. Cells were diluted in 
fresh complete DMEM and plated at a suitable concentration into tissue culture 
flasks. GHOST cells were grown in selection media which consisted of complete 
DMEM supplemented with 500µg/ml G418, 100µg/ml hygromycin and 1µg/ml 
puromycin. 
Non-adherent cell lines were maintained in RPMI 1640 media containing 
GlutaMAX supplemented with 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin 
(referred to as complete RPMI). Cells were passaged when the media changed 
colour by transferring a proportion of the cells to fresh complete RPMI. All cells 
were incubated at 37°C in a 5% CO2 atmosphere. Jurkat.CD4-CCR5 (Jurkat-CCR5) 
cells were grown in selection media which consisted of complete RPMI 
supplemented with 500µg/ml G418. 
For long term storage of cell lines, 1-5x10
6
 cells were centrifuged and the pellet was 
resuspended in FCS containing 10% (v/v) DMSO and frozen slowly overnight in an 
isopropanol freezing box at -80°C. Cells were then transferred into liquid nitrogen. 
Cells were rapidly thawed in a 37°C waterbath and slowly added to fresh complete 
media. Cells were centrifuged to remove DMSO and resuspended in fresh complete 
medium and transferred to a T25
2
 or T75
2
 tissue culture flask. 
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2.2.21 Isolation of peripheral blood mononuclear cells (PBMCs) 
Heparinised blood was obtained from healthy donors and peripheral blood 
mononuclear cells (PBMCs) were separated from the blood by centrifugation over 
20ml Ficoll at 800g, for 25 minutes with no brakes. PBMCs from the buffy coat 
were collected and washed twice in PBS. Cells were counted and seeded at 1x10
6 
cells per well in a 24 well plate in X Vivo-10 supplemented with 5% human AB 
serum and 100U/ml IL-2 with anti-CD3/anti-CD28 beads at a 1:1 ratio for 
activation. Half of the culture media was removed and replaced with fresh X Vivo-
10 with supplements to replenish IL-2 levels every two days. 
2.2.22 Production of retroviral vector 
2.2x10
6 
HEK293T were plated out in a 10cm dish and grown overnight to reach 
~80% confluency. 1.5µg vector plasmid, 1µg MLV gag-pol packaging plasmid and 
1µg vesicular stomatitis virus G protein expression plasmid (pMDG2) were mixed in 
a total volume of 15µl. This DNA was added to 200µl OptiMem containing 10µl 
FuGene-6, and incubated at room temperature for 15minutes. Cell medium was 
replaced with 8ml fresh complete DMEM and the DNA mix added. The following 
day the media was replaced with 8ml fresh complete DMEM. 48 and 72 hours after 
transfection the media was harvested, filtered at 0.45µm and stored at -80ºC.  
2.2.23 Production of lentiviral vector 
1.5x10
7
 HEK293T were plated out in a T175cm
2
 flask and grown overnight to reach 
~80% confluency. DNA mixture for each flask was made by mixing 50µg vector 
plasmid, 32.5µg gag-pol packaging plasmid pCMV-dR8.74 (for integrating virus) or 
pCMV-dR8.74 D64V (for non-integrating virus) and 17.5µg pMDG2 in 5ml 
OptiMem and 0.22µm filtered to sterilise. 2µM PEI was added to 5ml OptiMem  and 
sterilised by 0.22µm filtration and the two solutions mixed and incubated at room 
temperature for 20 minutes. Cells were washed in OptiMem before adding the DNA-
PEI complex and incubating at 37°C 5% CO2 for 4 hours, then replacing with 
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complete DMEM. After 24 hours the media was replaced with fresh complete 
DMEM. 48 and 72 hours after transfection the media was harvested and filtered at 
0.22µm to remove cell debris, before centrifugation at 100 000g for 2 hours in a 
Sorvall Discovery SE ultracentrifuge. Viral pellets were resuspended in DMEM 
without supplements and stored at -80°C. 
2.2.24 Production of replication competent HIV-1  
1x10
6
 HEK293T cells were plated out in a T25cm
2
 flask and incubated overnight. 
7.5µl of FuGene-6 was added to 90µl serum free DMEM and incubated at room 
temperature for 5minutes. 2.5µg HIV-1 plasmid was added and incubated at room 
temperature for 15minutes before adding directly to the media in the flask of cells. 
The following day media was replaced with 8ml fresh complete DMEM. 48 and 72 
hours after transfection the media was collected, filtered at 0.45µm and stored at       
-80ºC. Two full length HIV-1 clones were used: R9 and NL4-3 (BaL), which has a 
BaL envelope. These clones have an X4 and R5 tropism respectively. 
The amount of p24 in the harvested supernatant was quantified by p24 ELISA, as 
described above. 
2.2.25 Titration of viral vector 
2.2.25.1 GFP expression 
HEK293T cells were plated at 1x10
5
 cells per well in 24 well plates the day before 
transduction. Lentiviral vector was diluted in five-fold serial dilutions and added to 
the cells in a final volume of 300µl complete DMEM. Cells were harvested at 72 
hours after transduction and GFP expression measured by flow cytometry using a 
BD LSRII. Results were analysed using FlowJo software. The vector titre in 
infectious units per ml (IU/ml) was calculated from a well in which 1-10% of cells 
were GFP positive. The number of transduced cells was divided by the volume (in 
mls) of virus used to transduce the cells in this well. 
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MLV-YFP was titrated on 1x10
5 CRFK cells to avoid restriction by human TRIM5α 
in the human derived HEK293T cells. Two-fold serial dilutions of MLV vector were 
added in a final volume of 1ml complete DMEM to cells, which were harvested and 
YFP expression measured by flow cytometry 72 hours later. 
2.2.25.2 Quantification of WPRE copy number by qPCR 
Cells were transduced as above and harvested for DNA extraction as outlined in 
methods. qPCR was performed as described. The total number of copies of WPRE 
in the whole well was divided by the volume of virus used to transduce them. 
2.2.25.3 Quantification of physical titre by p24 ELISA 
Concentrated lentiviral vector was diluted 1:1x10
6
 in DMEM. P24 levels were 
measured using a p24 ELISA kit according to manufacturer’s guidelines as 
described above. Typically, there are 10-100 infectious units/pg of p24, which 
allowed calculation of viral titre.  
2.2.26 Flow cytometry 
Flow cytometry was performed on a BD LSR II (BD Biosciences) using FACSDiva 
software. Samples in 96 well plate format were captured on a BD FACSCalibur (BD 
Biosciences). All data were analysed using Flowjo software. Cells were sorted using 
a MoFlo XDP (Beckman Coulter). 
For separation of GFP and YFP in restriction assays, a 525LP Dichroic mirror and 
optical filters were used on the BD LSRII. GFP was detected at 510/10 nm and YFP 
was detected at 550/30 nm 
For measuring viability, cells were gated on forward/side scatter. Cell death was 
measured by a shift on the forward and side scatter axis as cells became smaller and 
more complex. The shift was confirmed as correlating with cell death by using 
LIVE/DEAD fixable stain according to manufacturer’s guidelines. Briefly, cells 
were pelleted and stained for 30 minutes at room temperature in the dark using stain 
diluted in PBS. Cells were washed in PBS before fixing in 4% paraformaldehyde. 
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Viable cells negative for the LIVE/DEAD stain were backgated on forward/side 
scatter to confirm that they were included in the original viability gate. 
For extracellular staining of CD4 and CCR5, cells were pelleted by centrifugation 
and incubated with antibody diluted in PBS for 20 minutes at room temperature in 
the dark. Cells were washed in PBS before resuspending for analysis by flow 
cytometry. 
2.2.27 Viral transduction 
For retroviral transduction with EXN, CRFK cells were plated at 1x10
5
 cells per 
well in a 6 well plate and 24 hours later media was replaced with 1ml virus and 
5mg/ml polybrene (PB). The plate was centrifuged at 500rpm for 1 hour and then 
incubated for 6 hours before adding G418 for antibiotic selection. Cells were 
cultured for approximately 7-10 days for G418 selection of transduced cells. 
Generally for lentiviral transduction, 1x10
5
 cells were seeded in a 24 well plate and 
incubated overnight. Lentiviral vector was added to the cells in a volume of 1ml 
media. Cells were cultured for at least 72 hours to allow gene expression before 
using for any further analysis or assays. 
PBMCs were obtained from healthy donors by centrifugation through Ficoll and 
plated at 1x10
6
 per well in a 24 well plate (see section 2.2.21). After 48 hours 
activation, lentiviral vector was added, typically at an MOI of 30-50. Half of the 
culture medium was removed and replaced with fresh medium and 200U/ml IL-2 
every two days throughout culture. 
2.2.28 Retroviral restriction assays 
Transduced cells were plated at 1x10
5
 cells per well in a 24 well plate and 
transduced with HIV-1 vector carrying either eGFP or YFP marker genes in a total 
volume of 1ml. The MOI used varied between experiments, but was typically 
between 1 and 10. HIV-1 reporter gene expression was measured in the cells by flow 
cytometry 72 hours post-transduction.  
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For measurement of endogenous TRIM5α restriction of retrovirus, TE671 cells were 
transduced with LNT/S-TRIMCyp-IEW. Cells were plated at 1x10
5
 per well in the 
presence or absence of 1000U IFNβ and the following day transduced with B- or N-
MLV-YFP (MOI=1000), or HIV-1-YFP (MOI=5). Flow cytometry was used to 
quantify the percentage of the eGFP positive population that co-expressed YFP. 
For restriction assays using full length HIV-1, cells were plated and incubated over 
night before infection with HIV-1. The day following infection, cells were washed 
with PBS to remove residual virus before replacement with fresh complete media. 
2.2.29 Adenoviral restriction assay 
TRIM21 restriction of adenovirus type 5 was measured following the protocol of 
Mallery et al (266). HeLa cells were transduced with LNT/SFFV-TRIMCyp-WPRE 
vectors without eGFP and seeded at 1x10
5
 cells per well with or without 1000U 
IFNα. Caesium chloride concentrated adenovirus expressing GFP (AdV-GFP) (a 
kind gift from Persis Amrolia) was incubated with increasing concentration of 
antibody for 30 minutes at room temperature, before infecting HeLa cells. GFP 
expression was measured after 48 hours. A polyclonal goat anti-hexon antibody 
(Millipore) was used in a total volume of 10µl in a concentration range of 200-
1600ng/ml.  
This neutralisation assay protocol was optimised by Choon Ping Tan, who also 
provided unconcentrated AdV-GFP preparations and an alternative antibody. The 
antibody 9C12 was used and incubated with AdV in a total volume of 500µl at a 
concentration range of 3.2-2000ng/ml. GFP expression was measured 48 hours 
following infection.  
2.2.30 Statistics 
Where stated, P values were obtained by performing two tailed, unpaired Student’s 
T test. 
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3 Human TRIMCyp proteins restrict  
HIV-1 
3.1 Aims 
 
 To generate humanised TRIM5- and TRIM21-Cyclophilin A fusion constructs 
in retroviral and lentiviral vectors 
 To produce high titre lentiviral vector stocks 
 To test the restriction of HIV-1 derived vectors by TRIMCyp proteins in cell 
lines and primary T cells 
3.2 Introduction 
Gene therapy has the potential to provide a functional cure of HIV-1 infection after a 
single dose of treatment and eliminate the need for HAART. There are a wide 
variety of potential antiviral genes that could be introduced into cells to provide 
them with a resistance to HIV-1, and in addition, the target cell and delivery 
methods could also influence the effectiveness of any potential treatment. For a 
transgene to be successful and provide long term treatment of infection, it must 
promote robust restriction of HIV-1 whilst preventing mutagenic escape of the virus. 
One possibility is to use a naturally occurring restriction factor which is shown to 
restrict HIV-1, such as owl monkey TRIM5Cyp (314, 315). This fusion protein is 
formed from LINE-1-mediated retrotransposition of CypA cDNA in between exons 
7 and 8 of the TRIM5 gene. This results in replacement of the B30.2 domain, which 
binds viral CA and determines the TRIM5α protein’s restriction specificity, with 
CypA. As owl monkey CypA binds HIV-1, this moiety recruits the antiviral function 
of TRIM5 to HIV-1, providing potent restriction of the virus.  
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Retrotransposition occurs frequently, but does not often result in a functional 
protein, yet remarkably this event has occurred a second time in Old World monkeys 
(317-319, 375, 376). In this instance, CypA cDNA is found in the non-coding region 
of exon 8. Independently of the retrotransposition, a single nucleotide polymorphism 
has resulted in the inactivation of the splice acceptor in exon 7. This results in 
skipping of exons 7 and 8 and splicing of TRIM5 exon 6 to the CypA splice 
acceptor. Therefore owl monkey TRIM5Cyp encodes exons 2-7 of TRIM5 and in 
Old World monkeys exons 2-6 are fused to the Cyp domain. These different CypA 
insertion sites indicate that these proteins have evolved through entirely independent 
retrotransposition events. The restriction specificity of the two proteins also differs, 
with owl monkey TRIM5Cyp targeting HIV-1 and FIV, mirroring the binding 
capacity of the native Cyp protein. The Cyp domain in macaque TRIM5Cyp has 
acquired a point mutation, H69R, which alters the Cyp binding specificity from the 
genomic Cyp protein. Therefore, macaque TRIM5Cyp is able to restrict HIV-2, FIV 
and group O HIV-1 (320, 376). 
 
Owl monkey TRIM5Cyp provides strong protection against HIV-1, but despite the 
high level of homology between human and owl monkey TRIM5 and CypA, there is 
a risk this protein would induce an immune response if expressed in humans in a 
gene therapy setting due to the variation between the human and primate sequences. 
However, production of a humanised TRIM5Cyp restriction factor mimicking the 
structure of the owl monkey protein may avoid this problem. A humanised 
TRIM5Cyp molecule was developed by Neagu et al independently of our efforts. 
The group has reported highly effective restriction of HIV-1 in vitro and in a 
humanised mouse model of HIV-1 infection (322). 
The owl monkey TRIM5Cyp protein consists of a 299 amino acid fragment of 
TRIM5 encoding the RBCC domains, followed by an 11 amino acid linker derived 
from the 5’ untranslated region of CypA, then amino acids 1-147 of CypA. The 
resultant protein has a weight of 54kDa (314, 315). Due to a lack of sequence 
homology between human and owl monkey, the 5’UTR cannot be used to generate a 
human fusion. Therefore Neagu et al generated several different TRIM5Cyp proteins 
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by fusion of CypA directly to TRIM5 at different amino acids along its length, 
varying from directly at the C terminal of the coiled coil domain, to over 100 amino 
acids within the B30.2 domain. These proteins were initially screened for restriction 
of an HIV-1 vector encoding GFP. There was significant variability in the restriction 
by different constructs, suggesting that the linker region between the TRIM5 and 
CypA fragments influences whether the protein is capable of restriction.  
In addition to these human fusion proteins, a TRIMCyp protein using feline TRIM5 
and CypA has been generated. Feline CypA is able to bind FIV and HIV-1 CA and 
accordingly this TRIMCyp can restrict these lentiviruses (323).  
Using a similar strategy, the mouse restriction factor Fv1 has been fused to CypA 
from owl monkey TRIM5Cyp, to form a potent inhibitor of HIV-1 and FIV (325). 
Fusion of CypA to Fv1 alters the antiviral specificity of Fv1 to be determined by the 
CA binding specificity of CypA. However the restriction mechanism of Fv1 is 
maintained, in which restriction occurs later in infection than that by TRIM5 or 
TRIM5Cyp as shown by the presence of reverse transcripts. This demonstrates that 
Cyp is able to recruit these restriction factors to the CA, resulting in viral restriction.  
 
Here, novel versions of human TRIM-Cyclophilin fusion molecules have been 
designed and tested for efficacy against HIV-1. The RBCC motifs of TRIM5 and its 
close phylogenetic relative, TRIM21, which shares the same domain structure, have 
been fused to human CypA. These constructs have been cloned into retroviral and 
lentiviral vectors to test their restriction of an HIV-1 vector to demonstrate their 
potential for anti-HIV-1 gene therapy. 
Initial restriction assays have been performed in cell lines, but the ultimate target cell 
for gene therapy would be T cells or HSCs. Restriction was measured using a single 
round of transduction with a second generation SIN HIV-1 vector. This vector was 
generated in HEK293T cells using the same plasmids for the generation of gene 
therapy vectors. In these virus particles, CA is derived from a GagPol expression 
plasmid encoding wild type HIV-1 CA sequence, which includes the CypA binding 
site. In experiments described here, the HIV-1 vector carries a fluorescent marker 
gene allowing rapid quantification of infection by flow cytometry. Experimentally 
99 
 
this is a convenient method to test restriction as work does not need to be performed 
at containment level 3 as for replication competent HIV-1.   
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3.3 Cloning TRIM5Cyp constructs into a gamma 
retroviral vector 
Three novel TRIM5 and CypA fusion constructs were designed that consisted of 
TRIM5 sequence, a NotI restriction site that translated to three alanine residues 
(AAA) and then the Cyp cDNA sequence at the C terminal (Figure 3.1A). The 
TRIM5 fragments were generated by PCR amplification of the TRIM5 RBCC motif 
and ligation into pEXN containing the human CypA cDNA sequence between NotI 
and SalI (a gift from Dr. Torsten Schaller). The resulting plasmid expressed HA-
tagged human TRIM5CypA under the control of the CMV promoter and was named 
pEXN/TRIM5Cyp. The constructs differed in the length of the linker region between 
the 3’ end of the TRIM5 RBCC motif and the start codon at the 5’ end of CypA. All 
constructs included the entire RBCC motif, with the longest protein including the 
first 8 amino acids of the B30.2 domain in the TRIM5 fragment 5’ of the NotI site. 
The number of the final amino acid of the TRIM5 RBCC sequence 3’ of the NotI 
restriction site and CypA sequence is denoted in the name of each construct i.e. 306, 
298 and 287 (Figure 3.1B). 
pEXN/T5Cyp was used to generate retroviral vector by transient transfection of 
HEK293T cells, in combination with an MLV gag-pol packaging plasmid and the 
VSV-G envelope plasmid, pMDG (Figure 3.2). Control vector was derived from the 
pEXN parent plasmid. 
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Figure 3.1 Design of TRIMCyp fusion constructs 
 A. Schematics of native TRIM5α and TRIMCyp fusion constructs. The figure shows RING, B-box2, 
coiled coil (CC) and B30.2 domains. Three TRIM5Cyp constructs were generated, which differed in 
the length of the linker region between the end of the RBCC and beginning of the CypA cDNA. The 
RBCC motif of TRIM21, which has a similar domain structure to TRIM5α, was also fused to CypA 
to create TRIM21Cyp. 
B. Amino acid sequence of native TRIM5α. RING, B-box2, coiled coil and B30.2 domains are 
labelled. The horizontal red lines and numbers above indicate the TRIM5 amino acid at the C 
terminal of the TRIM5 RBCC fragment to which CypA is fused. This number is used in the naming 
of each construct. 
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Figure 3.2 Plasmids for generation of retrovirus 
Three TRIM5Cyp constructs were cloned into a murine leukaemia virus (MLV) retroviral vector, 
pEXN, allowing expression from the Cytomegalovirus (CMV) promoter and addition of a 
haemagglutinin (HA) tag at the N terminal. pEXN or pEXN/TCyp, MLV packaging plasmid and 
pMDG VSV-G env plasmid were used to transiently transfect HEK293T for generation of retroviral 
particles. LTR=long terminal repeat, Neo=neomycin resistance gene, pA=polyA  
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3.4 Expression of TRIM5Cyp protein in cell lines 
CRFK cells were transduced with EXN/T5Cyp retrovirus carrying one of the three 
different TRIM5Cyp constructs, or EXN virus for control, and cultured in G418 
selection media. CRFK cells were used because feline cells do not express TRIM5α, 
leaving them susceptible to retroviral infection. They only express the RBCC 
domains as there is a premature stop codon in exon 8, from which the B30.2 domain 
is normally expressed (377).  
Western blotting was used to confirm the expression of the HA tagged TRIMCyp 
fusion protein from EXN using an anti-HA tag antibody (Figure 3.3). There were 
some non-specific bands present in all cell populations, but a highly specific band of 
the correct size present in TRIM5Cyp transduced populations, but not the controls. 
The molecular weights of the three different constructs are shown: T5Cyp306-55 
kilodaltons (kDa), T5Cyp298-54kDa and T5Cyp287-52kDa.  
 
 
Figure 3.3 Expression of TRIM5Cyp from retroviral vector 
Western blotting using anti- haemagglutinin (HA) tag antibody on transduced CRFK cells selected in 
puromycin. Untransduced (UT) or empty EXN vector transduced cells were used as controls. β-actin 
was used as a loading control.  
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3.5 CRFK cells transduced with TRIM5Cyp retroviral 
vectors are able to inhibit HIV-1 vectors 
CRFK cells transduced with EXN/TRIM5Cyp virus carrying one of the three 
different TRIM5Cyp constructs, or EXN virus as a control, were selected in G418 
media to produce a stably transduced polyclonal population of cells. In addition, 
limiting dilution was used to obtain individual clones for each of the three 
TRIM5Cyp constructs.  
To test lentiviral restriction, the cells were challenged with an eGFP-expressing 
HIV-1 vector (HIV-1-GFP) in the presence or absence of CsA, a competitive 
inhibitor of the interaction between CypA and HIV CA. After 48 hours, cells were 
analysed by flow cytometry to measure the number of eGFP positive cells. 
Restriction in the polyclonal bulk population (Figure 3.4A) and three clones for each 
of the three TRIM5Cyp constructs (Figure 3.4B) was measured by flow cytometry. 
All three TRIM5Cyp constructs were able to restrict HIV-1 entry into cells 
compared to the untransduced and the EXN transduced control cells, as shown by 
the reduction in eGFP positive cells. In particular, the inhibitory effect in the 
TRIM5Cyp306 and TRIM5Cyp298 bulk populations was most prominent, being 
able to reduce HIV-1 transduction approximately 10 fold. Addition of CsA at the 
point of HIV transduction prevented restriction by TRIM5Cyp in all instances. 
Minor variations between clonal populations were detected with approximately 10 
fold decrease in HIV-1 transduction in almost all clones.  
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Figure 3.4 Restriction of HIV-1 by TRIM5Cyp retroviral vectors 
A. CRFK cells transduced with the three different TRIM5Cyp vectors were transduced with an HIV-1 
lentiviral vector expressing GFP in the presence or absence of 5µM Cyclosporin A (CsA). 
Untransduced (UT) cells or EXN transduced cells were used as controls. The percentage of GFP 
positive cells was measured by flow cytometry 48 hours post transduction. Results shown are 
representative of two independent experiments. 
B. Bulk transduced populations of CRFK cells were plated out by limiting dilution to obtain clones. 
These cells were then transduced with an HIV-1-GFP lentiviral vector in the presence or absence of 
5µM CsA. Untransduced cells and EXN transduced cells were used as controls. The percentage of 
GFP positive cells was measured by flow cytometry 48 hours following transduction. Results shown 
are representative of two independent experiments.  
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3.6 Cloning TRIMCyp constructs into a lentiviral vector 
For use in gene therapy, lentiviral vectors may be advantageous to previously 
described gamma retroviral vectors because of their safer integration profile and 
their ability to transduce non-dividing cells. Therefore, the TRIM5Cyp constructs 
described above were cloned into an HIV-1 derived lentiviral vector backbone, 
pLNT/SIEW (373). This lentiviral backbone, abbreviated to SIEW, is a second 
generation HIV-1 derived vector, with a self-inactivating (SIN) 3’ LTR and cPPT. It 
includes the spleen focus forming virus U3 promoter (SFFV), an internal ribosomal 
entry site (IRES) and a Woodchuck post transcriptional regulatory element (WPRE). 
All three TRIM5Cyp constructs were amplified from pEXN by PCR and ligated into 
pLNT/SIEW at the unique BamHI site to produce the plasmid pLNT/S-TRIM5Cyp-
IEW (Figure 3.5). pLNT/SIEW expressed just eGFP and served as a vector 
backbone control. 
 
Another TRIMCyp construct using the first 284 amino acids encoding the RBCC 
domains from TRIM21 (as discussed further in chapter 5) fused to CypA was also 
tested (Figure 3.1A). Similar to the TRIM5Cyp constructs, TRIM21Cyp was 
synthesised by PCR amplification of the TRIM21 RBCC domains and ligated to 
CypA at the 3’ end via a NotI restriction site. The entire construct, TRIM21Cyp284, 
was provided in the lentiviral plasmid pSFXUC (a gift from Dr. Torsten Schaller). 
TRIM21Cyp284 was removed from pSFXUC by digestion with BamHI before 
ligation into pLNT/-SIEW. The resulting plasmid was named pLNT/S-TRIM21Cyp-
IEW (Figure 3.5). 
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Figure 3.5 Plasmids for generation of lentivirus 
A. TRIM5Cyp and TRIM21Cyp constructs were cloned into a self-inactivating lentiviral vector 
backbone, pLNT/SIEW, under control of the SFFV promoter and linked to eGFP expression with an 
IRES. Lentiviral vector particles were produced by transient transfection of HEK293T cells with this 
vector plasmid, the second generation lentiviral packaging plasmid p8.74 and pMDG. Ψ=packaging 
signal, RRE=Rev responsive element, cPPT=central polypurine tract, WPRE= Woodchuck hepatitis 
virus post transcriptional regulatory element, CMV=cytomegalovirus, pA=polyadenylation.  
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3.7 Expression of TRIMCyp protein in transduced cell 
lines 
TRIMCyp expression in CRFK cells transduced with LNT/S-TRIM5Cyp306-IEW 
and LNT/TRIM21Cyp284-IEW was detected using an anti-Cyp antibody. Blots 
were re-probed using an anti-β-actin antibody as a protein loading control (Figure 
3.6). 
Without the HA tag, the TRIMCyp proteins are approximately 1kD smaller than 
those expressed from the EXN vector, giving the following final molecular weights: 
T5Cyp306-54kDa, T21Cyp284-51kDa.  
Protein could be detected in TRIMCyp transduced populations, but not in the 
LNT/SIEW (GFP) transduced control. When using the anti-Cyp antibody, 
endogenous Cyp protein could also be detected. Although the antibody was raised 
against the human protein, human and feline CypA have over 95% amino acid 
sequence homology and both have a molecular weight of 18kDa. This band serves to 
act as an additional loading control.  
 
Figure 3.6 Expression of TRIMCyp from lentiviral vectors 
Western blotting using anti-Cyp antibody was used to confirm TRIMCyp expression in transduced 
CRFK cells. SIEW (GFP) transduced cells were used as controls. Anti-β-actin and endogenous Cyp 
were used as loading controls.  
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3.8 Expression of TRIMCyp does not restrict lentiviral 
packaging during vector production 
Lentiviral vector stocks were produced by transient transfection of HEK293T cells 
with the lentiviral vector plasmid, second generation lentiviral packaging plasmid 
p8.74 and VSV-G envelope plasmid, pMDG (Figure 3.5). The parental plasmid, 
pLNT/SIEW, was used to produce GFP virus for use as a control. Virus particles 
were harvested at 48 and 72 hours after transfection and concentrated by 
ultracentrifugation. The titre of each virus batch was quantified by transduction of 
HEK293T cells with serial dilutions of virus stock and enumeration of eGFP 
positive cells by flow cytometry 72 hours after transduction (Figure 3.7A). The 
number of infectious units per ml (IU/ml) was calculated. Values were only taken 
from samples where the percentage of transduced eGFP positive cells ranged 
between 1-10% to reduce the likelihood of multiple copies of integrated vector per 
cell.  
 
Producing an HIV-1 derived lentiviral vector expressing an anti-HIV-1 restriction 
factor could potentially cause a decrease in titre through restriction during 
packaging, so initial vector stocks were generated in the presence or absence of CsA. 
CsA reversibly inhibits CypA binding of HIV-1 CA and could therefore prevent 
interaction of TRIMCyp with Gag in packaging cells. CsA was added to the medium 
after transfection and virus production was performed as previously. Vector was 
titrated on HEK293T by measuring eGFP expression as described above (Figure 
3.7B).  
There was no difference in titre for the different vectors either in the presence or 
absence of CsA, with all stocks generating titres of above 1x10
8 
IU/ml. This is 
within the expected range of titre using this protocol to produce lentiviral vector 
concentrated by ultracentrifugation, and other subsequent vector preparations have 
reached this titre. 
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Figure 3.7 Titration of lentiviral vector 
A. 1x10
5
 HEK293T cells were transduced with serial dilutions of lentiviral vector stocks in a total 
volume of 300µl. eGFP positive cells were measured by flow cytometry 72 hours post transduction. 
The percentage of positive cells is displayed in the gate and was used to calculate titre in infectious 
units/millilitre (IU/ml). 
B. Lentiviral vector stocks were produced in the presence or absence of 5µM Cyclosporin A (CsA) to 
inhibit potential interactions between TRIMCyp and HIV CA. The titre of viral stocks was measured 
by flow cytometry and compared between the two treatments.  
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3.9 TRIMCyp restricts HIV-1 vector in cell lines 
Restriction of HIV-1 by TRIMCyp in CRFK cells 
Following production of lentiviral vector carrying the TRIM5Cyp and TRIM21Cyp 
constructs and confirmation of protein expression by Western blotting, it was 
necessary to test their function as a restriction factor. CRFK cells were stably 
transduced with one of the three TRIM5Cyp or the TRIM21Cyp constructs in the 
SIEW lentiviral vector at an MOI of 3. Untransduced and SIEW (GFP) transduced 
cells were used as controls. The cells were cultured for at least 72 hours to allow 
protein expression of eGFP, which could be visualised by microscopy, before 
challenge with an HIV-1 vector expressing YFP at an MOI of 3 in the presence or 
absence of CsA. Cells were analysed by flow cytometry to measure eGFP and YFP 
expression following a further 72 hours (Figure 3.8). 
The transduction efficiency with the SIEW vectors was high, with between 70 and 
90% of cells expressing eGFP. Approximately 40% of untransduced or SIEW 
transduced control cells became infected by HIV-1 when challenged. In TRIMCyp-
eGFP positive cells, there was a dramatic reduction in HIV-1-YFP transduction to 
less than 1% of cells as YFP positive.  
CsA acts as a reversible inhibitor of CypA binding to HIV-1 CA, by interacting with 
the CypA active site. Treatment of cells with CsA at the time of HIV-1-YFP 
transduction abrogated TRIMCyp inhibition allowing HIV-1-YFP transduction 
levels comparable to that in the control cells. 
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Figure 3.8 Restriction of HIV-1 by TRIMCyp proteins in CRFK cells 
A. CRFK cells transduced with three different S-TRIM5Cyp-IEW or S-TRIM21Cyp-IEW lentiviral 
vectors were challenged with HIV-1-YFP vector in the presence or absence of 5µM Cyclosporin A 
(CsA). Untransduced and SIEW (GFP) transduced cells were used as controls. eGFP and YFP 
expression was measured by flow cytometry 72 hours after HIV transduction. After gating on eGFP 
positive cells, the percentage of YFP positive cells was measured. 
B. Examples of flow cytometry plots of eGFP and YFP expression for the most potent inhibitors, 
TRIM5Cyp306 and TRIM21Cyp, are shown. Results shown are representative of two independent 
experiments.  
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Restriction of HIV-1 by codon optimised TRIM21Cyp 
An additional variant based on TRIM21Cyp was generated using a codon optimised 
TRIM21Cyp gene (TRIM21CypCO). Codon optimisation of transgenes maintains 
the amino acid sequence of the original protein, but adjusts the cDNA sequence to 
improve mRNA stability and optimise translation for improved protein expression. 
Adjustments include alteration of codon usage for expression in human cells, 
removal of repeat sequences, RNA secondary structures, cryptic splice sites, 
intragenic polyA signals and internal ribosomal entry sites and optimisation of GC 
content. Codon optimisation was undertaken by Geneart using a proprietary 
algorithm. Direct comparison between the original vector, pLNT/S-T21Cyp-IEW, 
and the codon optimised variant pLNT/S-T21CypCO-IEW was undertaken.  
Lentivirus was produced and the titre quantified by transduction of HEK293T cells 
and flow cytometry to measure eGFP expression. Both plasmids produced 
comparable titres of approximately 1x10
8
IU/ml (Figure 3.9A). Interestingly, the 
mean fluorescence intensity (MFI) of the eGFP expression from the vector carrying 
the codon optimised transgene was around 3 fold higher (1.6x10
4
) compared to the 
original vector (4.8x10
3
). Although all vector sequences, including the eGFP gene 
sequence, were identical in both plasmids, it is possible that codon optimisation of 
the TRIM21Cyp gene increased stability of the RNA transcripts and consequently 
allowed increased expression of eGFP. 
CRFK cells were transduced with vector encoding either the original or the codon 
optimised TRIM21Cyp, at an MOI of 3 and cultured for three days. 85-95% of cells 
were transduced as shown by GFP expression measured by flow cytometry. These 
cells were analysed by Western blot and shown to express TRIM21Cyp protein by 
using an anti-CypA antibody (Figure 3.9B). 
These cells were then transduced with HIV-1-YFP to measure viral restriction. 
Again, untransduced and GFP transduced cells were used as controls. eGFP and 
YFP expression were measured 72 hours after HIV-1-YFP transduction by flow 
cytometry (Figure 3.9C). Restriction by the codon optimised TRIM21Cyp was 
comparable to the original protein and suggests that simply increasing protein 
expression may not increase restriction. 
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Figure 3.9 Analysis of the codon optimised TRIM21Cyp construct 
The codon optimised TRIM21Cyp construct (TRIM21CypCO) was cloned into pLNT/SIEW for 
comparison with the original TRIM21Cyp transgene in terms of A) vector titre, B) protein expression 
and C) HIV-1-YFP restriction.  
A. S-T21Cyp-IEW or S-T21CypCO-IEW virus was titrated on 1x10
5
 HEK293T cells by serial 
dilution and quantification of GFP expression by flow cytometry 72 hours post transduction. Titre 
was calculated in infectious units/millilitre (IU/ml). 
B. Expression was measured by Western blotting of lysates from CRFK cells transduced with either 
of the TRIM21Cyp vectors, with untransduced or SIEW (GFP) transduced cells as control. 
Endogenous Cyp levels were used as a loading control. 
C. CRFK cells transduced with S-T21Cyp-IEW or S-T21CypCO-IEW were challenged by 
transduction with HIV-1-YFP at an MOI of 10. GFP and YFP co-expression was quantified by flow 
cytometry 72 hours post transduction.  
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Saturation of TRIMCyp restriction of HIV-1 
It is possible to saturate the restriction effect mediated by TRIM5α (183). To 
investigate the levels of restriction that TRIM5Cyp and TRIM21Cyp are able to 
provide against HIV-1, TRIMCyp expressing CRFK cells were subjected to 
increasing MOI of HIV-1-YFP, from 0.1 up to 1000. Levels of restriction were 
measured by flow cytometry for YFP expression at 72 hours after HIV-1-YFP 
transduction (Figure 3.10). At the lowest MOI of 0.1, HIV-1-YFP transduction was 
around background level in all populations. HIV-1-YFP transduction in 
untransduced and GFP control cells rapidly increased with increasing MOI, whereas 
the percentage of YFP positive cells in TRIMCyp expressing populations remained 
under 1% until an MOI of 10 was used. Control cells were fully transduced using an 
MOI of approximately 10, but an MOI of 1000 was required to saturate TRIMCyp 
restriction. 
 
Figure 3.10 Saturation of TRIMCyp restriction of HIV-1 at high MOI 
CRFK cells transduced with S-TRIM5Cyp-IEW or S-TRIM21Cyp-IEW lentiviral vectors were 
challenged with increasing multiplicities of infection (MOI) of HIV-1-YFP vector. Untransduced 
(UT) and SIEW (GFP) transduced cells were used as controls. eGFP and YFP expression was 
measured by flow cytometry 72 hours after HIV transduction. Gating on the eGFP positive 
population, the percentage of YFP positive cells was quantified. Data is representative of two 
separate experiments.  
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Comparable restriction of HIV-1 by TRIMCyp and published variants 
The TRIMCyp constructs described in this thesis were generated independently of 
the published humanised TRIM5Cyp proteins, which also mimic the owl monkey 
restriction factor (322). This published TRIM5Cyp construct, which here is referred 
to as TRIM5Cyp322, was tested in a lentiviral vector, pscALPS (a gift from Jeremy 
Luban), and has been shown to inhibit HIV-1 at levels comparable to the naturally 
occurring owl monkey TRIM5Cyp restriction factor. 
Although both the published construct and TRIM5Cyp306 are fusion proteins of 
human TRIM5 and full length CypA, there are differences in their design. Firstly, 
TRIM5Cyp322 has a longer linker region between the TRIM5 RBCC C terminal and 
beginning of the CypA domain. The TRIM5 fragment consists of the first 322 amino 
acids of full length TRIM5α, which includes the complete RBCC domain and the N 
terminal of the B30.2 domain. CypA, not including the ATG start codon, is then 
fused to the TRIM5α fragment at amino acid S322. Alternatively, TRIM5Cyp306 
has a TRIM5α fragment truncated at amino acid N306, resulting in a linker region 
between RBCC and CypA that is 16 amino acids shorter than in TRIM5Cyp322. 
This linker incorporates 8 amino acids of the B30.2 domain N terminal.  
Secondly, TRIM5Cyp306 includes a NotI restriction site between the TRIM5 C 
terminal and CypA N terminal, which was included in the construct during cloning. 
This restriction site encodes an additional three alanine residues. TRIM5Cyp322 was 
produced by overlapping PCR and therefore does not contain any extra sequences in 
addition to TRIM5 and CypA. DNA sequences of the TRIM5-Cyp junction of the 
two transgenes are aligned for comparison in Figure 3.11A. 
The pLNT/SIEW and pscALPS vector backbones were of different configurations. 
pLNT/SIEW consisted of the SFFV promoter driving TRIMCyp expression 
followed by an IRES-eGFP, whereas pscALPS is a bicistronic vector which uses 
SFFV to drive TRIMCyp expression followed by the CypA promoter for expression 
of eGFP (Figure 3.11B).  
To compare the restriction levels of this published TRIM5Cyp construct and the 
TRIMCyp constructs described in this project, lentivirus was produced using the 
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pLNT/SIEW and pscALPS plasmids carrying TRIM5Cyp306 and TRIM5Cyp322 
respectively and the previously described packaging and envelope plasmids.  
CRFK cells were transduced with LNT/S-TRIM5Cyp306-IEW, LNT/S-
TRIM21Cyp284-IEW or scALPS/TRIM5Cyp322, using LNT/SIEW as a control, at 
an MOI of 10. The resultant populations had a high level of transduction, with 
between 75 and 85% GFP positive. These cells were transduced with HIV-1-YFP at 
an MOI of 3 or 30. After a further 72 hours, eGFP and YFP co-expression was 
measured by flow cytometry (Figure 3.11D).  
By gating on eGFP positive cells, the percentage of cells co-expressing YFP was 
measured. All three TRIMCyp constructs were strong inhibitors of HIV-1-YFP, 
reducing YFP transduction by nearly 100 fold at the lower MOI. At the higher MOI 
of HIV-1-YFP of 30, TRIM5Cyp306 and TRIM21Cyp284 in the LNT/SIEW vector 
provided slightly more protection against HIV-1-YFP than scALPS-TRIM5Cyp322, 
with 2-3% of cells transduced compared to 9%, although this difference was not 
significant (P=0.15-0.16).  
The copy number of integrated vector was compared between cells transduced with 
the different vectors by qPCR with primers targeting WPRE. The copy number was 
approximately 2 fold higher in the TRIM5Cyp306 transduced cells (20.9 copies) 
compared to TRIM5Cyp322 (9.4 copies); with TRIM21Cyp284 cells (14.6 copies) 
having an intermediate copy number. This may explain the slightly enhanced 
restriction in TRIM5Cyp306 cells, although the restriction by all three constructs is 
essentially comparable. 
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Figure 3.11 Comparison of TRIMCyp with published TRIM5Cyp 
A. A humanised TRIM5Cyp construct has been independently designed and tested (322). This 
published variant, TRIM5Cyp322 (lower sequence) differs from the previously described 
TRIM5Cyp306 (upper sequence). The TRIM5 fragment is longer, terminating at amino acid 322 and 
does not include any sequences in addition to TRIM5 and Cyp, whereas TRIM5Cyp306 has a NotI 
restriction site (indicated by black box). The DNA sequences of the two TRIM5Cyp factors are 
aligned, showing the junction between TRIM5 (blue underlined) and Cyp sequences (red underlined). 
Nucleotides in pink differ between the two sequences and those in black are homologous. 
B. TRIM5Cyp306 and TRIM21Cyp284 were in pLNT/SIEW, which uses an IRES-eGFP 
configuration. TRIM5Cyp322 was in a lentiviral vector under control of the viral SFFV promoter, 
followed by eGFP under control of the CypA promoter (CypP).  
C. CRFK cells were transduced with S-TRIM5Cyp306-IEW, scALPS-TRIM5Cyp322 or S-
TRIM21Cyp284-IEW at a multiplicity of infection (MOI) of 3. Untransduced (UT) and SIEW (GFP) 
transduced cells were used as controls. Cells were challenged with HIV-1-YFP at a MOI of 3 and 30, 
and eGFP and YFP co-expression was measured by flow cytometry 72 hours later. Samples were 
performed in triplicate, error bars show standard error of the mean.  
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3.10 TRIMCyp vectors transduce primary T cells and 
restrict HIV-1 
For use in gene therapy, TRIMCyp vectors would be used to transduce patient cells 
ex vivo, producing a population that is resistant to HIV-1, before reintroducing them 
back into the patient. The primary target cells of HIV-1 are CD4
+
 T cells, making 
them an obvious choice for vector modification. It is necessary to show that these 
vectors are capable of transducing human T cells and driving transgene expression. 
PBMCs were harvested from healthy donors and activated with anti-CD3/anti-CD28 
beads and IL-2 to enhance transduction. After 48 hours activation, cells were 
transduced with TRIMCyp vectors (either TRIM5Cyp306 or TRIM21Cyp284), with 
untransduced and (SIEW) GFP transduced cells as controls. After 72 hours, cells 
were transduced with an HIV-1-YFP, and eGFP and YFP expression measured by 
flow cytometry after a further 72 hours (Figure 3.12). 
It was possible to efficiently transduce primary T cells with LNT/SIEW. However, 
there was great variation in efficiency. For TRIMCyp vectors the percentage of GFP 
positive cells after transduction ranged from 3-20%. In all experiments the 
transduction efficiency with the GFP vector was always higher than those also 
carrying the TRIMCyp transgene, reaching up to 40% in some experiments. 
In TRIMCyp transduced populations there was very little co-expression of eGFP and 
YFP, indicating restriction of HIV-1-YFP in TRIMCyp expressing cells. The 
percentage of YFP transduced cells in the TRIMCyp-eGFP population is 10 fold 
lower than in control cells. Although there is co-expression of YFP in GFP positive 
cells transduced with LNT/SIEW, this level is reduced compared to untransduced 
control cells. It could be that the initial transduction with LNT/SIEW affects fitness 
of the T cells, leading to less efficient subsequent transduction with the HIV-1-YFP 
vector. 
TRIMCyp expression could not be confirmed by Western blot in these cells. 
However, it has previously been shown difficult to obtain clear bands and therefore 
in the case of T cells, in which the percentage of transduced cells is much lower than 
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those seen in cell lines, it is not surprising that the protein could not be detected by 
Western blotting. 
 
 
Figure 3.12 TRIMCyp restriction of HIV-1 in primary T cells 
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were activated for 48 hours 
with anti-CD3/anti-CD28 beads, before transduction with S-TRIM5Cyp306-IEW or S-
TRIM21Cyp284-IEW vectors. Untransduced (UT) and SIEW (GFP) transduced cells were used as 
controls. After 72 hours, cells were challenged with HIV-1-YFP and flow cytometry used to measure 
eGFP and YFP expression after a further 72 hours.  
A. Example of flow cytometry plots showing eGFP and YFP expression. 
B. Gating on the eGFP positive population, the percentage of YFP positive cells was measured and 
shown. N=3, error bars show the standard error of the mean. 
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3.11 Summary 
Humanised TRIM5-Cyclophilin A fusions were designed mimicking the naturally 
occurring owl monkey restriction factor. They differed from previously published 
TRIM5Cyp restriction factors (322) in the length of the linker region between the 
end of the TRIM5 RBCC and the CypA cDNA and the presence of a NotI restriction 
site. Three different constructs were produced that varied in their linker lengths 
between the C terminal of the RBCC and start of the Cyp domain, with the longest 
linker in TRIM5Cyp306 including the first amino acids of the B30.2 domain.  
Initially, the different TRIM5Cyp constructs were expressed from the retroviral 
vector EXN in CRFK cells and protein expression was confirmed by Western blot 
using an antibody against the N terminal HA tag on RING domain.  
The function of the TRIM5Cyp proteins was then tested by restriction of an HIV-1 
vector carrying an eGFP marker gene. All three TRIM5Cyp proteins were able to 
provide strong restriction of transduction of the HIV-1-GFP vector, as measured by 
flow cytometry. Restriction was comparable between the three different constructs; 
with each one causing between 10 and 100 fold restriction compared to 
untransduced cells or those transduced with the empty EXN vector. To confirm that 
the TRIM5Cyp protein was responsible for restriction, cells were treated with CsA, a 
reversible inhibitor of Cyp-CA binding, which rescued HIV-1-GFP transduction. 
The similar levels of potent restriction between the three constructs was unexpected 
considering the great variation in restriction seen by Neagu et al between 
TRIM5Cyp proteins of different lengths (322). Variation in viral inhibition is not 
simply explained by a correlation between length and restriction. Modeling by 
Neagu et al suggests that the point at which the CypA domain is fused to TRIM5 
affects restrictive ability as fusion to TRIM5 at residues clustered around a variable 
region within the B30.2 domain generated the strongest HIV-1 inhibitors (322). This 
variable region has been shown to undergo strong selective pressure and be directly 
involved in interaction with CA of susceptible virus (239). It is proposed that 
positioning the CypA moiety at this point enables efficient interaction between 
CypA and CA and co-ordination with the TRIM5 RBCC domains for antiviral 
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function (322). The three TRIM5Cyp proteins designed in this project were all able 
to restrict HIV-1, despite CypA fusion in TRIM5Cyp287 and TRIM5Cyp298 
occurring outside of the variable region in B30.2. This suggests that there is a degree 
of flexibility for the site on TRIM5 at which CypA is attached and that factors other 
than fusion within the B30.2 variable domain may influence whether TRIMCyp is 
capable of viral restriction. 
 
In addition to the three TRIM5Cyp fusions, a humanised TRIM21-Cyclophilin A 
transgene, TRIM21Cyp284, was designed using the same principles (a gift from Dr. 
Torsten Schaller). TRIM21Cyp284 was also cloned into the lentiviral vector 
pLNT/SIEW under the SFFV promoter linked to IRES-eGFP. Western blots were 
used to confirm protein expression, but the blots were not very sensitive. Typically 
TRIM proteins are not detected efficiently by Western blot so tagged proteins are 
frequently used to look at protein levels. This was also seen by Neagu et al with both 
owl monkey and restrictive human TRIMCyp, which failed to be detected by 
Western blot. Conversely, some non-restrictive constructs gave rise to strong bands, 
indicating that there is no correlation between protein levels and restrictive capacity 
(322).  
The unclear blots could be due to a problem with antibody recognition of the 
epitopes, although other anti-Cyp and anti-TRIM5 antibodies were tested, neither 
yielding clear protein bands through Western blotting. Therefore it could be 
indicative of low levels of expression or rapid protein degradation. In several 
instances, the TRIM21Cyp band was more prominent than the TRIM5Cyp, which 
was barely visible. TRIM5α and TRIM5Cyp are ubiquitinylated and degraded by the 
proteasome continuously and rapidly, with the TRIM5α half-life only 50-60 
minutes. This degradation requires RING and B-Box domains. Substitution of the 
TRIM5α RING with that of TRIM21 increases the protein half-life to about 210 
minutes (219). TRIM21 is a very stable protein (378), and presence of the TRIM21 
RING domain in TRIM21Cyp probably influences its rate of degradation. Treatment 
of cells with proteasomal inhibitors, such as MG132, may result in more prominent 
bands on the Western blot for both TRIMCyp proteins. Alternatively proteins could 
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be tagged. Here, TRIMCyp with an HA tag expressed from EXN was more reliably 
detected by Western blot than the untagged protein, but this would be unsuitable in a 
clinical setting. Similar difficulties arose in quantifying protein expression of 
TRIM21Cyp after codon optimisation. The quality of the Western blots made it 
difficult to reliably quantify differences in protein levels between the original and 
codon optimised genes, but importantly, both were shown to produce high titre 
vector, detectable protein and mediate potent restriction. 
 
Problems could arise when producing HIV-1 vectors carrying anti-HIV-1 transgenes 
as production of the vector could be inhibited following transgene expression in 
packaging cells, resulting in lower titres. In the case of the TRIMCyp transgene, 
there was no effect. Also, treatment of packaging cells with CsA during vector 
production did not result in any change in titre. The lack of interference is probably 
because Cyp only binds monomeric Gag weakly (241), with interactions occurring 
with high avidity to the mature processed Gag protein in a hexameric form (233, 
379). This more complex CA structure is only found in virions that have undergone 
maturation after release from producer cells. Packaging cells during vector 
production only contain full length Gag protein which is not recognised by 
TRIMCyp. Similarly, TRIM5α hexameric viral CA after cell entry, restricting before 
reverse transcription (188). Although it has been proposed that TRIM5α targets full 
length Gag during packaging causing a reduction in virion production (380), this 
theory has largely been discredited (381). Therefore TRIMCyp only targets CA of 
incoming virions after uncoating, which does not interfere with the production of 
lentiviral vector expressing TRIMCyp. 
 
CRFK cells transduced with both TRIM5Cyp and TRIM21Cyp lentiviral vectors 
were highly resistant to HIV-1. HIV-1 transduction was reduced between 10 and 100 
fold compared to control cells. Again, CsA treatment abrogated this restriction. 
Transduction with increasing MOI of HIV-1-YFP led to increasing numbers of cells 
becoming YFP positive, even when cells are producing TRIMCyp. A characteristic 
of viral restriction factors, for instance TRIM5α, is that they can be saturated with 
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high levels of sensitive virus particles (183). It required an extremely high MOI of 
1000 to saturate restriction of TRIMCyp protein. It is difficult to correlate this vector 
MOI with levels of HIV experienced by patients in vivo as there is both free virus in 
the blood and cell associated virus, and viral levels vary throughout the body, with 
higher concentrations at the lymph nodes for example. Restriction by TRIMCyp 
proteins here was similar to that mediated by the published humanised TRIM5Cyp, 
which has also been shown to restrict full length NL4-3 HIV in a humanised mouse 
model (322). The comparable levels of restriction suggest TRIM5Cyp306 and 
TRIM21Cyp284 are good candidates for further testing in clinical trials. 
 
Restriction assays in primary T cells are important as these are the main HIV-1 
target cell and are likely to be the first cells used for gene therapy in patients. 
Challenge of primary T cells with HIV-1-YFP following transduction with 
TRIMCyp or control vectors resulted in variable levels (5-40%) of infectivity. T 
cells are most efficiently transduced 48-72 hours after stimulation and in these 
experiments, challenge with HIV-1-YFP was undertaken 5 days after initial anti-
CD3/anti-CD28 bead stimulation to ensure prior integration and expression of 
TRIMCyp vectors. Thus, the difference in HIV-1-YFP infection between control and 
TRIMCyp modified groups was less prominent than detected in cell lines. 
In the future, these restriction experiments could use an HIV-1 vector carrying an 
alternative marker gene, such as red fluorescent protein. This would remove the 
requirement of separation of GFP and YFP fluorescence using alternative optical 
filters to the default filters of the flow cytometer. Although these filters and 
compensation allows GFP/YFP separation, use of an alternative to YFP would be 
more experimentally convenient. 
 
The fact that retrotransposition has occurred twice independently in different primate 
species to produce functional restriction factors suggests that fusion of TRIM5 and 
CypA is a successful strategy to produce strong retrovirus inhibitors. Although the 
natural target of these TRIM5Cyp proteins is not known, their maintenance in the 
species throughout evolution, particularly in owl monkeys which express no other 
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TRIM5 allele (315), suggests that they have played an important role in these 
primates in the protection against pathogens.  
Synthetic TRIMCyp fusion proteins have been generated using other TRIM RBCC 
motifs fused to CypA and have been shown to strongly restrict HIV-1 (324), but 
only restriction factors including the TRIM5 RBCC have been identified in nature. 
Therefore the TRIM5 RBCC must function particularly efficiently as a restriction 
factor effector domain, most likely due the roles of the native protein in innate 
immunity. Firstly, TRIM5α is a restriction factor and, although its specificity varies 
between species, provides potent inhibition of different retroviruses. Its C terminal 
B30.2 domain is involved in retroviral CA recognition, and the RBCC is involved in 
eliciting the downstream antiviral effect, including multimerisation and proteasomal 
degradation. Therefore after TRIM5Cyp recruitment via CypA recognition of viral 
CA, TRIM5 RBCC is able to function appropriately for retroviral restriction. 
Secondly, TRIM5α has a role in innate immune signaling by acting as a pattern 
recognition receptor. Binding of viral CA by the B30.2 domain increases the E3 
ubiquitin ligase activity of the TRIM5 RING domain, generating K63-linked 
ubiquitin chains. These in turn activate the TAK1 kinase complex causing 
upregulation of AP1 and NFκB signaling (252). This provides antiviral activity in 
addition to direct viral binding and degradation. Similarly with TRIM5Cyp, CA 
recognition by its Cyp domain allows downstream signaling via the RBCC domains 
as with TRIM5α (252). Of all of the members of the large TRIM family, this 
function as an effector in signaling has only been observed with TRIM5α. However, 
this role of activating innate immunity in response to retroviral infection is likely to 
be an important reason why there has been the evolution of efficient restriction 
factors by the fusion of the TRIM5 RBCC to Cyp on two separate occasions. 
 
Here we have designed TRIM5Cyp and TRIM21Cyp fusion constructs and cloned 
them into lentiviral vectors. Restriction assays in cell lines show that these proteins 
are able to provide potent restriction of HIV-1 derived vectors. Using the RBCC 
domains from either TRIM5 or TRIM21 produce equally efficient restriction factors 
that show promise for further development as an anti-HIV-1 gene therapy transgene.  
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4 TRIMCyp proteins restrict replication 
competent HIV-1 
4.1 Aims 
 To demonstrate restriction of wild type HIV-1 by TRIMCyp proteins in cell 
lines and primary T cells 
 To investigate whether TRIMCyp proteins provide cells with a survival 
advantage when infected with replication competent HIV-1 
4.2 Introduction 
Chapter 3 presents results in which TRIMCyp restriction of a single round of 
transduction by an HIV-1 derived vector is shown in different cell lines and primary 
T cells. These viral vectors include the CypA binding domain in their CA, enabling 
them to be targeted and efficiently inhibited by both TRIM5Cyp and TRIM21Cyp 
fusion proteins. In this chapter we have continued to investigate the restrictive 
abilities of one of the TRIM5Cyp proteins, TRIM5Cyp306, and TRIM21Cyp284, 
which are referred to as TRIM5Cyp and TRIM21Cyp respectively from this point 
forwards. 
Although these restriction factors have been shown to mediate potent restriction of 
HIV-1 vectors it is also necessary to measure restriction of full length, replication 
competent HIV-1. Replication competent virus, in contrast to the SIN HIV-1 vector 
would be able to continually replicate in a population of susceptible cells, leading to 
cell death, mirroring the loss of T cells seen in HIV-1 infected patients. Ideally 
following gene therapy, TRIMCyp expressing cells would have a strong survival 
advantage over untransduced cells, allowing their continued growth and proliferation 
to repopulate the host’s immune system. This would reduce the characteristic CD4+ 
T cell decline seen in HIV-1 patients and alleviate the associated pathology. A 
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therapeutic transgene that promotes a strong survival advantage is highly desirable 
in any gene therapy situation as it means that a smaller population of cells needs to 
be transduced to see a clinical benefit. 
 
To test the restriction of full length HIV-1 it is necessary to use cells that express the 
required receptors to allow HIV-1 entry, namely CD4 and either of the co-receptors 
CCR5 or CXCR4, depending upon the tropism of the virus. CCR5 is rarely 
expressed at high levels in cell lines and thus experiments described here have used 
Jurkats and GHOST cells which have been either been stably transfected or 
transduced with retroviruses to express CCR5/CXCR4. These lines allowed ready 
and reproducible quantification of HIV-1 restriction. 
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4.3 TRIMCyp proteins restrict HIV-1 in cell lines  
Restriction of replication competent HIV-1 was first measured in the GHOST cell 
line. GHOST-CCR5 cells are derived from human osteosarcoma cells and have been 
transduced with a retrovirus to express high levels of CD4 and CCR5 to allow 
infection with R5 tropic HIV-1 (371). These cells were transduced with LNT/SIEW 
expressing GFP alone as a control or the S-TRIMCyp-IEW vectors. Cells were 
cultured for several days to allow expansion and stable expression of TRIMCyp 
before staining with an anti-CCR5 antibody and FACS sorting for eGFP/CCR5 
double positive cells (Figure 4.1). These cells were infected with a single round of 
4.8ng p24 of the HIV-1 clone NL4-3 (BaL), which was derived from NL4-3 but with 
a BaL envelope to confer a CCR5 tropism. Seven days after infection, supernatant 
was harvested from cells. Levels of Gag protein within the media were measured by 
p24 ELISA and comparison to a standard curve of serially diluted p24 antigen 
(Figure 4.2A). Both untransduced and GFP transduced cells supported HIV-1 
replication leading to high levels of p24 being released into the culture medium 
(Figure 4.1B). However, in the cells expressing either TRIM5Cyp or TRIM21Cyp 
levels of p24 were highly significantly reduced compared to untransduced cells 
(P=0.001) and there was virtually no p24 detectable in the media. TRIM5Cyp and 
TRIM21Cyp appeared to restrict at a similar level with no significant difference 
between the levels of p24 in these populations (P=0.38). 
 
Recombinant replication competent lentivirus is not detected in TRIMCyp 
expressing cultures 
One concern associated with gene therapy is recombination events leading to the 
development of RCL. This could result in novel, pathogenic strains of virus and 
uncontrolled infection. This must be thoroughly tested before use in clinic, but here 
preliminary investigations have carried out to see whether recombinants could be 
detected.  
Culture supernatant was harvested from the transduced GHOST cells infected with 
HIV-1 in the above experiment. Supernatant was added to HIV-1 permissive Jurkat-
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CCR5 cells, which were grown for two weeks. Cell samples were taken at days 7 
and 14 and for WPRE copy number quantification by qPCR (Figure 4.2C). 
If RCL containing WPRE had formed in the GHOST-CCR5 cells after co-infection 
with lentiviral vector and full length HIV-1, this virus would be able to infect the 
permissive Jurkat cells. Therefore integrated WPRE would be detectable in these 
cells which have had no other exposure to vector. Once this occurred, further 
replication of RCL would lead to an increase in WPRE copy number over time. 
HEK293T transduced with LNT/S-T5Cyp-IEW DNA, and therefore containing 
integrated WPRE, was used as a positive control for the qPCR. In all Jurkat samples, 
the copy number of WPRE was never above the untransduced Jurkat negative 
control. 
This was a very preliminary experiment to detect mobilisation of WPRE from the 
vector construct in RCL, but thorough testing must be performed before any vectors 
can be used in patients, particularly for HIV-1 therapy as there is theoretically more 
chance of recombination occurring between both the HIV-1 derived vector and the 
infectious virus. Also, for use in a clinical setting, third generation packaging 
plasmids would be used rather than this second generation system. This would 
reduce the likelihood of RCL development by separation of the required genes over 
four plasmids and by deletion of the tat gene. 
 
 
 
Figure 4.1 Flow cytometric sorting of GFP
+
 CCR5
+
 GHOST cells 
GHOST-CCR5 cells were transduced with SIEW (GFP), S-TRIM5Cyp-IEW or S-TRIM21Cyp-IEW 
vectors and stained with an anti-CCR5 antibody. GFP and CCR5 expression was measured by flow 
cytometry as shown in the plots. CCR5 GFP double positive cells were sorted using a MoFlo XDP 
sorter and expanded for further experiments.  
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Figure 4.2 Restriction of replication competent HIV-1 in cell lines 
A. Representative graph of the protein standard curve used in p24 ELISAs. P24 antigen standard 
provided by the manufacturer was serially diluted to generate a standard curve, which was used to 
quantify p24 in culture supernatants. 
B. GFP/CCR5 double positive cells sorted from Figure 4.1 and untransduced (UT) control cells were 
infected with the HIV-1 clone NL4-3 (BaL). Culture supernatant was harvested 7 days after infection 
and levels of HIV-1 p24 in the medium measured by ELISA. Samples were performed in triplicate, 
error bars show the standard error of the mean.  
C. Culture supernatant was collected from the four cell lines in the experiment described in B and 
added to Jurkat-CCR5 cells. The cell population providing the supernatant (sup.) sample is indicated 
in the second column. Jurkat cells were cultured for 14 days with cell samples taken at days 7 and 14.  
DNA was extracted and WPRE copy number measured by quantitative PCR. Untransduced 
HEK293T cell DNA (UT 293T) was used as a negative control (top row). HEK293T cells transduced 
with S-T5Cyp-IEW (T5Cyp 293T) resulting in 8% eGFP positive were used as a positive control. 
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4.4  TRIMCyp confers a survival advantage to Jurkat cells 
infected with HIV-1 
Jurkat-CCR5 cells were transduced with LNT/SIEW, LNT/S-T5Cyp-IEW or 
LNT/S-T21Cyp-IEW at an MOI of 50 to produce a mixed population of partially 
transduced cells. Approximately 20-25% of cells were eGFP positive, as measured 
by flow cytometry (Figure 4.4A). This mixed population of cells was infected with 
0.32ng of replication competent HIV-1 R9, which is X4 tropic. The cells were 
grown in culture for one month, with regular passaging and flow cytometry to 
measure the number of viable cells. 
In preliminary experiments, R9 infected Jurkats were stained with fixable viability 
dye to measure the percentage of viable cells. The viable cells, which were negative 
for the stain, were backgated and a viable gate drawn on the forward/side scatter plot 
(Figure 4.3). There was a strong correlation between cell viability measured by 
live/dead staining or by forward/side scatter spread. Therefore for convenience in 
subsequent experiments, measurements of viability were taken simply by looking at 
the shift on forward/side scatter. 
 
Cells uninfected with HIV-1 maintained high viability of 80-90% throughout the 
experiment. In contrast after HIV-1 infection, viability in populations of partially 
transduced cells (containing 20-25% transduced cells) dropped dramatically in all 
samples to between 1 and 20% viable (Figure 4.4B). However, by day 17 post 
infection the TRIM5Cyp and TRIM21Cyp partially transduced cultures started to 
recover and there was an increase in the percentage of viable cells in these samples 
as protected cells replicated. By day 29 post infection, there were similar numbers of 
viable cells, approximately 70-80% of total cells, in the TRIMCyp transduced 
cultures as in the samples uninfected with HIV-1.  
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Figure 4.3 Confirmation of cell death using viability dye 
Cells were stained with viability dye and a viable gate drawn around viable cells, which were 
viability dye negative, in the total population (left hand panels). These cells were then backgated onto 
a forward/side scatter (FSc/SSc) plot and a gate drawn around the cells (central panels). This gate was 
then used to determine viable cells in the total cell population (right hand panels) and change in 
viability was measured as a shift on the FSc/SSc from this gate. Panels in A are from uninfected cells 
with high viability, in B cells are infected with HIV-1 and have a low viability. 
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Figure 4.4 TRIMCyp proteins confer a survival advantage to cells cultured with HIV-1 
A. Jurkat-CCR5 cells were transduced with TRIM5Cyp or TRIM21Cyp vectors to reach 
approximately 20% of total cells transduced. Untransduced (UT) and SIEW (GFP) transduced cells 
were used as controls.  
B. Cells were infected with a single dose of R9 HIV-1. Cell samples were taken regularly to measure 
cell viability by flow cytometry using the gating described in 4.3. 
  
134 
 
4.5 Restriction of HIV-1 by TRIMCyp in primary T cells 
As the predominant cell type infected by HIV-1, the most likely target cell for gene 
therapy in the first instance would be CD4
+
 T cells. It is important that TRIMCyp 
vectors are able to transduce and express in this cell population and to provide potent 
inhibition of HIV-1 as seen in the experiments in cell lines. 
Healthy volunteer donor PBMCs were separated through Ficoll gradient 
centrifugation of whole blood. These cells were activated using anti-CD3/anti-CD28 
beads and 100U/ml IL-2 for 48 hours before transduction with LNT/SIEW or 
TRIMCyp vectors at an MOI of between 10 and 30. Cells were expanded for 7 days 
to allow transgene expression, before staining for CD4 and FACS sorting for 
CD4/eGFP double positive cells (Figure 4.5). 
5x10
4
 sorted cells were seeded in a 96 well U bottomed plate and infected with 
0.45ng p24 NL4-3 (BaL) HIV-1. Five days post infection, p24 levels were measured 
in the media by ELISA (Figure 4.6A). Levels of p24 released into the media from 
TRIMCyp transduced cells was highly reduced compared to control samples. 
An MTT assay was performed on the cell pellets at the end of the experiment, but 
there was little cell death in HIV-1 infected cells compared to uninfected cells. Cells 
transduced with all vectors, including the SIEW (GFP) control, had increased 
survival compared to untransduced HIV-1 infected cells (Figure 4.6B). It is likely 
that as the cells were only cultured for five days after infection, this time period was 
not sufficient for cell death to occur, as with HIV-1 infected Jurkat cells, a decrease 
in viability was not seen until at least 10 days post infection. Ideally cells would be 
cultured for a longer time period to confirm whether a survival advantage is also 
seen in primary T cells, as for Jurkats, but it is difficult to culture these primary cells 
for such an extended period. 
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Figure 4.5 Flow cytometric sorting of CD4
+
 GFP
+
 T cells 
Peripheral blood mononuclear cells activated with anti-CD3/anti-CD28 beads and IL-2 were 
transduced with SIEW (GFP) or TRIMCyp vectors. Cells were stained with anti-CD4 antibody before 
sorting for CD4
+
 GFP
+ 
double positive cells. The top panel shows a representative forward and side 
scatter plot (FSc and SSc respectively) and the gate used for viable cells. The bottom four panels 
show each sorted sample, and the gate used for double positive cells. Untransduced cells were sorted 
for CD4
+
 only. The sorted cells, shown in red, were then used for HIV-1 restriction experiments. 
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Figure 4.6 TRIMCyp restriction of HIV-1 in primary T cells 
CD4/GFP double positive primary T cells obtained by flow cytometric sorting (shown in Figure 4.5) 
were infected with replication competent HIV-1 NL4-3 (BaL). At day 5 post infection, p24 was 
measured in the media by ELISA (A) and cell pellets were used for MTT assay (B). n=6 from two 
different donors, error bars show standard error of the mean. 
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Similarly, experiments in which a small proportion of TRIMCyp modified cells 
within an a bulk, unsorted T cell population were not extended sufficiently to detect 
a survival advantage. CD3/CD28 activated primary T cells were transduced with 
50µl LNT/SIEW or TRIMCyp vectors (MOI of 5-10), which resulted in 2-3% of 
TRIMCyp transduced cells as eGFP positive at the time of challenge with NL4-3 
(BaL) (Figure 4.7A). The proportion of eGFP positive cells remained constant over a 
period of 7 days after which cells were harvested and stained for viability (Figure 
4.7B). DNA was also extracted and WPRE copy number was measured by qPCR 
(Figure 4.7C). There was an increase in copy number per cell in TRIMCyp 
populations after infection with HIV-1. This suggests that transduced cells do have a 
survival advantage, although it is not large enough to be detected by flow cytometry 
with this experimental protocol. 
 
 
Figure 4.7 HIV-1 infection of primary T cells expressing TRIMCyp 
A. Primary T cells were transduced with LNT/SIEW (GFP) or TRIMCyp vectors and eGFP 
expression measured by flow cytometry. B. Seven days post infection with NL4-3 (BaL), cells were 
stained with viability dye and measured by flow cytometry. The percentage of viable cells in each 
population was calculated relative to uninfected cells of the same transduction. Samples were 
performed in triplicate, error bars represent standard error of the mean. C. DNA was extracted from 
cell seven days after infection. WPRE copy number was measured by quantitative PCR in uninfected 
populations and those infected by HIV-1.  
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4.6 Summary 
This chapter has shown that both TRIM5Cyp and TRIM21Cyp elicit strong 
inhibition of full length, replication HIV-1 clones. This has been shown in different 
permissive cell lines engineered to express HIV-1 receptors and also in primary T 
cells.  
 
In pure populations of GHOST cells expressing TRIMCyp, HIV-1 replication is 
effectively terminated, with very low levels of p24 present in the medium after 
infection. Similarly, in sorted T cell populations there was a significant decrease in 
p24 levels in the media of TRIMCyp expressing cells. 
Importantly, in experiments that are relevant to a clinical gene therapy situation, 
TRIMCyp expressing Jurkat cells have a survival advantage in mixed populations of 
partially transduced cells infected with replication competent HIV-1. Initially there 
was a drastic decrease in cell viability and the majority of cells died, but the 
TRIMCyp transduced populations recovered, with a large increase in viability. The 
percentage of cells that remain viable after the initial HIV-1 infection are around 
20%, which correlates with the percentage of transduced cells in the initial culture, 
indicating that it is TRIMCyp expressing cells that survive. This survival advantage 
is an appealing situation for gene therapy as it would mean that a smaller percentage 
of cells could be modified ex vivo prior to re-infusion back into a patient, and that 
these cells would survive and reconstitute a patient’s immune system with HIV-1 
resistant cells. The requirement of only a low percentage of transduced cells means 
that the transduction efficiency does not need to be as high and reduces the 
likelihood of multiple copies per cell, and therefore lowers the risk of insertional 
mutagenesis. 
Sufficient data was not collected to demonstrate this survival advantage in primary T 
cells. In a population of primary T cells with 2-3% of cells expressing TRIMCyp 
there was no significant difference in viability in TRIMCyp populations compared to 
untransduced cells. Longer culture periods may lead to an expansion of TRIMCyp 
expressing cells and loss of unmodified cells so that a difference between the two 
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populations could be detected. Prolonged culture of primary T cells in vitro will also 
have a negative effect on cell viability, making this protocol more problematic. 
However, it is important to be able to show that these TRIMCyp vectors can be used 
to transduce T cells, providing restriction of HIV-1, and that these cells have a 
survival advantage in infected populations. 
The survival and expansion of modified, resistant cells has been demonstrated in 
vivo in some clinical trials. For instance, CD34
+
 HSCs transduced to express a 
dominant negative Rev protein (130) and CD4
+
 T cells expressing antisense trans-
activation response (TAR) element and/or trans-dominant Rev (132) exhibited a 
survival advantage when under the selective pressure of HIV in patients. Therefore, 
to fully benefit from the survival advantage of transduced cells and promote their 
expansion, it may be necessary to interrupt HAART to allow an increase in viral 
load to drive selection and expansion of transduced cells. There are obvious risks 
with this method and viral load in these patients must be carefully monitored during 
this procedure.  
However, it would still be necessary for sufficient numbers of cells to be initially 
modified and expressing high enough levels of protein. Modeling and preclinical 
trials show that it is preferential to start with as large a number of modified cells as 
possible for a more successful therapeutic outcome (126). The actual percentage of 
cells that would need to be transduced to confer a therapeutic benefit to a patient is 
not known and would best be tested in patients in clinical trials.  
 
Although it has not been observed, gene therapy presents a theoretical risk of 
mobilisation of the vector and the development of RCL. This is predicted to be most 
probable during vector production due to recombination between the transfer vector 
and packaging plasmid. Recombination of the viral protein encoding genes with the 
cis-acting elements of the transfer vector could result in RCL. In HIV-1 patients, use 
of an HIV-1 derived vector for gene therapy increases this potential risk due to the 
additional presence of HIV-1 genes from the infectious virus, which includes the 
virulent accessory genes not present during vector production.  
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In preliminary experiments described here we were unable to detect by qPCR any 
mobilised vector in cells exposed to both lentiviral vector and full length HIV-1. 
This method would only detect RCL that includes WPRE. As RCL have never been 
observed, their genome can only be predicted so it is not known whether there would 
be inclusion of this element and therefore if this assay would detect their presence. 
This qPCR was only a preliminary measurement, and biosafety must be more 
thoroughly tested once clinically useable vector stocks are produced. This can be 
performed by companies such as Bioreliance, which use a highly sensitive assay to 
detect RCL RT activity. Briefly, vector stocks are used to transduce the C8166 T cell 
line, which is highly permissive and supports efficient viral replication. These cells 
are cultured for 8 passages to allow amplification of RCL and removal of vector RT. 
Supernatant from the later passages is harvested and RT activity is quantified using a 
highly sensitive PCR based assay. This involves reverse transcription of an RNA 
template and PCR amplification of the resultant cDNA.  
To detect vector mobilisation in vivo, plasma of treated patients can be screened by 
qRT-PCR for the presence of vector genome RNA that is unique to the vector and 
absent from wild type HIV-1. This procedure was performed on patients who 
received T cells transduced with a conditionally replicating lentiviral vector with 
intact LTRs to detect mobilised vector (120).  
 
A major problem with the development of anti-HIV-1 therapies is that the virus has 
a high mutation rate and is frequently able to escape restriction. For therapy to be 
successful, preventing this phenomenon is crucial. During the month long culture of 
TRIMCyp expressing cells infected with HIV-1 clones, resistance to virus was 
maintained as demonstrated by the high viability of cells expressing TRIMCyp. This 
suggests that viral escape mutants did not develop over this time course. Similarly, 
TRIMCyp resistant HIV-1 strains could not be identified by Neagu et al (322). 
Conversely, in vivo experiments have shown that despite initial restriction of 
susceptible SIVsm strains, CA mutations developed allowing escape from both 
TRIM5α and TRIM5Cyp restriction, and rescue of infection after forced passage 
through rhesus macaques. However, in these experiments, there was forced viral 
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transmission primarily through intravenous injection using high levels of virus. 
These large MOI may saturate TRIM5α and TRIM5Cyp restriction and not be truly 
representative of naturally occurring infection, conferring an advantage on the virus 
over the restriction factors (382). 
In addition in vitro experiments using HIV-1 clones with mutated CA sequences that 
do not bind CypA avoid TRIMCyp restriction (311). However, these CA mutations 
come at a cost to viral fitness, as resultant strains have reduced infectivity probably 
due to the requirement of CypA for proper uncoating and the viral lifecycle (306). 
Therefore the maintenance of the CypA binding region of HIV-1 CA is thought to be 
critical for productive infection.  
One possible explanation for the requirement of CypA binding is that it is needed for 
correct nuclear import and influences integration site. Several Nup proteins, such as 
Nup358, have been identified as important for the HIV lifecycle by an RNAi screen 
of cellular proteins (383). Nup358 includes a cyclophilin-like domain, which has 
been shown to interact directly with the HIV-1 CA via its Cyp binding loop (45). In 
human cells, CypA binding to HIV-1 CA promotes nuclear entry in a 
Nup358/Nup153 dependent pathway. This results in integration in the host genome 
in regions of optimal gene density, allowing efficient transcription of viral genes. 
Some CA mutants, for instance the G89V mutant, have an altered integration site 
profile that does not target gene dense regions (270). CA mutations that disrupt the 
Cyp binding loop disrupt interactions with CypA and Nup358. Therefore 
Nup358/Nup153 independent pathways must be used, resulting in integration in 
suboptimal locations that do not support proviral transcription, leading to a 
termination of the viral lifecycle in primary macrophages (45).  
This suggests that conservation of CA interaction with CypA and Nup358 is 
essential for utilisation of the optimal nuclear import mechanism and integration site 
targeting. If TRIMCyp resistant viral strains develop by mutation of their Cyp 
binding loop, interactions with both CypA and Nup358 would also be disrupted. 
This would force these HIV-1 strains to utilise alternative pathways of nuclear entry 
and possibly uncoating, altering the site of integration and affecting transcription and 
viral replication. Therefore, maintaining the HIV-1 CypA binding loop appears to be 
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crucial for productive viral infection in vivo and could explain the conservation of 
CypA binding. 
This suggests that HIV-1 will be unlikely to develop escape mutants that are 
resistant to TRIMCyp binding and restriction. If any escape mutants evolve, their 
reduced fitness will limit their infection and replication, even in unmodified cells, 
preventing expansion of these resistant strains. Evidence suggests that HIV-1 is 
unable to mutate to avoid binding to CypA, and therefore avoiding restriction by 
TRIMCyp restriction factors, making them a highly attractive protein for use in gene 
therapy against HIV-1. However, it will be important to test whether any CA 
mutants emerge and whether they are capable of productive infection.  
 
Results presented here have shown TRIMCyp restriction of both R5 and X4 tropic 
HIV-1 in different assays. In the future it will be important to also measure 
restriction of primary isolates of HIV, including drug resistant strains.  
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5 Interaction of TRIMCyp with 
endogenous TRIM proteins 
5.1 Aims 
 To assess whether TRIMCyp expression interferes with the endogenous 
TRIM5 or TRIM21 activity 
5.2 Introduction 
Chapter 3 assesses restriction by two engineered anti-HIV-1 factors based upon the 
naturally occurring primate TRIM5CypA fusion proteins that provide potent 
inhibition of lentiviruses. In all of the assays performed, there was no significant 
difference in the level of restriction mediated by TRIM5Cyp or TRIM21Cyp. 
Although it is the TRIM5 RBCC domains that are linked to CypA in both the natural 
fusions proteins and the published restriction factor (322), these data show that 
fusion of CypA to the RBCC domains of other TRIM molecules can provide equally 
potent restriction. For future development as a gene therapy treatment, it is important 
to decide which of the proteins should be developed further and would be most 
effective in a clinical setting. As the level of restriction against HIV-1 that they 
provide is comparable, investigating whether they interfere with the normal function 
of cells can be used to determine if one has an advantage over the other. 
 
Both TRIM5 and TRIM21 have been demonstrated to play an important function in 
human immune responses. TRIM5α has been identified as an antiretroviral 
molecule, which is important in innate immunity via two different mechanisms. 
Firstly, TRIM5α functions as a restriction factor capable of recognising and binding 
incoming retroviruses in cells (188). The antiviral specificity of TRIM5α is species 
specific, with the human protein being a strong inhibitor of N tropic MLV but only a 
144 
 
weak inhibitor of HIV-1 
179, 180. As well as a restriction factor, TRIM5α has recently 
been identified as a PRR and affects gene expression. This is also true for the 
naturally occurring owl monkey TRIMCyp restriction factor (252).  
TRIM21 functions by a different mechanism, bridging innate and humoral 
immunity. Unlike TRIM5α, whose B30.2 domain binds retroviral capsid and 
determines the specificity of its antiviral activity, in TRIM21 this domain acts as an 
IgG receptor (259, 265). It plays an antiviral role by binding antibody coated virus in 
the cytosol and targeting it for proteasomal degradation (266). TRIM21 also plays a 
role in innate immune signaling and is involved in IFN signaling through interaction 
with various IRFs. 
As both of these TRIM proteins may play critical roles in normal antiviral immune 
responses, it is important that expression of the TRIMCyp fusion proteins does not 
cause any interference in their function, leaving transduced cells susceptible to 
infection from other pathogens or negatively affecting immune function. 
TRIM proteins are known to form multimers, and that this is necessary for their 
normal function (223, 224, 228). There are several different splice variants of 
TRIM5, but only TRIM5α functions as an antiviral restriction factor, as it is the only 
full length protein that includes the B30.2 domain that is required for CA binding. 
However, the truncated transcripts, TRIM5δ and TRIM5γ, that terminate before the 
B30.2 can act as dominant negative proteins and downregulate TRIM5α antiviral 
activity by interaction via their coiled coil domains. A similar mechanism could 
occur between different splice variants of TRIM5 and TRIM5Cyp as all would 
include compatible coiled coil domains.  
In addition to a possible physical interaction with endogenous TRIM proteins, as 
both TRIM5 and TRIM21 are involved in innate immune signaling, it is possible 
that expression of TRIMCyp proteins may affect normal signaling mediated by 
TRIM proteins within the cell.  
 
In this chapter antiviral restriction mediated by TRIM5 and TRIM21 is measured in 
cells expressing the TRIMCyp transgenes to identify any interference that they may 
have with the endogenous proteins.  
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5.3 Production and titration of MLV 
B and N tropic MLV vector carrying a YFP marker gene was made using the 
plasmids depicted in Figure 5.1A. Vector particles were titrated on CRFK cells. 
Titration of other vectors was performed on HEK293T cells, but because these cells 
are human derived they express TRIM5α and therefore restrict N-MLV, leading to a 
much lower titre than B-MLV. CRFK cells were transduced with serial dilutions of 
virus and YFP expression measured by flow cytometry 3 days later (Figure 5.1B). 
Titres were 7.9x10
5
 and 4.4x10
5
 IU/ml for B and N tropic MLV respectively. 
 
 
Figure 5.1 Production and titration of MLV 
A. Plasmids used to produce murine leukaemia virus (MLV). The transfer plasmid contained a YFP 
marker gene under control of the Cytomegalovirus (CMV) promoter. The gag-pol packaging plasmid 
was either B or N tropic MLV. Virus was pseudotyped with VSV-G using envelope plasmid pMDG. 
B. MLV-YFP titre was measured by transduction of CRFK cells with serial dilutions of MLV stocks. 
YFP positive cells were measured by flow cytometry 72 hours after transduction and titre in 
infectious units/millilitre calculated.  
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5.4 TRIM5α activity is disrupted by TRIM5Cyp, but not 
TRIM21Cyp  
TRIM5α from different species restricts a distinct range of retroviruses. Often 
TRIM5α is unable to restrict viruses native to the same species, but is effective 
against viruses from other species. Therefore, although it does not significantly 
inhibit HIV-1 or -2, human TRIM5α is a strong inhibitor of N-MLV 179, 180. It may 
be important that this function of TRIM5 is not disrupted by introduction of the 
TRIM5Cyp transgene in modified cells. To investigate whether there is an 
interaction between TRIMCyp and endogenous TRIM5α, the ability of TRIM5α to 
restrict N-MLV in TRIMCyp expressing cells was quantified. N-MLV restriction 
was used as a measure of TRIM5α function. 
TE671 cells, a human cell line which expresses TRIM5α and can therefore restrict N 
tropic, but not B-MLV, were transduced with SIEW (GFP), TRIM5Cyp or 
TRIM21Cyp vectors to obtain over 95% of cells eGFP positive. These cells were 
then challenged with HIV-1 (MOI of 5), B-MLV or N-MLV (MOI of 2), all carrying 
a YFP marker gene. Cells were treated with 1000U/ml IFNβ at the time of seeding. 
72 hours following transduction, YFP positive cells were quantified by flow 
cytometry after gating on eGFP positive cells (Figure 5.2).  
Similar to results in CRFK cells in chapter 3, HIV-1 was strongly restricted 
approximately 100 fold in TRIM5Cyp and TRIM21Cyp expressing cells, compared 
to untransduced and GFP transduced control cells (Figure 5.2A). There is slightly 
stronger restriction conferred by TRIM21Cyp than TRIM5Cyp (P=<0.05) in this 
experiment. 
B-MLV was able to transduce all cell populations at an equal level (Figure 5.2C). 
Treatment with IFNβ caused a minor reduction in transduction across groups, though 
the percentage of transduced cells remained high. 
N-MLV was restricted in untransduced and GFP transduced cells, with nearly 100 
fold lower transduction of this virus compared to unrestricted B-MLV (Figure 5.2B). 
The same decrease in transduction was seen in TRIM21Cyp expressing cells.  
However, in cells expressing TRIM5Cyp the level of transduction by N-MLV was 
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similar to that of unrestricted B-MLV (17% for N-MLV and 20% for B-MLV) 
suggesting that there is no N-MLV restriction, and was significantly higher than in 
the other three cell populations (P=<0.0001). This suggests that restriction of N-
MLV by endogenous TRIM5α is abrogated by co-expression of TRIM5Cyp. 
Even after treatment with IFNβ to upregulate endogenous TRIM5α expression, 
TRIM5α restriction of N-MLV could not be seen in TRIM5Cyp cells. In other cell 
types, IFNβ treatment led to complete restriction of N-MLV with the percentage of 
YFP positive cells not reaching above background levels. 
 
Recently, TRIM5α and primate TRIM5Cyp were shown to be involved in activating 
AP-1 and NFκB signaling (252) which may be involved in a negative feedback loop, 
leading to downregulation of TRIM5α expression. Therefore, qRT-PCR was 
performed to assess whether the increase in N-MLV transduction in TRIM5Cyp 
expressing cells was due to differences in TRIM5 expression levels. RNA was 
extracted from TE671 transduced cells and reverse transcribed. qRT-PCR was 
performed to measure the relative levels of expression of both TRIM5 and TRIM21 
in these cells (Figure 5.3). The primer sets used for these reactions bound to either 
the TRIM5 or TRIM21 cDNA at the 3’ end in a region that is not present in the 
TRIMCyp fusion proteins to avoid detection of the transgene. 
In the two experiments performed, co-expression of TRIM5Cyp in cells caused a 
very slight increase in TRIM5 expression, but additional repeats would be required 
to confirm that this increase is consistent upon TRIM5Cyp expression. There did not 
appear to be a noticeable decrease in TRIM5 expression, which could have 
explained the loss of N-MLV restriction seen upon TRIM5Cyp expression. 
Therefore the increase in N-MLV infection in TRIM5Cyp expressing cells is 
unlikely to be due to a loss of TRIM5α expression, but through titration of active 
homodimers into inactive TRIM5α/TRIM5Cyp heterodimers. 
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Figure 5.2 Restriction of retrovirus in cell lines 
TE671 cells transduced with SIEW (GFP), TRIM5Cyp or TRIM21Cyp vectors and untransduced 
(UT) control cells were cultured overnight in the presence or absence of interferon-β (IFN). Cells 
were then challenged with HIV-1 (A), N-MLV (B) or B-MLV (C) vectors encoding YFP. eGFP and 
YFP co-expression was measured by flow cytometry 72 hours after transduction. Arrows in B 
indicate samples with YFP positive percentages below background levels. Samples were performed 
in triplicate, error bars show standard error of the mean. 
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Figure 5.3 Endogenous TRIM expression in TE671 cells 
TE671 cells transduced with SIEW (GFP) or TRIMCyp vectors and untransduced (UT) control cells 
were harvested and RNA extracted using Trizol before reverse transcription. Quantitative PCR was 
performed to measure TRIM5 (A) and TRIM21 (B) expression. TRIM5 data is from two experiments 
and error bars show standard deviation, TRIM21 data from one experiment.  
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5.5 TRIM21 activity is maintained in TRIMCyp expressing 
cells  
Recently, TRIM21 has been shown to act as an intracellular receptor for opsonised 
pathogens by binding the IgG Fc region with very high affinity and then targeting 
them for proteasomal degradation via its RING domain (266). The importance of 
TRIM21 mediated restriction in vivo is not known and interfering with the native 
function of TRIM21 could leave an individual susceptible to viral infections.  
Therefore, the ability of TRIM21 to restrict antibody coated adenovirus particles in 
cells transduced to express TRIMCyp was assessed. Following the protocol 
described by Mallery et al, adenovirus encoding GFP (AdV-GFP) was incubated 
with increasing concentrations of a polyclonal anti-adenoviral hexon antibody. This 
opsonised virus was then used to infect HeLa cells which had been seeded the 
previous day with or without IFNα. Interferon treatment has been shown to cause an 
increase in TRIM21 expression (262). After 48 hours, GFP expression was 
measured by flow cytometry. Untransduced (UT) HeLa cells were compared to cells 
transduced with TRIM5Cyp and TRIM21Cyp vectors without GFP (Figure 5.4). 
Incubation of adenovirus with anti-hexon IgG prior to infection caused a decrease in 
AdV-GFP infection, although even at the highest concentration, GFP expression was 
only reduced to 20% of the no antibody control in which there was no viral 
restriction. Treatment with IFNα caused no significant change to adenoviral 
restriction. In published work, HeLa cells were transduced to express high levels of 
TRIM21, which resulted in potent restriction of adenoviral infection. In experiments 
described here, adenoviral restriction was reliant on endogenous TRIM21 which, 
even after IFNα treatment, was not sufficient to mediate very strong restriction. As 
restriction was mild, it was more difficult to identify any potential differences in 
restriction between untransduced and TRIM21Cyp transduced cells. 
Following this, a protocol optimised by a post-doctoral researcher in the lab, Dr. 
Choon Ping Tan, was tested. A different antibody was used and incubated with 
adenovirus in a greater total volume before infection. This led to a stronger 
restriction of adenoviral infection. AdV-GFP incubated with this alternate antibody 
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was specifically restricted by TRIM21, as shown by the rescue of infection after 
TRIM21 depletion by TRIM21 shRNA expression (Figure 5.5A). Figure 5.5B shows 
the specificity of shRNA causing a decrease in TRIM21 levels. Figures 5.5A and B 
were kindly provided by Dr. Choon Ping Tan. 
Using this modified protocol, the experiment was repeated and resulted in a greater 
decrease in infection with increasing antibody concentration (Figure 5.5C). In all 
cells, IFNα treatment enhanced adenoviral restriction, presumably by upregulating 
TRIM21 expression. At the highest antibody concentration all cells incubated with 
IFNα reduced GFP expression to around 5% of the no antibody control, compared to 
20% with the original method. There was no significant difference in restriction of 
adenovirus in TRIM21Cyp expressing cells compared to control cells.  
TRIM21 expression measured by qRT-PCR was shown to be maintained at a similar 
level in cells expressing either of the TRIMCyp proteins (Figure 5.6). This reflects 
the results that show TRIM21 mediated antiviral activity is maintained upon 
TRIMCyp expression. There appeared to be some upregulation of TRIM5 
expression in cells co-expressing TRIM5Cyp. Again, experiments were performed 
only once, and must be repeated for more accurate measurements. 
Therefore, cells expressing either TRIM5Cyp or TRIM21Cyp are capable of 
efficient restriction of IgG coated adenovirus at levels equal to untransduced control 
cells suggesting that endogenous TRIM21 function has remained intact. 
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Figure 5.4 Adenoviral neutralisation by TRIM21 
Adenovirus-GFP was incubated with anti-Adenovirus antibody at increasing concentrations and then 
used to infect untransduced (UT) HeLa cells or those expressing TRIMCyp. GFP expression was 
measured by flow cytometry 48 hours later. All samples were performed in triplicate, error bars 
represent the standard error of the mean. 
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Figure 5.5 TRIM21 mediated neutralisation of adenovirus using an optimised protocol 
The adenoviral neutralisation assay was repeated using a modified protocol and an alternative anti-
adenoviral antibody both provided by collaborators at UCL. A. HeLa cells with stable knockdown of 
TRIM21 (T21 kd) or control cells with non-targeting shRNA (Con kd) were infected with 
adenovirus-GFP incubated with neutralising antibody (Neut mAb) or isotype matched control 
(control mAb). Infection was quantified by GFP expression 48 hours later by flow cytometry.  
B. Western blot showing TRIM21 (T21) expression following interferon-α (IFN) stimulation and 
expression of either control (Con) or T21 shRNA.  
C. HeLa cells transduced with TRIM5Cyp or TRIM21Cyp vectors and untransduced (UT) control 
cells were cultured overnight in the presence or absence of interferon-α (IFN). Adenovirus-GFP was 
incubated with increasing concentrations of the neutralising antibody tested in A and used to 
challenge HeLa cells. GFP expression was measured by flow cytometry 48 hours later. Samples were 
performed in triplicate, error bars represent the standard error of the mean.  
Data in panels A and B provided by Dr. Choon Ping Tan. 
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Figure 5.6 Endogenous TRIM expression in HeLa cells 
HeLa cells transduced with TRIMCyp vectors devoid of GFP or untransduced (UT) control cells 
were harvested and RNA extracted using Trizol before reverse transcription. Quantitative PCR was 
performed to measure TRIM5 (A) and TRIM21 (B) expression. Data from one experiment only. 
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5.6 Summary 
Although in vitro experiments presented in chapters 3 and 4 have shown that both 
TRIM5Cyp and TRIM21Cyp are strong inhibitors of HIV-1, it is important that their 
expression does not affect normal functioning of transduced cells. In this chapter 
experiments have been carried out to test whether there is any interaction between 
TRIMCyp and the endogenous TRIM proteins that interferes with their function. 
Both TRIM5 and TRIM21 play complex roles in the immune system, the full 
importance of which are still emerging. Therefore there could potentially be 
problems with therapy if TRIMCyp proteins interact with endogenous TRIM 
proteins and disturb their function.  
 
TRIM5α restricts retrovirus in a species specific pattern, with the human protein 
potently restricting N-MLV, but not HIV-1 or B-MLV (180). This is seen here in the 
human TE671 cell line; untransduced and GFP transduced control cells are easily 
transduced with both B-MLV and HIV-1, but N-MLV is strongly restricted. Despite 
typically low basal levels of TRIM5α expression and expression being IFN inducible 
(211), untreated cells were still able to mediate effective restriction of N-MLV. 
Restriction was further enhanced upon IFNβ treatment of cells. 
In contrast, N-MLV infection is rescued in TRIM5Cyp expressing cells. RT-PCR 
shows that there is no difference in TRIM5 expression levels in these transduced 
cells compared to controls. Another possible explanation for the loss of restriction is 
the dimerisation of TRIM5Cyp with TRIM5α resulting in a non-functional protein 
complex. TRIM5δ and γ, the splice variants that lack the B30.2 domain, are able to 
form multimers with TRIM5α which are non-restrictive, acting as a dominant 
negative protein (182, 192). Similarly, expression of rhTRIM5α or omTRIMCyp in 
human cells interferes with the restrictive abilities of huTRIM5α against N-MLV, 
due to the different C termini, which confers the antiviral specificities of the protein 
(384). Presumably expression of humanised TRIM5Cyp facilitates the formation of 
non-functional dimers with endogenous TRIM5 as both proteins include compatible 
coiled coil domains, which are required for dimerisation (205). In cells expressing 
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TRIM21Cyp, N-MLV restriction is equal to the control cells, indicating that 
TRIM21Cyp does not cause any interference with TRIM5α mediated restriction. 
This is supported by the fact that different TRIM proteins rarely heterodimerise with 
each other (205). 
Conversely, restriction of HIV-1 by TRIMCyp was also measured in these cells to 
see if there was any rescue of HIV-1 infection by endogenous TRIM5α. However, 
even with TRIM5α upregulation by IFN treatment, there was no detrimental effect to 
TRIM5Cyp or TRIM21Cyp restriction of HIV-1. It is likely that high levels of 
TRIMCyp were expressed from the SFFV promoter possibly from multiple copies 
per cell, so could not be saturated by heterodimerising with endogenous TRIM5α.  
To confirm this multimerisation of TRIM and TRIMCyp proteins, transduced cells 
could be treated with glutaraldehyde which crosslinks and stabilise multimers (232). 
Multimers could be studied by Western blotting to look for complexes of TRIM and 
TRIMCyp. However, using the anti-Cyp antibody in previous Western blots here did 
not produce very clear bands, so this method would probably be more effective 
using tagged proteins. 
Rhesus macaques express different TRIM5α alleles, including a TRIM5Cyp fusion 
protein. If these different alleles are co-expressed within a cell they illicit a dominant 
negative effect on each other. It is speculated that high expression levels of protein 
in this in vitro system over exaggerates these dominant negative effects caused by 
heteromultimerisation. In TRIM5α heterozygotes, when there are more equal levels 
of expression of different TRIM5α alleles, they may act in a co-dominant way (193). 
This co-dominance is seen with different Fv1 alleles in mice and heterozygote cell 
lines, and the dominant negative effect of certain Fv1 alleles only occurs upon 
overexpression (180). Therefore if heterodimerisation is the cause of the dominant 
negative effect of TRIM5Cyp on endogenous TRIM5α, it could possibly be avoided 
or reduced by lower expression levels more equal to that of endogenous TRIM5. The 
promoter used in the vectors here was the highly active and constitutive SFFV 
promoter, but expression of the transgene from the endogenous TRIM5 promoter 
would produce more physiological levels of expression. As the TRIM5 promoter is 
IFN stimulated, both endogenous TRIM5 and transgenic TRIMCyp expression 
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would be high upon viral infection. Limiting upregulation of expression to respond 
to IFN stimulation would prevent high levels of background expression. 
Restriction factors are important in preventing cross-species transmission of 
retroviruses. HuTRIM5α has been shown to restrict N-MLV in vitro, and so it may 
be involved in protecting humans from retroviral infection. Although viruses such as 
the recently described xenotropic MLV-related virus (XMRV) have a CA sequence 
highly homologous to B-MLV and are not restricted by huTRIM5α (385), until the 
role of this restriction factor is more clearly understood, the consequences of its 
disruption by expression of TRIM5Cyp are not known. 
 
As well as binding and restricting retroviruses, huTRIM5α, and TRIM5Cyp, are 
proving to be important in immune signaling (252). TRIM5α and TRIM5Cyp 
promote NFκB signaling via TAK1 which may lead to negative feedback and 
downregulation of TRIM5α expression, consequently abrogating N-MLV restriction. 
Results shown here suggest that TRIMCyp does not affect the expression levels of 
endogenous TRIM5 thereby explaining the loss of N-MLV restriction. 
Throughout any gene therapy treatment, it is important that the role of TRIM5α in 
innate immune signaling is also maintained. This could be investigated by following 
protocols from Pertel et al (252) in which NFκB and AP-1 signaling is monitored by 
using luciferase reporter plasmids. These reporters could be transfected into cells 
expressing TRIM and TRIMCyp, either together or individually, and luciferase 
activity quantified. This will determine whether the artificial humanised TRIM5Cyp, 
like owl monkey TRIM5Cyp, can mediate NFκB signaling and whether signaling is 
further enhanced by retroviral CA recognition, as is the case with TRIM5α. It will 
also be interesting to investigate whether TRIM21Cyp mediates NFκB immune 
signaling in response to viral recognition. TRIMCyp mediated activation of innate 
immune responses upon viral infection could be beneficial and influence infection 
and disease progression.  
Owl monkeys only have the TRIM5Cyp allele and no other TRIM5 alleles (315), 
suggesting that primates can function normally in the absence of a TRIM5 protein. 
Rhesus macaques may also be heterozygous for TRIMCyp, having one TRIMCyp 
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and one TRIM5 allele. Therefore, interference of TRIM5Cyp with endogenous 
TRIM5 function may not actually prevent normal functionality of the cell. 
 
The TRIM21 mediated restriction of antibody coated adenovirus was tested using 
the experimental protocol from Mallery et al (266). However, this group used HeLa 
cells that were transduced to express high levels of TRIM21 and therefore 
experienced much higher levels of viral restriction. However, when just using 
endogenously expressed TRIM21 and the published protocol, adenoviral restriction 
was low. Therefore a modified protocol provided by collaborators at UCL was used, 
in which larger volumes of a different antibody were used. This resulted in much 
higher levels of restriction, which increased with increasing concentrations of 
antibody. Also in this final assay, crude preparations, rather than caesium chloride 
purified adenovirus, were used. It is possible that the purification method may affect 
epitopes recognised by the restricting antibody resulting in less efficient antibody 
recognition and therefore restriction. 
In both experimental setups there was no difference in restriction of opsonised 
adenovirus between untransduced and TRIMCyp expressing cells. Similarly there 
was no difference in endogenous TRIM expression in the different cells. IFNα 
treatment significantly enhanced adenovirus restriction in all cells using the 
modified protocol. 
TRIM21 is also known to be intricately involved in IFN signaling through 
interaction with several members of the IRF family. It is important that both the 
direct antiviral activity of TRIM21 against adenovirus and its role in signaling are 
maintained in modified cells. Although expression of TRIMCyp did not interfere 
with restriction of opsonised adenovirus, effects on IFN signaling were not 
investigated. IFN responses measured by using an IFNβ luciferase reporter or qRT-
PCR of IFNβ responsive genes, such as IFNβ, ISG56 and RANTES, could be 
compared in untransduced and TRIM21Cyp expressing cells. 
As well as interference with IFN signaling, another potential problem with the use of 
TRIM21Cyp is that TRIM21 is the autoantigen in the autoimmune disease Sjogren’s 
disease. The antibody target in this disease is found in the B30.2 domain, which has 
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been removed in the TRIM21Cyp construct. However, all healthy individuals 
possess auto-antibodies against regions throughout the TRIM21 protein, the most 
antigenic being the B30.2 domain, but also the coiled coil domain, which remains in 
the TRIM21Cyp fusion protein. In contrast, TRIM5 is not associated with 
autoimmunity (386). It is important that overexpression of this domain in the 
TRIM21Cyp protein does not lead to autoimmune pathology. 
 
The reason for the detrimental interaction of TRIM5Cyp with TRIM5α, but for no 
detectable effect on TRIM21 restriction may be due to differences in the 
stoichiometry of the binding of each TRIM B30.2 domain with its target. TRIM21 
binds IgG Fc with high affinity at a stoichiometry of one TRIM21 molecule to one 
Fc fragment (266). In contrast, TRIM5α binds N-MLV CA in multimers, the 
formation of which is likely to be interrupted by the presence of TRIM5Cyp, which 
maintains the TRIM5 domains required for dimerisation and high order 
multimerisation, namely the coiled coil and B-Box2 respectively, but differs at the C 
terminus with the presence of a CypA moiety. 
 
In summary, there is no significant difference between restriction of HIV-1 provided 
by TRIM5Cyp or TRIM21Cyp. Therefore study of the interaction and interference 
with endogenous TRIM proteins may provide reasons to use one restriction factor 
over another. Results shown here suggest that TRIM21Cyp may have an advantage 
as a therapeutic gene as its expression does not interfere with endogenous TRIM 
function whilst still providing potent restriction of HIV-1.  
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6 Site specific integration of TRIMCyp 
and disruption of CCR5 using zinc finger 
nucleases 
6.1 Aims 
 To produce CCR5 specific ZFNs and donor templates in a non-integrating 
lentiviral vector (NILV) 
 To modify the CCR5 gene using NILV-ZFNs in cell lines 
 To introduce TRIMCyp into the CCR5 locus in cell lines by homology 
directed repair 
 To compare restriction of HIV-1 in cell lines modified with ZFNs and 
expressing TRIMCyp constructs compared to either method alone 
6.2 Introduction 
CCR5 is the primary co-receptor used for entry of HIV-1 alongside CD4 (5-9). 
Homozygotes for the CCR5 Δ32 mutation are highly resistant to HIV-1 infection, 
even after repeated exposure to virus (332, 333). This has resulted in substantial 
interest in targeting CCR5 expression as a means of anti-HIV-1 therapy. In addition, 
CCR5 Δ32 homozygotes do not have any significant adverse phenotypes, suggesting 
that this locus is ideal as a safe harbour for site specific integration as there is no 
pathology associated with its loss. The potential of CCR5 as an HIV therapeutic 
target, and the feasibility of reconstituting a patient’s immune system with resistant 
cells has been demonstrated by a single case in which an HSC transplant of an HIV-
1 patient with cells from a CCR5 Δ32 homozygous donor led to the eradication of 
the virus (339). Despite the success of this first example of a functional cure of HIV-
1, it would not be possible to routinely treat infected individuals with HSC 
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transplant. CCR5 Δ32 donors are rare with only approximately 1% of the Caucasian 
population being homozygous for the allele, and below this in Western and central 
Africa (333). The risks and high mortality rate associated with allogenic transplant 
reduce wider applicability. However, it could be possible to replicate the phenotype 
seen in Δ32 individuals by knockout of CCR5 using ZFNs in a patient’s own cells. 
 
The biopharmaceutical company Sangamo has produced ZFNs that specifically 
target and disrupt CCR5. Each ZFN of the pair contain four ZF binding motifs 
recognising a 12bp sequence. In total, the ZFN pair recognises a 24bp sequence in 
the first transmembrane region of CCR5 (369). These ZFNs have been tested in a 
variety of cell types and animal models and have been shown to knockout CCR5 
expression and consequently restrict R5 tropic HIV-1 infection (369, 370). These 
ZFNs are also currently in a phase I/II clinical trial in which autologous T cells have 
been modified ex vivo by CCR5 specific ZFNs delivered via an adenoviral vector. 
So far, preliminary results from this trial have been promising; the procedure has 
been well tolerated by patients and modified cells function normally. In addition 
they show some cases of successful engraftment of modified cells, and an increase in 
T cell numbers (135). In this trial, adenoviral vectors were used to deliver the ZFNs 
as they do not integrate into the genome, thereby providing only transient expression 
of the two ZFN genes. Continuous expression of the genes and presence of the ZFNs 
would promote toxicity by increasing the likelihood of off target cleavage. 
Adenoviral vectors are used in both research and clinical trials. However, a major 
problem with this delivery method is that most people have pre-existing immunity 
against adenovirus and vectors induce both innate and adaptive immune responses 
(387). An alternative delivery method to adenoviral vectors to provide transient ZFN 
expression is to use non-integrating lentivirus (NILV). 
 
After cell entry, lentiviruses and their derived vectors undergo uncoating and reverse 
transcription within the cytoplasm. Reverse transcription of the viral RNA genome 
results in a double stranded DNA molecule capable of integration into the host 
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genome. Normally, this linear strand of DNA is transported to the nucleus where the 
viral IN protein mediates integration. 
However not all DNA is integrated and there is accumulation of circularised viral 
DNA in two different forms: 1-LTR circles formed by homologous recombination 
(388) and 2-LTR circles due to NHEJ (389). This occurs in normal lentiviral 
infection, but can be enhanced by introducing mutations in the IN gene. As well as 
integration, IN also plays a role in reverse transcription and transport of the PIC into 
the nucleus. IN mutations can be grouped into two categories depending upon the 
effect of the mutation. Class I mutations solely affect the ability of IN to promote 
viral DNA integration, whereas class II mutations affect all IN functions including 
reverse transcription and nuclear import and therefore would be of no use in the 
development of vectors. The catalytic core of IN contains a highly conserved amino 
acid motif, D,D-35-E, which consists of two aspartic acids and one glutamic acid 
with a 35 amino acid region between the second and third residues. Alteration of any 
of these three residues disrupts integration and significantly reduces provirus 
formation. The D64V mutation is commonly used to produce NILV as it reduces 
integration by about four logs, whilst maintaining a high viral titre (390, 391).  
 
The use of NILV greatly improves the safety of gene therapy; integration, and 
consequently the likelihood of insertional mutagenesis, is greatly reduced. NILV are 
useful tools for transient gene expression in dividing cells, as episomal DNA is 
progressively diluted out through cell division. Alternatively, NILVs are able to 
transduce similar post-mitotic target cells as integrating lentivirus, for example in the 
brain and retinal tissue, where they can support continued gene expression (392, 
393).  
Despite this, there is evidence to suggest that expression from NILV is not as high as 
that from integrating vectors, which could be a problem in particular therapeutic 
circumstances (394). However, they could still be appropriate to deliver ZFNs, as 
only transient expression is sufficient to cause a permanent disruption of the target 
gene, which is passed on to the cell’s progeny. 
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Site specific integration of a transgene is the ideal in gene therapy. However, 
performing this by homologous recombination is too inefficient to be of therapeutic 
benefit. Introduction of a DSB within the genome increases the likelihood of HDR 
of a DSB three or four fold, and this can be further enhanced by the presence of a 
large amount of donor template. This is the rationale behind ZFN technology; 
transient expression of ZFNs causes a DSB which is repaired by HDR using a donor 
template delivered to the cells in a high concentration.  
CCR5 Δ32 homozygotes do not express any functional protein but do not suffer any 
detrimental consequences. Therefore CCR5 specific ZFNs could be used to insert an 
array of different transgenes at the CCR5 locus, utilising it as a safe harbour site to 
avoid insertional mutagenesis. It could be possible to use this technology to insert a 
gene encoding an anti-HIV restriction factor at this specific locus in the host 
genome. This would be additionally beneficial as not only would the restriction 
factor gene be integrated at a safe location to reduce insertional mutagenesis, but by 
knockout of CCR5 expression, the modified cells would be protected from cell entry 
by R5 tropic HIV-1. This would provide a dual mode of protection for modified 
cells and confer resistance to both R5 and X4 tropic strains of HIV-1. 
 
Here CCR5 specific ZFNs have been delivered to cells using NILV alongside two 
donor templates, one encoding GFP as a marker and the other TRIM21Cyp to 
provide dual protection against HIV infection. 
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6.3 Production of ZFNs and CCR5 donor lentivirus 
Sangamo provided heterodimerising ZFNs targeting the CCR5 locus and two CCR5 
donor template plasmids; one consisting of PGK promoter and GFP transgene 
flanked by CCR5 homology arms (CCR5-PGK-GFP) and the second a BglI 
restriction site flanked by CCR5 homology arms (CCR5-BglI). This second donor 
plasmid allows the construction of alternative donor templates by cloning genes into 
the BglI site, which can then be integrated into the CCR5 locus by HDR. Here the 
codon optimised TRIM21Cyp under control of the PGK promoter was cloned into 
the BglI site (PGK-TRIM21CypCO). To assist in cloning of this second donor, a 
plasmid was generated consisting of the PGK promoter driving TRIM21Cyp 
expression, with appropriate restriction sites. This was performed by Geneart, who 
used their in house GeneOptimizer software to produce a codon optimised 
TRIM21Cyp (TRIM21CypCO) transgene (see Chapter 3.9). 
The two ZFNs, EL and KK, were cloned separately into lentiviral backbones under 
control of the SFFV promoter (Figure 6.1A). The CCR5 flanked PGK-GFP donor 
and PGK-TRIM21CypCO donor were also cloned into a lentiviral backbone (Figure 
6.1B and C). As there was a polyA signal at the end of the TRIM21CypCO 
transgene, inserts were cloned between the CCR5 homology arms in the reverse 
orientation. This was to avoid premature termination of transcription at the polyA, 
allowing production of genomic viral RNA. All four plasmids were used to make 
non-integrating lentivirus using the IN mutant D64V and pMDG. 
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Figure 6.1 Plasmids used to generate ZFN and donor template non-integrating lentiviral vector 
(NILV) 
A. CCR5 specific zinc finger nucleases (ZFNs) were cloned into pLNT/SFFV-MCS, with each 
member of the pair in a separate plasmid.  
Donor templates for homology directed repair expressing a green fluorescent protein (GFP) gene (B) 
or a codon optimised TRIM21Cyp transgene (TCyp) (C) under control of the human 
phosphoglycerate kinase (PGK) promoter, flanked by CCR5 sequence homologous to the ZFN target 
site. These plasmids were used to generate non-integrating lentiviral vector using the integrase 
deficient gag-pol packaging plasmid (D64V) and pseudotyped with VSV-G. SFFV=spleen focus-
forming virus, WPRE=Woodchuck hepatitis virus post transcriptional regulatory element, RRE=rev 
response element, cPPT=central polypurine tract 
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6.4 ZFNs knockout CCR5 in GHOST cells 
The two different ZFNs have distinct DNA recognition sites and they bind opposing 
DNA strands, allowing their FokI nuclease domains to dimerise and cause a DSB in 
the DNA. 
GHOST-CCR5 is a human osteosarcoma cell line that has been transduced with 
MLV vectors to express high levels of CD4 and CCR5 to allow infection by R5 
tropic HIV-1. These GHOST cells contain on average four copies of CCR5 cDNA 
so for cells to become CCR5 negative it requires targeting of all copies within the 
cell. 
Transduction of GHOST-CCR5 cells with either of the individual ZFN NILV does 
not cause any loss of CCR5 expression (Figure 6.2A), which supports the obligate 
heterodimeric nature of these ZFNs. Transduction of GHOST cells with both ZFNs 
resulted in a loss of CCR5 over time and five days after transduction the level of 
CCR5 expression reached a stable low point of approximately 20% of cells (Figure 
6.2B). CCR5 was measured by staining with an anti-CCR5 antibody conjugated to 
APC-Cy7 and flow cytometry 
The percentage of cells in which CCR5 was knocked out could be increased by the 
addition of increasing volumes of ZFN NILV. CCR5 expression was measured 
seven days post transduction (Figure 6.2C and D). Therefore, in all subsequent 
experiments, 10µl of each ZFN NILV were used unless otherwise stated.  
The physical titre of the vector preparations was subsequently determined by p24 
ELISA. The two ZFN vectors EL and KK had titres of 5.7x10
7 
and 1.3x10
7
 pg/ml 
respectively. Therefore as equal volumes of the two ZFNs had been added, the total 
number of virus particles was different. Addition of equal titres of each ZFN may 
improve the efficiency of targeting. 
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Figure 6.2 ZFNs lead to knock down of CCR5 in cell lines 
A. GHOST-CCR5 cells transduced with individual ZFNs and stained for CCR5, which was measured 
by flow cytometry. 
B. GHOST-CCR5 cells were transduced with ZFNs and measured for cell surface CCR5 at regular 
intervals for 10 days post transduction. Data is representative of two experiments. 
GHOST-CCR5 cells were transduced with increasing volumes of the pair of ZFNs. Cells were 
cultured for 14 days, before staining for CCR5 and measuring by flow cytometry. Examples plots are 
shown in C. The experiment was performed on four independent samples shown in D. Error bars 
represent the standard error of the mean.  
168 
 
6.5 Site specific integration of GFP in GHOST cells 
LNT/CCR5-PGK-GFP NILV was generated and titrated by transducing HEK293T 
cells and measurement of GFP expression by flow cytometry. GHOST-CCR5 cells 
were then transduced with ZFN NILVs and increasing MOI of CCR5-GFP donor 
NILV. GFP expression was measured in the cells by flow cytometry for two weeks 
following transduction (Figure 6.3A). Initially, between 30 and 40% of cells were 
GFP positive, with the higher MOI leading to a greater percentage of transduced 
cells. However, over the two week period, the percentage of GFP positive cells 
rapidly decreased, finally reaching stable expression in about 1-3% of cells. There 
was a slight difference in the final percentage of GFP positive cells depending upon 
the MOI of CCR5-GFP NILV used. Similarly, higher ZFN volume also resulted in 
increased levels of stable GFP expression at day 14 at all CCR5-GFP MOI tested. 
Staining of transduced cells for CCR5 revealed that there were low levels of GFP 
expression even in cells that remained positive to CCR5 (0.58% compared to 0.14% 
in untransduced cells) (Figure 6.3B). As GHOST-CCR5 cells contain multiple 
copies of the CCR5 gene, it is also possible that GFP was integrated at the correct 
locus but not all of the CCR5 genes were disrupted by ZFNs. Alternatively, GFP 
expression could be a result of background integration of the donor DNA, which is 
observed at low levels (approximately 1/10 000) even when using NILV. 
To try to optimise the efficiency of HDR and GFP site specific integration, 
following ZFN transduction, GHOST-CCR5 cells were transduced with the CCR5-
GFP donor at different time points. GFP expression was measured by flow 
cytometry 14 days after ZFN transduction (Figure 6.3C). However, there was little 
difference between the samples that were transduced with the GFP donor template at 
various time points.  
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Figure 6.3 Site specific integration of GFP using zinc finger nucleases 
A. Increasing multiplicities of infection (MOI) of CCR5-GFP donor non-integrating lentivirus 
(NILV) were used to transduce GHOST-CCR5 cells simultaneously with CCR5 ZFNs. GFP 
expression was measured over time by flow cytometry until 14 days post transduction.  
B. GHOST-CCR5 cells were transduced with CCR5 ZFN and GFP donor NILV. 19 days post 
transduction cells were stained with an anti-CCR5 antibody and CCR5 and GFP expression measured 
by flow cytometry.  
C. GHOST-CCR5 cells were transduced with CCR5 ZFN at time 0. CCR5-GFP donor NILV was 
used to transduce the cells at the following different time points after ZFN transduction: 0, 24 and 48 
hours. GFP expression was measured 14 days after ZFN transduction.  
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6.6 CCR5 site specific integration of TRIM21Cyp in 
GHOST cell line 
To provide a second method of protection against HIV-1, it is possible to integrate 
an anti-HIV transgene in the CCR5 locus by HDR. In addition to the CCR5-GFP 
donor template, a donor consisting of PGK-TRIM21CypCO flanked by CCR5 was 
also cloned into the lentiviral backbone pLNT/SFFV-MCS-WPRE and used to make 
NILV. The titre of this virus was determined by measuring p24 levels in the viral 
preparation by ELISA (2.7x10
7
 pg/ml). 
GHOST-CCR5 cells were first transduced with the two ZFN NILV, and then 
transduced with the CCR5-TRIM21CypCO NILV at different time points after the 
ZFNs. Cells were cultured for two weeks after transduction, by which time non-
integrated episomal DNA would be diluted out by cell division. Then cells were 
challenged with HIV-1-YFP at an MOI of 150 to obtain very high levels of YFP 
expression in cells untransduced by ZFNs (referred to as UT in Figure 6.4). Cells 
were stained with an anti-CCR5-APC-Cy7 antibody, and CCR5 and YFP expression 
was measured by flow cytometry (Figure 6.4). HIV-1-YFP restriction was taken as a 
marker of TRIM21CypCO integration and expression. 
The high MOI of HIV-1-YFP used resulted in nearly all cells of the ZFN/donor 
untransduced population becoming YFP positive. In the populations transduced with 
both ZFNs and TRIM21CypCO donor NILV, there were a small proportion of cells, 
between 17 and 24%, that were CCR5 and YFP double negative (Figure 6.4). This 
suggested that they were successfully modified to knockout CCR5 expression and 
were expressing TRIM21Cyp, which caused the restriction of HIV-1-YFP. This 
population of CCR5 and YFP double negative cells were sorted by flow cytometry 
and plated as single cells in a 96 well plate and cultured to obtain clones. 
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Figure 6.4 Site specific integration of TRIM21CypCO using zinc finger nucleases (ZFNs) 
GHOST-CCR5 cells were transduced with ZFN NILV at time 0. CCR5-TRIM21CypCO donor NILV 
was used to transduce the cells at the following different time points after ZFN transduction: 0, 24, 48 
and 72 hours. 14 days post transduction, cells were replated and transduced with HIV-1-YFP. After 
72 hours, cells were stained using an anti-CCR5-APCCy7 antibody and CCR5 and YFP expression 
measured by flow cytometry. Restriction of YFP expression was taken as an indicator of TRIM21Cyp 
expression. Top panels show control cells untransduced (UT) with ZFN or TRIM21CypCO donor, 
bottom panels are transduced with ZFNs and then TRIM21CypCO donor at different time points.  
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Sorted colonies were expanded and when sufficient cells were acquired, the cells 
were transduced with HIV-1-YFP to confirm restriction shown by inhibition of YFP 
expression (Figure 6.5). The level of restriction varied between clones and in some 
cases, clones were fully permissive to HIV-1-YFP. As HIV-1-YFP expression in 
ZFN untransduced cells was not quite 100% efficient before sorting (Figure 6.4), it 
is likely that these non-restricting clones were within this small population, but do 
not express TRIM21CypCO. 
 
Protein and DNA was extracted from the colonies able to restrict HIV-1-YFP for 
further analysis. Western blots were performed using an anti-CypA antibody to look 
for production of TRIM21Cyp protein (Figure 6.6A). In clones 14 and 16, 
appropriate sized bands were visualised. However, despite certain cell populations 
appearing to restrict HIV-1-YFP, TRIM21Cyp protein could not be detected clearly 
by Western blot in most of the clones. As previously mentioned, the anti-Cyp 
antibody for Western blot has not been very effective at detecting protein expression 
and even positive controls transduced at high levels with LNT/S-TRIM21Cyp-IEW 
did not produce prominent bands in Western blots of this cell line. 
 
PCR was carried out on the clones using primer sets binding in the integrant within 
the PGK promoter and within the CCR5 locus outside of the homology region of the 
donor template to produce a product of 1507bp. This would amplify the junction 
between integrant and genomic DNA at the 3’ end (Figure 6.6B). Therefore, a PCR 
product would only be produced if the TRIM21CypCO gene was present at the 
correct locus in the CCR5 gene. However, despite there being some HIV-1-YFP 
restriction in several of the clones, the correct sized PCR product could only be 
detected in one of the clones tested (Figure 6.6D). This PCR product was purified, 
cloned into a TOPO plasmid and then sequenced. Sequencing results confirmed that 
TRIM21CypCO had integrated at the correct CCR5 locus.  
PCR using primers to amplify the junction between the integrant and genomic DNA 
at the 5’ end of the integrant could not detect bands of the correct size for any of the 
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clones tested, including clone 14 which tested positive for the amplification of the 
other junction. 
Another PCR was carried out to amplify the TRIM21CypCO gene using primers that 
both bind within the transgene. As the Western blot results were not very reliable, 
this PCR enabled more conclusive evidence that particular clones contained an 
integrated copy of the transgene, although not necessarily integrated at the CCR5 
locus. As shown in the schematic (Figure 6.6B) one primer bound within TRIM21 
and the other in Cyp to avoid amplification of either of the individual genes and 
produce a 486bp product that spans the TRIM21-Cyp junction. The lentiviral 
plasmid pLNT/CCR5-PGK-TRIM21CypCO was used as a positive control. Both 
clone 14 and 16, and other clones, produced a band of the correct size (Figure 6.6C). 
Some clones produced a PCR product for this TRIM21Cyp reaction but did not 
produce bands on the Western blot. This could be due to problems with the Western 
blot, or could also indicate that the transgene has been silenced in these clones. 
Clones in which the TRIM21CypCO transgene itself was detected, but not the 
expected integrant/CCR5 junction, could contain randomly integrated copies of the 
entire donor NILV genome. In this case, this would also include integration of 
WPRE. Therefore qPCR was performed using primer and probe sets for WPRE and 
β-actin to calculate the average WPRE copy number in the TRIM21CypCO positive 
clones. Clones 2, 12 and 16 had approximately 1-1.5 copies of WPRE per cell 
(Table 6.1). This suggests that these clones contain an integrated copy of the entire 
lentiviral genome, including WPRE. If site specific integration had occurred by 
HDR, PGK-TRIM21CypCO flanked by CCR5 homology arms would be integrated, 
but WPRE would be absent from the cells. Clone 14 had a lower average copy 
number of 0.36 per cell, which could be due to contamination in the sample, rather 
than representing actual integrated copies.  
Collectively these results suggest that only clone 14 contains a correctly integrated 
TRIM21CypCO transgene as it tested positive for the TRIM21CypCO PCR and the 
junction PCR, as well as detection of protein by Western blot. The very low WPRE 
copy number indicates that there is no background integration of the vector genome. 
Of the other clones, some did not appear to contain TRIM21CypCO at all, whereas 
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in others, the transgene could be detected by PCR, but is likely to be from 
background integration of the transgene as indicated by the inability to amplify the 
integrant/CCR5 junction and the high WPRE copy number. 
Results of molecular analysis are summarised in Table 6.1. 
 
Of the clones that grew after the single cell sort, there were very few that restricted 
HIV-1-YFP in subsequent restriction assays. Approximately 200 clones were grown 
from two separate single cell sorts for CCR5/YFP double negative cells. Of these, 
about 10 were able to restrict HIV-1-YFP when tested after sorting. This implies that 
this method for selecting modified cells is not efficient. It is also difficult to test for 
integration as there is only one set of PCR conditions that have been optimised to 
detect TRIM21CypCO integration. PCRs were attempted to amplify the 5’ end of 
the expected integrant, with one primer binding in the CCR5 gene and the other in 
the polyA tail at the end of the TRIM21Cyp transgene. However, this product could 
not be amplified in any of the reactions conditions tested. There was no positive 
control for this reaction, so the absence of a product could have been an 
experimental problem or it could be because the integrant is not actually at the 
correct site. It is possible that in clone 14 TRIM21Cyp is integrated at one end by 
HDR giving the expected junction between integrant and CCR5, with the other end 
being repaired by NHEJ. In this case, the PCR used to detect the junction would not 
produce a product. 
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Figure 6.5 Restriction of HIV-1 by CCR5-TRIM21Cyp clones 
YFP and CCR5 double negative single cell clones were flow cytometrically sorted from the 
experiment in Figure 6.4 and expanded. Each colony was challenged by transduction with HIV-1-
YFP. 72 hours later, HIV-1-YFP expression was measured by flow cytometry to quantify restriction. 
A. FACS plots of untransduced (UT) cells (top panels) and examples of some clones tested (bottom 
panels).  
B. Selection of clones that restricted HIV-1-YFP as measured by flow cytometry. Clones 2-29 and 
clones 122 and 164 were from two separate transductions and sorts. 
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Figure 6.6 Molecular analysis of GHOST CCR5-TRIM21Cyp clones  
A. Western blot of GHOST clones that restricted HIV-1-YFP using an anti-Cyp antibody to identify 
TRIM21Cyp protein expression. Loading control with anti-β-actin antibody is shown in the bottom 
panel. UT-untransduced, T21C-sample from cells transduced with LNT/S-TRIM21Cyp-IEW. 
B. Schematic diagram to show the primer binding sites (blue arrows) used in the two PCRs to identify 
clones that had an integrated TRIM21CypCO transgene (486 base pair (bp) product) and integration 
at the correct locus enabling amplification of the integrant-CCR5 junction (1507bp product). DNA 
was extracted from GHOST clones that restricted HIV-1-YFP and subject to PCR analysis. 
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C. PCR using primers that bind within the TRIM21CypCO transgene, allowing identification of 
clones with an integrated copy irrespective of integration site. One primer binds within TRIM21 and 
the other in Cyp to avoid detection of either individual endogenous gene. A 486bp product of the 
correct size was identified in several clones and is indicated with the black arrow. CCR5-PGK-
TRIM21CypCO donor template plasmid (+) was used as a positive control. 
D. PCR was performed using primers that bind in the TRIM21Cyp insert and in the genomic CCR5 
DNA to amplify the junction between insert and endogenous CCR5 sequence if integration occurred 
at the correct locus. For the one clone which had a band of the correct size (clone 14), the PCR 
product was sequenced to confirm the integration site in the CCR5 gene. The correct band is 
indicated with a black arrow. Examples of some of the other clones without the correct sized bands 
are shown. 
 
 
 
 
Clone 
TRIM21Cyp 
PCR 
Western blot 
(anti-Cyp) 
Junction PCR 
WPRE qPCR 
(copy number) 
2 ✓ X X 1.5 
7 X X X - 
12 ✓ X X 1.18 
14 ✓ ✓ ✓ 0.36 
16 ✓ ✓ X 1.06 
25 X X X - 
28 X X X - 
29 ✓ X X 1.38 
122 X - X - 
164 X - X - 
 
Table 6.1 Molecular analysis of GHOST clones  
Summary of PCR and Western blot analysis of GHOST clones derived from cell sorting. 
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6.7 HIV-1 restriction in GHOST cells transduced with 
ZFNs and integrating TRIMCyp vectors 
The use of CCR5 specific ZFNs to site specifically integrate TRIMCyp would 
provide cells with two modes of protection against HIV infection. CCR5 would be 
absent from the cell surface and TRIMCyp would be expressed, providing a second 
level of defence against any virus that was able to enter cells, in particular X4 or 
dual tropic strains. Due to the inefficiency of HDR and time restrictions, these two 
levels of defence could not be tested through site specific integration of TRIMCyp at 
the CCR5 locus. As a proof of principle experiment, GHOST-R5X4 cells were 
transduced with CCR5 ZFN NILV and after several days in culture, also with 
LNT/S-TRIMCyp-IEW. This GHOST cell line expresses both CCR5 and CXCR4 
co-receptors, as well as CD4 to allow infection with R5, X4 and dual tropic HIV-1 
strains. 
After the two rounds of transduction, cells were stained with anti-CCR5 antibody 
before FACS sorting to obtain GFP positive populations, either positive or negative 
for CCR5. These cells had knockout of CCR5 by ZFNs and expression of TRIMCyp 
from an integrating vector, rather than a transgene specifically integrated at the 
CCR5 locus.  
After sorting cells, eGFP expression remained low in all TRIMCyp populations 
(Figure 6.7A). To confirm high levels of TRIMCyp in all cells in the sorted 
population, cells were transduced with HIV-1-YFP, and YFP expression measured 
by flow cytometry 72 hours later (Figure 6.7C). Despite inefficient eGFP expression 
in the sorted cell populations nearly all TRIMCyp transduced cells were are able to 
restrict HIV-1-YFP, compared to 80% of cells untransduced with TRIMCyp vectors 
(UT in Figure 6.7). As HIV-1-YFP was pseudotyped with VSV-G, giving it a broad 
tropism, the presence or absence of CCR5 on the cell surface did not affect levels of 
HIV-1-YFP transduction. DNA samples were extracted from cells and the ZFN site 
amplified by PCR. The PCR product was then used for a T7 endonuclease assay to 
detect the presence of mismatched DNA binding characteristic of NHEJ and CCR5 
knockout (Figure 6.7B).  
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Figure 6.7 Restriction of HIV-1-YFP by TRIMCyp and CCR5 specific ZFN 
A. GHOST-R5X4 cells were transduced with CCR5 specific ZFNs. Cells were subsequently 
transduced with LNT/S-TRIMCyp-IEW vectors. Cells were stained with an anti-CCR5-APCCy7 
antibody and were then flow cytometrically sorted for GFP expression and the presence or absence of 
CCR5. Flow cytometry of cells after sorting are shown.  
B. DNA was extracted after sorting and subject to a T7 endonuclease assay. Each sample also had a 
no enzyme (-) control.  
C. After sorting, cells were transduced with HIV-1-YFP. 72 hours later restriction was measured by 
YFP expression by flow cytometry to measure restriction in the whole population independently of 
GFP expression.  
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These sorted cells were then infected with R5 tropic replication competent HIV-1 
NL4-3 (BaL) to investigate whether there is an added benefit to have both CCR5-
ZFN and TRIMCyp mechanisms of restriction. 
Culture supernatant was harvested 7 days after infection to measure p24 levels by 
ELISA (Figure 6.8A). Cells were passaged every 3 to 4 days to prevent cell 
overcrowding. At day 18 cell viability was measured by flow cytometry to gauge the 
level of cytotoxic effects from HIV-1 replication (Figure 6.8B). 
Untransduced cells expressing CCR5 supported replication of R5 tropic HIV-1 and 
high levels of p24 were detected in the culture medium by ELISA. Knockout of 
CCR5 expression by ZFNs led to an approximately 50 fold decrease in p24 levels in 
the media compared to this control. Even after sorting there was a small percentage 
of cells that was CCR5 positive, which supported viral replication and lead to 
increased p24 levels detectable by ELISA. TRIMCyp expressing cells produced 
levels of p24 that were undetectable above background levels in cells both with and 
without CCR5. 
This inhibition of HIV-1 replication was mirrored in the cell viability. By around 
day 14 there was a noticeable loss of cell density when passaging CCR5
+
 cells not 
expressing TRIMCyp. CCR5
-
 cells continued to grow rapidly throughout the 
experiment, whether expressing TRIMCyp or not. Cell death was quantified by 
staining cells for viability of day 18. Cells expressing CCR5 had a low viability of 
only 9% compared to 59% for uninfected control cells. 
All other cell populations had similar viabilities to the uninfected control. However, 
there was a 12% increase in viability in TRIMCyp CCR5
-
 cells compared to 
TRIMCyp CCR5
+
 cells, despite neither population supporting viral replication. 
 
These results suggest that TRIMCyp factors confer such a strong level of restriction 
that there is little additional benefit, in terms of viral replication, in disrupting CCR5. 
However, using ZFNs for site specific integration has safety benefits in drastically 
reducing the likelihood of insertional mutagenesis.   
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Figure 6.8 Restriction of HIV-1 by TRIMCyp and CCR5 zinc finger nucleases 
GHOST cells with or without CCR5 (R5
+
 and R5
-
 respectively) and either untransduced (UT), T5Cyp 
or T21Cyp transduced (from Figure 6.7) were infected with R5 tropic HIV-1 NL4-3 (BaL).  
A. Culture supernatant was harvested 7 days post infection and p24 levels measured by ELISA.  
B. At day 18 post infection cells were harvested and stained with live/dead fixable stain to measure 
viability by flow cytometry. 
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6.8 Summary 
CCR5 has been a target in anti-HIV-1 therapy since the identification of the Δ32 
mutation in the CCR5 gene that provides protection against infection (332, 333). 
One possible way to disrupt CCR5 expression is ZFNs. 
ZFNs are advantageous compared some other techniques as they only require 
transient expression to provide permanent knockout in cells and all of their progeny, 
thereby increasing safety by eliminating the need for integrating genes and reducing 
the risk of an immune response to these artificial proteins.  
Knockout of both CCR5 alleles is required to provide full resistance to R5 tropic 
HIV-1. In alternative approaches using RNAi and ribozymes there is often only 
partial knockdown and there can be problems with maintaining protection due to 
shut down of gene expression. Low levels of cell surface CCR5 would be sufficient 
to allow some HIV-1 infection. 
There are several different methods that can be used for delivery of ZFN genes. 
Here, NILV have been used, but it is also possible to use nucleofection or adenoviral 
and AAV vectors. Different methods may affect the efficiency of gene delivery, and 
this may occur in a cell type dependent manner. Combination of both ZFN genes on 
one NILV by using a bicistronic vector, IRES or P2A (369, 370) construct may 
increase efficiency as cells would only need to be transduced with two viral vectors; 
one encoding the ZFNs and the other as the donor template, rather than three as used 
in these experiments.  
 
ZFNs were initially tested in the GHOST cell line, which have been transduced with 
a gamma retroviral vector to express high levels of CCR5. Therefore, each cell 
contains multiple copies of CCR5 cDNA and all copies would need to be targeted by 
ZFNs for the cell to become CCR5 negative. Despite this, CCR5 knockout was quite 
efficient, with nearly 80% of cells becoming CCR5 negative. Incomplete knockout 
targeting just some of the multiple copies per cell may lead to reduced levels of 
CCR5. In vivo this has been suggested to result in a slower disease progression and 
onset of AIDS, as seen in Δ32 heterozygotes which only have one functional copy of 
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the CCR5 gene (335, 336). However, these cells would not be resistant to R5 tropic 
HIV-1. 
 
In addition to using ZFNs to disrupt gene expression, introduction of a DSB 
increases the efficiency of HDR which can allow site specific integration of a 
transgene. The aim here was to use a donor template encoding TRIMCyp to promote 
HDR and integration of this transgene at the CCR5 locus. This strategy would 
provide dual protection against HIV-1; firstly by knockout of CCR5, and secondly 
by expressing TRIMCyp, which would target virus that is able to enter the cell, 
presumably a strain that utilises CXCR4 for cell entry. Additionally, site specific 
integration would reduce the risk of insertional mutagenesis. In situations where 
ZFNs are aimed at replacing a mutated gene with the correct, functional sequence by 
HDR, repair of DSB by NHEJ would be non-beneficial. However, in anti-HIV-1 
gene therapy aiming to integrate TRIMCyp by HDR, knockout of the CCR5 gene by 
NHEJ will still provide some protection by restricting R5 tropic HIV-1. Targeting 
two different points in the HIV lifecycle is an attractive option as it reduces the 
possibility of mutagenic escape by the virus. 
 
CCR5 is the predominant tropism for HIV-1 responsible for initial infection (328), 
but even with complete CCR5 knockout, cells are still susceptible to X4 tropic virus. 
Individuals may harbour X4 or dual tropic viral strains, and although rare, there have 
been several cases of Δ32 CCR5 homozygotes becoming infected with HIV-1 (395). 
Restricting just R5 tropic virus could result in selection and expansion of X4 tropic 
strains that are often associated with CD4
+
 T cell loss and more rapid disease 
progression.  
Targeting these strains of virus in addition to R5 tropic strains would provide a more 
comprehensive and effective therapy. CXCR4 specific ZFNs have been designed 
and shown to specifically disrupt CXCR4 in human T cells, resulting in HIV 
resistance and a survival advantage for modified cells (396). However, in a NSG 
mouse model only a transient restriction of HIV-1 was seen. This was hypothesised 
to be due to the evolution and emergence of either dual tropic or R5 tropic strains. 
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Another problem with this strategy is that unlike CCR5, CXCR4 does not have such 
a redundant role in the immune system. Although no effect on cell growth or 
function was reported, CXCR4 knockout mice have severe problems in 
haematopoiesis and cerebellar and cardiac development (397). Therefore, using 
TRIMCyp restriction factors could be a more applicable mode of protection to target 
X4 and dual tropic strains of HIV-1. This could be carried out either by using ZFNs 
and HDR, or using ZFNs and integrating lentivirus expressing TRIMCyp if the 
efficiency of HDR is too low. 
 
In preliminary experiments, CCR5 specific ZFNs and a PGK-eGFP donor template 
NILV were used. This allowed easy quantification of integration by flow cytometry. 
After transduction with ZFN and GFP donor NILV, cells were cultured for two 
weeks to allow dilution of episomal DNA. The final percentage of GFP positive 
cells increased with higher quantities of both ZFNs and donor virus. However, even 
at the highest concentrations, only 2-4% of cells stably expressed GFP.  
Published data has already shown that efficiency of HDR varies greatly between cell 
types. When using NILV to deliver ZFNs and a GFP donor template, the rate of site 
specific integration of GFP ranged from 39% in Jurkats to 3.5% in human 
embryonic stem cells to 0.11% in CD34
+
 haematopoietic stem cells (361). In the 
published data, rates of integration were much higher than seen here in GHOST 
cells. One problem in initial experiments was the use of unequal quantities of ZFNs. 
ZFN EL had approximately 4 times higher p24 levels than ZFN KK (0.05µg/µl 
compared to 0.013µg/µl) and this only became apparent on retrospective p24 based 
titre analysis. The low efficiency of integration by HDR is an obstacle that must be 
overcome before this technology could become a feasible therapeutic option.  
Some possible methods to increase efficiency include targeting cells during the G2 
phase of the cell cycle, a variable that was not controlled for in these experiments. 
At G2, the likelihood of cells repairing DSB by HDR rather than NHEJ increases, so 
treatment of cells with vinblastine to arrest the cell cycle could increase donor 
integration (398). Providing the cells with a cold snap at 30ºC after delivery has also 
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been shown to improve efficiency of ZFN action, at least in part due to accumulation 
of ZFN protein (399).  
 
A second donor template was generated that encoded codon optimised TRIM21Cyp 
(TRIM21CypCO) driven by the PGK promoter. This would allow integration of the 
TRIMCyp transgene into the safe harbour CCR5 locus. Targeting different points in 
the HIV lifecycle is an attractive option as it should reduce the possibility of 
mutagenic escape by the virus. Again, NILV was used to deliver ZFNs and the 
TRIM21CypCO donor into GHOST-CCR5 cells. To distinguish which cells were 
expressing TRIM21Cyp, cells were then transduced with HIV-1-YFP. HIV-1-YFP 
restriction was taken as a marker of TRIM21Cyp expression and cells were 
subsequently sorted by flow cytometry for YFP and CCR5 double negative cells to 
produce clones predicted to have TRIM21Cyp integrated at the CCR5 locus.  
This method produced lots of clones, and after two individual transductions of 
GHOST cells with ZFNs and TRIM21CypCO donor, approximately 200 colonies 
were grown and tested for restriction of HIV-1-YFP. However, the majority of these 
clones were not resistant to HIV-1, and molecular analysis did not confirm correct 
integration at the CCR5 locus. The high number of false positive clones is probably 
a result of incomplete transduction of the entire population of cells prior to sorting 
despite the high MOI of HIV-1-YFP used. 
As discussed previously, TRIMCyp protein is not reliably detected by Western blot. 
This caused difficulties in confirming TRIM21Cyp protein in the clones by this 
method. Therefore further analysis was performed by PCR. Of the clones tested, 
only one clone produced the correct amplicon of the TRIMCyp/CCR5 junction. 
If this PCR product, or that of the other TRIMCyp/CCR5 junction, cannot be 
amplified, it could be because this end was repaired not by HDR as expected, but by 
NHEJ, resulting in the insertion of the remainder of the vector DNA. This resulting 
incorrect junction could be too long to amplify by the PCR using the tested 
conditions.  
Other clones that did not contain this expected junction, but tested positive in the 
TRIM21Cyp PCR, had approximately one copy of WPRE per cell suggesting 
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integration of the whole vector genome. This could either be random integration of 
the vector DNA or off target integration mediated by ZFNs. Random background 
integration is likely to be a result of recombination between the vector and genomic 
DNA rather than IN activity (400). Alternatively, if the ZFNs cause off target DSBs, 
linear vector DNA can be integrated at this site by NHEJ. In fact this phenomenon 
has even been exploited for the identification of off target ZFN sites (401). These off 
target events can be identified by using ligation-mediated PCR and high throughput 
sequencing. Briefly, this involves digestion of genomic DNA from transduced cells, 
and ligation of linkers to the overhanging DNA ends. The genomic-viral DNA 
junction is amplified by PCR using primers that bind within the viral DNA and to 
the linker. 
Although background integration could still provide protection to the cell if it allows 
expression of TRIMCyp, there would be no additional protection by CCR5 knockout 
and the risk of insertional mutagenesis will be similar to using integrating vector. 
 
Bioinformatics can be used to predict ZFN off target sites. The simplest method 
locates sites with high homology to the binding sites of the two ZFN monomers and 
the top 15 predicted sites for the CCR5 ZFNs have been identified and further 
analysed by high throughput sequencing (369). However, calculating putative off 
target sites by sequence homology with the binding site of each individual ZFN may 
not identify genuine target sites of the dimeric pair of ZFNs. Binding by a ZFN pair 
may tolerate a greater number of base pair mismatches than the two individual ZFN 
binding sites. Using alternative methods, more recent investigations have confirmed 
previously identified off target sites and also determined additional sites for CCR5 
ZFNs (401, 402). Off target sites shown to be cleaved by CCR5 ZFNs include 
CCR2, BTBD10 and ABLIM2 (369, 401, 402). 
CCR2 has a high level of sequence homology to CCR5 and each CCR5 ZFN DNA 
binding site is only one base pair different to a homologous sequence of the CCR2 
gene. Like CCR5, CCR2 is a G protein coupled chemokine receptor and knockout of 
the gene results in mice that develop normally, but have impaired recruitment of 
monocytes and macrophages to sites of inflammation (403-405). Despite this, off 
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target knockout of CCR2 is likely to be tolerated, and as CCR2 mutations have been 
shown to delay the onset of AIDS, disruption of CCR2 may provide some protection 
in HIV patients (406). However, CCR2 is located adjacent to CCR5 on chromosome 
3 and it has been shown that simultaneous cleavage at CCR5 and CCR2 can lead to 
deletion of large 15kb region of DNA (407). This could even potentially result in a 
CCR5-CCR2 fusion protein, which may trigger an immune response against 
transduced cells expressing this novel epitope. 
As well as background integration, the cytotoxic effects of ZFNs must also be 
assessed. Cytotoxicity is primarily is caused by off target DSBs, which can be 
visualised within a cell by staining for 53BP1, which is recruited to the site of DSB 
(408).  
 
If cells have a strong survival advantage, modification of only a small number of 
cells by HDR to insert TRIMCyp may be sufficient to observe a therapeutic benefit, 
especially if targeting HSCs that are able to produce resistant cells of all 
haematopoietic lineages. However, whilst the current methods to induce site specific 
integration through HDR are inefficient, a more feasible method may be to transduce 
cells separately with integrating TRIMCyp vector and with CCR5 ZFN NILV.  
Adenoviral vectors for ZFN delivery, especially with T cells, have been used by 
other groups. This vector system is being used in the Sangamo clinical trial, where 
preliminary data show that this vector is likely to be able to mediate CCR5 knockout 
at a therapeutically beneficial efficiency. However, a major drawback with this 
delivery method is that most people initiate an immune response to adenovirus, 
which could result in immune pathologies. 
In the future, alternative nucleases called TALENs, which use a similar principle to 
ZFNs, could be used (366, 367). These proteins are proposed to be more efficient, 
but with lower off target cytotoxicity causing less cell death, and less cleavage at 
CCR2. If the efficiency and toxicity of these nucleases is more suitable, they may be 
preferential to use as a potential gene therapy method. An additional benefit of using 
TALENs is that TALEs bind DNA in a context independent fashion. This makes 
assembling TALEs to bind a specified sequence simpler than when using ZFs, which 
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are influenced by their neighbouring ZFs. Therefore, designing ZFNs also requires 
time consuming screening of potential proteins, a step which could be eliminated if 
using TALENs. 
 
Data presented here has shown that TRIMCyp expressing cells provide such strong 
inhibition of HIV-1 that the additional knockout of CCR5 using ZFNs does not 
provide any further viral restriction. Despite there being no enhancement of 
restriction, using ZFNs to site specifically integrate TRIMCyp at the CCR5 locus 
would improve the safety profile of gene therapy. However for this to become a 
viable therapeutic mechanism, the efficiency of the technology must be greatly 
increased. Here, modification of the GHOST cell line by HDR was highly inefficient 
and targeting T cells or HSC, as would be required in a patient, is likely to be even 
more inefficient. However, the principle of site specific integration of an anti-HIV-1 
transgene at the CCR5 locus to provide a dual mechanism of protection against HIV-
1 is highly desirable, and optimisation of ZFN technology, for HIV-1 and other 
diseases, is being continued to improve this possibility. 
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7 Discussion 
Here we have designed TRIMCyp constructs using both human TRIM5 and 
TRIM21 RBCC domains fused to human Cyclophilin A (Cyp) based upon the 
naturally occurring owl monkey TRIM5Cyp protein. Both of these human proteins 
were found to be potent inhibitors of HIV-1. However, TRIM5Cyp, but not 
TRIM21Cyp, was shown to interfere with the antiretroviral function of endogenous 
TRIM5α. The endogenous function of TRIM21, quantified by adenoviral restriction, 
was not disrupted by expression of either TRIMCyp variant. Thus, although the role 
of endogenous TRIM5 in human immunity is poorly defined, TRIM21Cyp may be a 
more suitable choice for clinical therapy than TRIM5Cyp. 
These transgenes could form the basis of a new gene therapy treatment against HIV 
and this discussion illustrates some of the aspects that must be further considered 
before application of this technology. 
7.1 Vector modification for clinical use  
In anticipation of further testing of these restriction factors, the TRIM5Cyp and 
TRIM21Cyp vectors have been modified to increase their suitably for clinical use. 
Important alterations include the removal of the eGFP reporter gene and replacement 
of the strong viral SFFV promoter with the clinically approved human PGK 
promoter. This promoter also provides high, constitutive expression, but as it is 
human, rather than viral, in origin, it is less likely to be silenced or induce an 
immune response. For these changes, the TRIMCyp constructs have been cloned 
into the third generation lentiviral plasmid, pCCL, which has been approved for 
clinical use and is currently in clinical trial.  
The third generation packaging system uses a constitutive viral promoter in the 
3’LTR of the transfer plasmid, rather than U3. This eliminates the requirement of 
Tat, which is removed from the packaging plasmid. The rev gene is also removed 
from the packaging plasmid, and is supplied in trans on a separate plasmid to the 
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packaging cells upon transfection (107). Vector must also be treated with benzonase 
for the removal of contaminating DNA to improve purity before use. 
Although the human PGK promoter has been used in clinical trials and promotes 
strong constitutive expression, preliminary work has shown that the TRIM5 
promoter may drive expression comparable to human PGK. Use of physiological 
promoters reduces the risk of cytotoxicity in transduced cells (102) and using the 
TRIM5 promoter would allow more cell specific expression at a physiological level. 
The TRIM5 promoter is also IFN inducible (211), which would allow upregulation 
of TRIMCyp expression upon viral infection. This would relieve the requirement of 
high, constitutive expression of TRIMCyp and any associated toxic side effects. The 
full length TRIM5 promoter is just over 1kb in length, but for use in a vector could 
possibly be reduced in length whilst still maintaining high levels of expression with 
the IFN inducible elements.  
Another possible scenario to use the native TRIM promoter would be to use ZFNs to 
insert CypA cDNA into the TRIM5 locus to produce a TRIMCyp fusion protein 
under control of the endogenous TRIM5 promoter. This would result in 
physiological levels of expression and IFN induced upregulation upon viral 
infection. However, ZFNs currently have problems of low efficiency, particularly 
for HDR. This strategy would also reduce expression of TRIM5, which is now 
known to be important in innate signaling (252). 
 
In patients it is possible that lentiviral therapeutic vectors could come into contact 
with replication competent wild type HIV-1, from which the vector was originally 
derived. This means that HIV-1 gene therapy has a higher possibility of generating 
RCL through recombination between the vector and the wild type virus. Although 
this phenomenon has yet to be observed in any setting, it is important to use all 
possibilities to limit the likelihood of these events occurring. The third generation 
system includes fewer HIV-1 sequences, so reduces the likelihood of recombination. 
Clinical grade vector must be subject to stringent testing to detect the presence of 
any RCL. In addition, bespoke RCL assays will be required to screen patients for 
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replication competent recombinants formed by recombination between HIV-1 vector 
and wild type virus. 
7.2 Target cell populations for HIV-1 gene therapy 
If TRIMCyp is considered for clinical trials, it would be necessary to decide whether 
to target T cells or HSC for ex vivo modification using third generation vectors. Both 
populations have already been targeted in different HIV-1 gene therapy trials, and 
both are associated with different benefits which are summarised below. 
A key factor with targeting T cells is that they are less likely than HSCs to be 
transformed and cause leukaemia, which has been shown to be a problem in HSCs 
gene therapy (100, 101). In various gene therapy trials targeting T cells that have 
been performed to date, there has been no evidence of mutagenesis, including in 
anti-HIV-1 trials (120, 125, 409-412). Analysis of T cells transduced with  a 
retroviral vector show that even with some gene upregulation, T cell function is not 
disrupted and there is no evidence of clonal expansion (413), suggesting that T cell 
transduction will be safely tolerated in patients. It would be necessary to check that 
modified T cells expressing TRIMCyp are still able to function and replicate as 
normal to restore the immune system of the patient. Functional assays to assess this 
could include measuring proliferation, cytokine expression, chromium release assays 
and response to infections that are common problems in HIV-1 patients, such as 
CMV.  
 
Transduced T cells may survive for many years, enabling continued protection and 
maintenance of a functional T cell count, particularly if both naïve and memory cells 
are targeted. Ideally, the ratio of naïve to memory T cells would be maintained after 
transduction, but stimulation of the cells prior to transduction may skew the cells 
towards a memory phenotype. Stimulation with cytokines alone may cause less of an 
effect (414, 415) than via the TCR, but it is important that transduction efficiencies 
remain high. As T cells are already differentiated, they have a reduced life span 
compared to HSCs, which improves their safety profile, but reduces the longevity of 
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the treatment. T cell gene therapy is highly appealing for adult patients for whom the 
ability to reconstitute the immune system from HSCs is limited. 
As CD4
+
 T cells are the prime target cell of HIV-1 and numbers are depleted 
throughout infection, it may be difficult to acquire sufficient cell numbers for 
transduction in patients with low CD4
+
 counts. Trials would need to be performed 
on patients with a sufficient T cell counts, or cells could be expanded ex vivo to 
increase the initial numbers of cells provided to a patient. However, there are 
associated problems with ex vivo expansion of cells in terms of negatively affecting 
their naivety and fitness. Also, using a cell population that could potentially harbour 
HIV-1 adds logistical complications in terms of manipulating cells, and sufficient 
safety measures must be taken during ex vivo transduction and culture protocols. 
Any cells that are already infected with HIV-1 will receive no protection by 
subsequent TRIMCyp transduction. 
 
In vitro experiments can be performed to test transduction and expression in HSCs 
using the TRIMCyp lentiviral vector. Transduced HSCs can be cultured and 
differentiated into CD4/CD8 double positive cells in vitro (416) and then 
subsequently challenged with HIV-1. Alternatively, transduced HSCs can be 
transplanted into NSG mice and allowed to differentiate in vivo before infection with 
HIV-1. T cell numbers and viral load can be measured to test the efficiency of 
engraftment and TRIMCyp expression. 
It is generally considered that HSCs are not infected by HIV-1, eliminating the 
concern with T cells of transducing already infected cells. However, there has been 
some evidence that shows latent infections of haematopoietic progenitor cells (417), 
which must be considered if this cell population is to be targeted. 
An important safety concern with HSCs is that they are more susceptible to 
insertional mutagenesis than T cells as they have prolonged and increased replicative 
capacity. This involves higher expression of genes involved in proliferation, which 
are likely to be frequently targeted as an integration site, potentially disrupting 
normal expression. There are already examples of gene therapy clinical trials for 
SCID-X1 targeting HSCs in which insertional mutagenesis led to T cell clonal 
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expansion and the development of leukaemia (100, 101). However, these trials used 
gamma retroviral vectors with intact LTRs to drive IL γ chain expression. 
Subsequent vector design was improved by using SIN LTRs with weaker internal 
promoters driving expression, which significantly increased safety in in vitro 
toxicity assays. Furthermore, replacement of retroviral vectors with lentiviral vectors 
further improves safety, primarily due to the differences in their respective 
integration profiles (104, 418). Although current SIN lentiviral vectors have a 
significantly higher safety profile than retroviral vectors used in the SCID-X1 trial, 
this trial has highlighted the risks associated with HSC modification. Further 
observations and longer follow-up periods in current trials are required to determine 
the in vivo toxicity of these latest vectors. 
If HSCs are used as target cells, it is important to ensure that the potency of the 
HSCs is not affected. Ex vivo culture of HSCs requires a cocktail of cytokines to 
promote expansion and maintain an undifferentiated state, but this has been 
associated with loss of potency after transplant. These culture methods are being 
optimised to reduce loss of potency whilst maximising transduction efficiency (419).  
Despite these concerns, modification of HSCs would be the ideal ultimate target 
cells as this would result in transfer of the transgene to all haematopoietic lineages 
that are susceptible to HIV-1 infection through differentiation. A supply of protected 
T cells could be provided by HSCs to prevent the characteristic HIV-1 induced T 
cell loss. Similarly, macrophages, dendritic cells and other haematopoietic cells 
derived from the modified HSCs would be protected. There are various pathologies 
associated with HIV-1 infection that do not appear to be simply due to depletion of 
T cells, and these may be prevented or reduced with HSC gene therapy, rather than 
modification of only T cells.  
HSC gene therapy is particularly appealing in a paediatric setting due to the higher 
thymic activity of these patients, which would support development of T cells to 
replace those lost by HIV-1 infection. Also, as these patients are likely to have been 
on HAART for many years since birth, giving them a high risk of drug resistant 
escape mutants, they would be ideal candidates for clinical trials. 
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For initial trials, patients who have developed AIDS lymphoma and are receiving 
HSC transplant offer ideal opportunities to test this method as autologous cells that 
have been mobilised and harvested could be transduced with the therapeutic vector 
prior to infusion. This setting has already been used to transduce CD34
+
 HPCs with 
RNA based anti-HIV genes (129). Four patients with lymphoma were transplanted 
with both unmodified and lentiviral vector transduced cells. Although there was 
limited therapeutic benefit from the transduced cells, the procedure was tolerated 
and gene marking was detected in cells of all lineages for up to 24 months, 
indicating that the procedure did not adversely affect cell viability or potency. 
Patients receiving HSCs as part of treatment for lymphoma will already be receiving 
chemotherapy and/or irradiation prior to transplant to eradicate leukaemic cells and 
to ablate HSCs to enhance engraftment of transplanted cells. This resolves any 
ethical issues associated with the provision of potentially dangerous treatments prior 
to HSC transplant being performed solely for gene therapy. 
Conditioning prior to transplant, for instance using busulfan, may have additional 
advantages of reducing latent cellular reservoirs of HIV and improving engraftment 
of transduced cells. Although myeloblation and HSC transplant from a healthy donor 
is not sufficient to eradicate the viral latent reservoir, it is thought that the 
combination of chemotherapy and total body irradiation received by the ‘Berlin’ 
patient may have had a beneficial effect in eradicating latent reservoirs of HIV. This 
could in part be responsible for the absence of X4 HIV-1 after transplant, despite 
their presence before the procedure.  
 
It is likely than any initial trials performed in patients will involve transduction of T 
cells. This will allow observation of any adverse effects associated with TRIMCyp 
expression and also whether there is a detectable therapeutic benefit. If results from 
preliminary T cell trials are positive, further work can be carried out by treating 
patients with modified HSCs. 
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7.3 Host responses in gene therapy 
Using viral vectors expressing TRIMCyp proteins for the treatment of HIV-1 
infection has potential issues with inducing a host immune response, against both the 
virus and transgene product.  
Ex vivo transduction of cells would be the most likely method used for anti-HIV-1 
therapy. This would reduce the likelihood of developing an immune response against 
viral proteins as long as there is no residual lentivirus remaining associated with 
cells during transduction. Even with ex vivo transduction, retroviral vectors may 
induce expression of immunogens, leaving transduced cells susceptible to cytotoxic 
immune responses (420). 
Both TRIM5 and CypA are naturally expressed in humans, reducing the likelihood 
of TRIMCyp inducing an immune response. However, the junction formed at the 
site of fusion between the two proteins could result in novel immunogenic epitopes. 
Also, as mentioned previously, TRIM21 is a known autoantigen associated with 
autoimmune diseases such as Sjogren’s disease, so TRIM21Cyp may be more likely 
to induce an immune response. However, removal of the highly immunogenic B30.2 
domain will hopefully eliminate this problem. Whether TRIMCyp induces an 
immune response and whether host mediated rejection of gene modified cells arises 
will not be determined until the strategy is tested in humans. 
7.4 The HIV latent reservoir 
A major hurdle to the complete eradication of HIV-1 infection by gene therapy, or 
any other treatment, is the extensive latent viral reservoir. Even with intense 
HAART and undetectable circulating levels of HIV-1, latent reservoirs are 
unaffected, and once HAART is discontinued, there is a rapid increase in viral load 
from these reservoirs. These cell reservoirs are one of the reasons that HAART will 
not be able to cure a patient of HIV. 
The most well characterised reservoir is the resting memory CD4
+
 T cells, but 
various other cell types have been proposed to harbour latent provirus, including 
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naïve T cells, macrophages, microglia, astrocytes and  recently, HSCs (417). These 
cells can survive for many years, resulting in a stable reservoir that decays so slowly 
that without intervention it would persist for far longer than the survival of an 
infected individual (421). It has not been fully determined how normal viral 
replication is prevented in latency. Different mechanisms have been proposed 
including chromatin effects, an absence of proteins required for transcription such as 
P-TEFb, NFκB and NFAT, disruption of Tat levels and inhibition by microRNAs 
present in resting CD4
+
 T cells (422).  
 
TRIMCyp gene therapy would only provide resistance to T cells from new 
infections, but would not eradicate any latent virus. However, if there are significant 
numbers of resistant T cells this could be sufficient to relieve symptoms and 
pathogenesis of HIV-1 infection. Importantly, as TRIMCyp acts to restrict HIV-1 
before integration, and typically before reverse transcription, it will prevent the 
development of further latent reservoirs in modified cells. If HSCs are the gene 
therapy target, daughter cells of all lineages susceptible to infection will be protected 
and prevented from becoming host to latent virus, including macrophages and cells 
of the nervous system.  
 
Proposed strategies to eliminate the reservoir include intensification of HAART, or 
its earlier initiation during acute rather than chronic infection to prevent such 
extensive establishment of the reservoir. Alternative methods aim to use drugs to 
drive cells out of latency by activating them, leading to the initiation of viral 
replication. One possible example is to use valproic acid to inhibit histone 
deacetylases, promoting proviral transcription without the activation and expansion 
of T cells (423). If this is used alongside an effective HAART regimen or, if it 
proves successful, TRIMCyp gene therapy, further infection should be prevented 
and the cells drawn out of latency should be killed by productive infection. 
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7.5 Combining TRIMCyp restriction factors with CCR5 
knockout 
The only recorded functional cure of HIV was shown in a single patient who 
received a bone marrow transplant from a CCR5 Δ32 homozygous donor (339). 
Clinical trials are already underway to test knockout of CCR5 using ZFNs in T cells 
to mimic the Δ32 resistant cell phenotype (135). So far results are promising, both in 
terms of safety and efficacy. This, in addition to the case of the ‘Berlin’ patient, 
underlines the importance that an absence of CCR5 expression can have on treating 
HIV-1 infection.  
However, all of the aspects of the Δ32 transplant that contributed to the apparent 
cure are not fully understood. As well as provision of R5 tropic resistant Δ32 donor 
cells, the patient received intensive chemotherapy and irradiation before the 
transplant. This was required for destruction of leukaemic cells, and to assist 
engraftment of transplanted progenitor cells.  In addition, it could have played a role 
in destruction of latent reservoirs leading to the eradication of X4 tropic virus which, 
despite being able to infect CCR5 negative cells, was undetectable after transplant. 
This conditioning could play an important part in any gene therapy treatment before 
delivery of ex vivo modified cells, but cannot be relied on to eliminate X4 tropic 
virus. 
Therefore a major drawback with the knockout of CCR5 is that cells remain 
susceptible to X4 and dual tropic virus strains, requiring an additional strategy to 
provide protection from all viral tropisms. In contrast, TRIMCyp proteins are able to 
restrict HIV-1 using any co-receptor after cell entry. Restriction mediated by 
TRIMCyp proteins has shown to be highly potent and additional knockout of CCR5 
using ZFNs may not provide any further protection. However, the benefit of 
combining CCR5 specific ZFNs with TRIMCyp is not just enhancing protection of 
the cells, but in greatly reducing the likelihood of insertional mutagenesis, by 
exploiting the CCR5 locus as a safe harbour site using only NILVs. Although 
knockout of CCR5 in TRIMCyp expressing cells may not further restrict viral 
replication in in vitro experiments using a single round of infection, use of two 
198 
 
antiviral strategies in vivo may reduce the emergence of HIV-1 escape mutants as 
modeling suggests that the use of multiple transgenes will enhance the antiviral 
effect and prevent viral escape (126).  
Both of these restriction methods act upon HIV-1 early in its life cycle, at cell entry 
via CCR5 ZFNs and before reverse transcription by TRIMCyp. Any X4 or dual 
tropic virus that is able to enter cells not expressing CCR5 would then be susceptible 
to restriction by TRIMCyp. Restriction early in the viral lifecycle is ideal for gene 
therapy as it will avoid the pathogenic effects associated with viral protein 
expression, reducing T cell death and subsequent associated pathology (424). It will 
prevent the establishment of latent reservoirs and reduce the likelihood of mutations 
conferring resistance occurring during reverse transcription.  
7.6 Conclusion 
TRIMCyp shows great potential as a possible transgene for anti-HIV therapy, as in 
vitro they have been shown to provide cells with a strong resistance to infection that 
so far has been not been susceptible to viral escape. This suggests that they may be 
able to form the basis of a novel mode of treatment in infected patients based around 
the intracellular immunisation of susceptible cell populations. The next step of 
development is to produce clinical grade vector for evaluation in T cells, in the first 
instance, to determine safety and evidence of a therapeutic effect. If successful, 
further trials could target HSCs and possibly incorporate conditioning to enhance 
engraftment and reduction of latent reservoirs. 
Gene therapy is still in its early stages, but more and more anti-HIV trials are being 
performed. Although progress is slow, gene therapy has great opportunity for the 
treatment of HIV infection, with continual improvements in areas such as vector 
design, transgene efficacy and transduction protocols. In the future, this method 
could potentially provide long term protection after only a single intervention, which 
would be a highly desirable alternative or complement to current drug regimens.  
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